Advanced search
Publication Cover
Drug Metabolism Reviews Volume 37, 2005 - Issue 1
Submit an article Journal homepage
2,712
Views
205
CrossRef citations to date
0
Altmetric
Research Article

Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance

Dr. Shufeng Zhou Department of Pharmacy, Faculty of Science, National University of Singapore, Science Drive 4, 117543, Singapore; Department of Pharmacy, Faculty of Science, National University of Singapore, Science Drive 4, 117543, Singapore
, Ph.D.,
Eli Chan Department of Pharmacy, Faculty of Science, National University of Singapore, Science Drive 4, 117543, Singapore
, Ph.D.,
Wei Duan Department of Biochemistry, Faculty of Medicine, National University of Singapore, Singapore
, Ph.D.,
Min Huang Department of Clinical Pharmacology, School of Pharmaceutical Sciences, Zhongshan University, Guangzhou, China
, Ph.D. &
Yu-Zong Chen Department of Computational Science, Faculty of Science, National University of Singapore, Science Drive 4, 117543, Singapore
, Ph.D.
Pages 41-213 | Published online: 09 Oct 2008

References

  • Abdel-Rehim, M., Bielenstein, M., Askemark, Y., Tyrefors, N., Arvidsson, T. (2000). High-performance liquid chromatography-tandem electrospray mass spectrometry for the determination of lidocaine and its metabolites in human plasma and urine. J. Chromatogr., B, Biomed. Sci. Appl. 741:175–188.
  • Abernethy, D. R. (1997). Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist. Am. J. Cardiol. 80:C4–C11.
  • Abt, A., Oh, J. Y., Huntington, R. A., Burkhart, K. K. (1995). Chinese herbal medicine induced acute renal failure. Arch. Intern. Med. 155:211–212. [PUBMED], [INFOTRIEVE], [CSA]
  • Abul-Hajj, Y. J., Cisek, P. L. (1988). Catechol estrogen adducts. J. Steroid Biochem. 31:107–110. [PUBMED], [INFOTRIEVE], [CSA]
  • Adams, J., Vorhees, C. V., Middaugh, L. D. (1990). Developmental neurotoxicity of anticonvulsants: human and animal evidence on phenytoin. Neurotoxicol. Teratol. 12:203–214. [PUBMED], [INFOTRIEVE], [CSA]
  • Adessi, C., Miege, C., Albrieux, C., Rabilloud, T. (1997). Two-dimensional electrophoresis of membrane proteins: a current challenge for immobilized pH gradients. Electrophoresis 18:127–135. [PUBMED], [INFOTRIEVE], [CSA]
  • Agarwal, R. C., Wiessler, M., Hecker, E., Bhide, S. V. (1968). Tumor promoting effects of chili extracts in BALB/c mice. Int. J. Cancer 38:689–695.
  • Akira, K., Uchijima, T., Hashimoto, T. (2002). Rapid internal acyl migration and protein binding of synthetic probenecid glucuronides. Chem. Res. Toxicol. 15:765–772., [PUBMED], [INFOTRIEVE], [CSA]
  • Allen, R. W. Jr., Ogden, B., Bentley, F. L., Jung, A. L. (1980). Fetal hydantoin syndrome, neuroblastoma, and hemorrhagic disease in a neonate. JAMA. 244:1464–1465. [PUBMED], [INFOTRIEVE]
  • Alvir, J. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., Schaaf, J. A. (1993). Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N. Engl. J. Med. 329:162–167. [PUBMED], [INFOTRIEVE]
  • Amacher, D. E., Schomaker, S. J., Retsema, J. A. (1991). Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob. Agents Chemother. 35:1186–1190. [PUBMED], [INFOTRIEVE]
  • Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., Gottesman, M. M. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:361–398. [PUBMED], [INFOTRIEVE], [CSA]
  • Amouzadeh, H. R., Bourdi, M., Martin, J. L., Martin, B. M., Pohl, L. R. (1997). UDP-glucose:glycoprotein glucosyltranserase associates with endoplasmic reticulum chaperons and its activity is decreased in vivo. Chem. Res. Toxicol. 10:59–63. [PUBMED], [INFOTRIEVE], [CSA]
  • Anderson, J. R., Nawarskas, J. J. (2001). Cardiovascular drug–drug interactions. Cardiol. Clin. 19:215–234. [PUBMED], [INFOTRIEVE], [CSA]
  • Anderson, T. F., Voorhees, J. J. (1980). Psoralen photochemotherapy of cutaneous disorders. Annu. Rev. Pharmacol. Toxicol. 20:235–257. [PUBMED], [INFOTRIEVE]
  • Andersson, B., Nordenskjold, M., Rahimtula, A., Moldeus, P. (1982). Prostaglandin synthetase-catalyzed activation of phenacetin metabolites to genotoxic products. Mol. Pharmacol. 22:479–485. [PUBMED], [INFOTRIEVE], [CSA]
  • Anderson, N. L., Copple, D. C., Bendele, R. A., Richardson, F. C. (1992). Covalent protein modifications and gene expression changes in rodent liver following administration of methapyrilene: a study using two-dimensional electrophoresis. Fundam. Appl. Toxicol. 18:570–580. [PUBMED], [INFOTRIEVE], [CSA]
  • Anderson, I. B., Mullen, W. H., Meeker, J. E., Khojasteh-Bakht, S. C., Oishi, S., Nelson, S. D., Blanc, P. D. (1996). Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann. Intern. Med. 124:726–734. [PUBMED], [INFOTRIEVE], [CSA]
  • Ando, Y., Fuse, E., Figg, W. D. (2002). Thalidomide metabolism by the CYP2C subfamily. Clin. Cancer Res. 8:1964–1973. [PUBMED], [INFOTRIEVE], [CSA]
  • Antoine, M., Fabris, D., Fenselau, C. (1998). Covalent sequestration of the nitrogen mustard mechlorethamine by metallothionein. Drug Metab. Dispos. 26:921–926. [PUBMED], [INFOTRIEVE], [CSA]
  • Anttila, S. A., Leinonen, E. V. (2001). A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 7:249–264. [PUBMED], [INFOTRIEVE], [CSA]
  • Appleton, E., Farrell, K., Applegarth, D. A., Dimmick, J. E., Wong, L. T. K., Davidson, A. G. F. (1990). The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can. J. Neurol. Sci. 17:145–148. [PUBMED], [INFOTRIEVE]
  • Arlen, R. R., Wells, P. G. (1996). Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. J. Pharmacol. Exp. Ther. 277:1649–1658. [PUBMED], [INFOTRIEVE], [CSA]
  • Arlt, V. M., Stiborova, M., Schmeiser, H. H. (2002). Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17:265–277. [PUBMED], [INFOTRIEVE], [CSA]
  • Astrup, A. V. (2001). Licorice-induced high blood pressure. Ugeskr. Laeger 163:7284–7285. [PUBMED], [INFOTRIEVE], [CSA]
  • Atkin, K., Kendall, F., Gould, D., Freeman, H., Lieberman, J., O'Sullivan, D. (1996). The incidence of neutropenia and agranulocytosis in patients treated with clozapine in the UK and Ireland. Br. J. Psychiatry 169:483–488. [PUBMED], [INFOTRIEVE]
  • Back, D. J., Houlgrave, R., Tjia, J. F., Ward, S., Orme, M. L. (1991). Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J. Steroid Biochem. Mol. Biol. 38:219–225., [PUBMED], [INFOTRIEVE]
  • Baidas, S. M., Winer, E. P., Fleming, G. F., Jet, L. (2000). Phase II evaluation of thalidomide in patients with metastatic breast cancer. J. Clin. Oncol. 18:2710–2717. [PUBMED], [INFOTRIEVE]
  • Bailey, M. J., Dickinson, R. G. (1996). Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. Chem. Res. Toxicol. 9:659–666. [PUBMED], [INFOTRIEVE], [CSA]
  • Bailey, D. G., Spence, J. D., Munoz, C., Arnold, J. M.O. (1991). Interaction of citrus juices with felodipine and nifedipine. Lancet 337:268–269. [PUBMED], [INFOTRIEVE]
  • Bailey, D. G., Malcolm, J., Arnold, O., Spence, J. D. (1998a). Grapefruit juice–drug interactions. Br. J. Clin. Pharmacol. 46:101–110. [PUBMED], [INFOTRIEVE], [CSA]
  • Bailey, M. J., Worrall, S., Dejersey, J., Dickinson, R. G. (1998b). Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system. Chem.-Biol. Interact. 115:152–166. [CSA]
  • Bailey, D. G., Dresser, G. R., Kreeft, J. H., Munoz, C., Freeman, D. J., Bend, J. R. (2000). Grapefruit–felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin. Pharmacol. Ther. 68:468–477. [PUBMED], [INFOTRIEVE], [CSA]
  • Baillie, T. A. (1988). Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem. Res. Toxicol. 1:195–199. [PUBMED], [INFOTRIEVE]
  • Bajpai, M., Roskos, L. K., Shen, D. D., Levy, R. H. (1996). Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 24:1401–1414. [PUBMED], [INFOTRIEVE], [CSA]
  • Bargetzi, M. J., Aoyama, T., Gonzalez, F. J., Meyer, U. A. (1989). Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin. Pharmacol. Ther. 46:521–527. [PUBMED], [INFOTRIEVE]
  • Barry, M., Gibbons, S., Back, D., Mulcahy, F. (1997). Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 32:194–209. [PUBMED], [INFOTRIEVE], [CSA]
  • Bartolone, J. B., Sparks, K., Cohen, S. D., Khairallah, E. A. (1987). Immunochemical detection of acetaminophen-bound liver proteins. Biochem. Pharmacol. 36:1193–1196. [PUBMED], [INFOTRIEVE], [CSA]
  • Bartolone, J. B., Birge, R. B., Bulera, S. J., Bruno, M. K., Nishanian, E. V., Cohen, S. D., Khairallah, E. A. (1992). Purification, antibody production, and partial amino acid sequence of the 58-kDa acetaminophen-binding liver proteins. Toxicol. Appl. Pharmacol. 113:19–29. [PUBMED], [INFOTRIEVE], [CSA]
  • Bartoshesky, L. E., Bhan, I., Nagpaul, K., Pashayan, H. (1982). Severe cardiac and ophthalmologic malformations in an infant exposed to diphenylhydantoin in utero. Pediatrics 69:202–203. [PUBMED], [INFOTRIEVE]
  • Barzilai, A., Zilkha-Falb, R., Daily, D., Stern, N., Offen, D., Ziv, I., Melamed, E., Shirvan, A. (2000). The molecular mechanism of dopamine-induced apoptosis: identification and characterization of genes that mediate dopamine toxicity. J. Neural Transm. 60:59–76.
  • Basma, A. N., Morris, E. J., Nicklas, W. J., Geller, H. M. (1995). L-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J. Neurochem. 64:825–832. [PUBMED], [INFOTRIEVE]
  • Bauer, K. S., Dixon, S. C., Figg, W. D. (1998). Inhibition of angiogenesis by thalidomide requires metabolic activation which is species-dependent. Biochem. Pharmacol. 55:1827–1834. [PUBMED], [INFOTRIEVE], [CSA]
  • Beaune, P., Dansette, P. M., Mansuy, D., Kiffel, L., Finck, M., Amar, C., Leroux, J. P., Homberg, J. C. (1987). Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc. Natl. Acad. Sci. U. S. A. 84:551–555. [PUBMED], [INFOTRIEVE], [CSA]
  • Beaune, P., Bourdi, M., Belloc, C., Gautier, J. C., Guengerich, F. P., Valadon, P. (1993). Immunotoxicology and expression of human cytochrome P450 in microorganisms. Toxicology 82:53–60. [PUBMED], [INFOTRIEVE], [CSA]
  • Beaune, P., Pessayre, D., Dansette, P., Mansuy, D., Manns, M. (1994). Autoantibodies against cytochromes P450: role in human diseases. Adv. Pharmacol. 30:199–245. [PUBMED], [INFOTRIEVE]
  • Becquemont, L., Lecoeur, S., Simon, T., Beaune, P., Funck-Brentano, C., Jaillon, P. (1997). Glutathione S-transferase theta genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer's patients. Pharmacogenetics Jun. 7(3):251–253., [PUBMED], [INFOTRIEVE], [CSA]
  • Bejjani, B. A., Lewis, R. A., Tomey, K. F., Andersen, K. L., Dueker, D. K., Jabak, M., Astle, W. F., Otterud, B., Leppert, M., Lupski, J. R. (1998). Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudia Arabia. Am. J. Hum. Genet. 62:325–333. [PUBMED], [INFOTRIEVE], [CSA]
  • Belghazi, M., Jean, P., Poli, S., Schmitter, J. M., Mansuy, D., Dansette, P. M. (2001). Use of isotopes and LC-MS-ESI-TOF for mechanistic studies of tienilic acid metabolic activation. Adv. Exp. Med. Biol. 500:139–144. [PUBMED], [INFOTRIEVE], [CSA]
  • Ben Yahia, M., Mavier, P., Metreau, J. M., Zafrani, E. S., Fabre, M., Gatineau-Saillant, G., Dhumeaux, D., Mallat, A. (1993). Chronic active hepatitis and cirrhosis induced by wild germander. 3 cases. Gastroenterol. Clin. Biol. 17:959–962. [PUBMED], [INFOTRIEVE], [CSA]
  • Bencharit, S., Morton, C. L., Howard-Williams, E. L., Danks, M. K., Potter, P. M., Redinbo, M. R. (2002). Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat. Struct. Biol. 9:337–342. [PUBMED], [INFOTRIEVE], [CSA]
  • Benedetti, M. S. (2001). Biotransformation of xenobiotics by amine oxidases. Fundam. Clin. Pharmacol. 15:75–84. [PUBMED], [INFOTRIEVE], [CSA]
  • Benowitz, N. L., Meister, W. (1978). Clinical pharmacokinetics of lignocaine. Clin. Pharmacokinet. 3:177–201. [PUBMED], [INFOTRIEVE]
  • Benson, J. R., Pitsinis, V. (2003). Update on clinical role of tamoxifen. Curr. Opin. Obstet. Gynecol. 15:13–23. [PUBMED], [INFOTRIEVE], [CSA]
  • Bensoussan, C., Delaforge, M., Mansuy, D. (1995). Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem. Pharmacol. 49:591–602. [PUBMED], [INFOTRIEVE], [CSA]
  • Bensoussan, A., Myers, S. P., Drew, A. K., Whyte, I. M., Dawson, A. H. (2002). Development of a Chinese herbal medicine toxicology database. J. Toxicol., Clin. Toxicol. 40:159–167. [CSA]
  • Bergman, K., Olofsson, I., Sjoberg, P. (1998). Dose selection for carcinogenicity studies of pharmaceuticals: systemic exposure to phenacetin at carcinogenic dosage in the rat. Regul. Toxicol. Pharmacol. 28:226–229. [PUBMED], [INFOTRIEVE], [CSA]
  • Berson, A., Renault, S., Letteron, P., Robin, M. A., Fromenty, B., Fau, D., Le Bot, M. A., Riche, C., Durand-Schneider, A. M., Feldmann, G., Pessayre, D. (1996). Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. Gastroenterology 110:1878–1890. [PUBMED], [INFOTRIEVE], [CSA]
  • Bertilsson, L., Dahl, M. L., Dalen, P., Al-Shurbaji, A. (2002). Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53:111–122. [PUBMED], [INFOTRIEVE], [CSA]
  • Bessems, J. G. M., Vermeulen, N. P. E. (2001). Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit. Rev. Toxicol. 31:55–138. [PUBMED], [INFOTRIEVE], [CSA]
  • Bischer, A., Zia-Amirhosseini, P., Iwaki, M., McDonagh, A. F., Benet, L. Z. (1995). Stereoselective binding properties of naproxen glucuronide diastereomers to proteins. J. Pharmacokinet. Biopharm. 23:379–395. [PUBMED], [INFOTRIEVE], [CSA]
  • Bjorge, S. M., Baillie, T. A. (1991). Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations. Drug Metab. Dispos. 19:823–829. [PUBMED], [INFOTRIEVE]
  • Blatter, E. E., Abriola, D. P., Pietruszko, R. (1992). Aldehyde dehydrogenase. Covalent intermediate in aldehyde dehydrogenation and ester hydrolysis. Biochem. J. 282:353–360. [PUBMED], [INFOTRIEVE]
  • Bock, K. W., Forster, A., Gschaidmeier, H., Bruck, M., Munzel, P., Schareck, W., Fournel-Gigleux, S., Burchell, B. (1993). Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases. Biochem. Pharmacol. 45:1809–1814. [PUBMED], [INFOTRIEVE]
  • Bocker, D., Breithardt, G. (1991). Induction of arrhythmia by licorice abuse. Z. Kardiol. 80:389–391. [PUBMED], [INFOTRIEVE]
  • Boelsterli, U. A. (1993). Specific targets of covalent drug–protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury. Drug Metab. Rev. 25:395–451., [PUBMED], [INFOTRIEVE], [CSA]
  • Boelsterli, U. A. (2002a). Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Safety. 25:633–648. [PUBMED], [INFOTRIEVE], [CSA]
  • Boelsterli, U. A. (2002b). Nimesulide and hepatic adverse effects: roles of reactive metabolites and host factors. Int. J. Clin. Pract. 128:30–36.
  • Boelsterli, U. A. (2002c). Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr. Drug Metab. 14:439–450.
  • Boelsterli, U. A., Zimmerman, H. J., Kretz-Rommel, A. (1995). Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Crit. Rev. Toxicol. 25:207–235. [PUBMED], [INFOTRIEVE], [CSA]
  • Boitier, E., Beaune, P. (1999). Cytochromes P450 as targets to autoantibodies in immune mediated diseases. Mol. Aspects Med. 20:84–137. [PUBMED], [INFOTRIEVE], [CSA]
  • Bolze, S., Bromet, N., Gay-Feutry, C., Massiere, F., Boulieu, R., Hulot, T. (2002). Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metab. Dispos. 30:404–413. [PUBMED], [INFOTRIEVE], [CSA]
  • Bonierbale, E., Valadon, P., Pons, C., Desfosses, B., Dansette, P. M., Mansuy, D. (1999). Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds. Chem. Res. Toxicol. 12:286–296. [PUBMED], [INFOTRIEVE], [CSA]
  • Boocock, D. J., Brown, K., Gibbs, A. H., Sanchez, E., Turteltaub, K. W., White, I. N. (2002). Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23:1897–1901. [PUBMED], [INFOTRIEVE]
  • Borgelt-Hansen, L. (2001). Oral contraceptives: an update on health benefits and risks. J. Am. Pharm. Assoc. (Wash.). 41:875–886. [CSA]
  • Borum, M. L. (2001). Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am. J. Gastroenterol 96:1654–1655. [PUBMED], [INFOTRIEVE]
  • Botting, R. (2000a). Paracetamol-inhibitable COX-2. J. Physiol. Pharmacol. 51:609–618. [PUBMED], [INFOTRIEVE], [CSA]
  • Botting, R. M. (2000b). Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin. Infect. Dis. 31:S202–S210. [PUBMED], [INFOTRIEVE]
  • Boughton, B. J., Sheehan, T. M. T., Wood, J., Obrien, D., Butler, M., Simpson, A., Hale, K. A. (1995). High-performance liquid chromatographic assay of plasma thalidomide—stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. Ann. Clin. Biochem. 32:79–83. [PUBMED], [INFOTRIEVE]
  • Bourdi, M., Larrey, D., Nataf, J., Bernuau, J., Pessayre, D., Iwasaki, M., Guengerich, F. P., Beaune, P. H. (1990). Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J. Clin. Invest. 85:1967–1973. [PUBMED], [INFOTRIEVE], [CSA]
  • Bourdi, M., Tinel, M., Beaune, P. H., Pessayre, D. (1994). Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol. Pharmacol. 45:1287–1295. [PUBMED], [INFOTRIEVE], [CSA]
  • Bourdi, M., Demady, D., Martin, J. L., Jabbour, S. K., Martin, B. M., George, J. W., Pohl, L. R. (1995). cDNA cloning and baculovirus expression of the human liver endoplasmic reticulum P58: characterization as a protein disulfide isomerase isoform, but not as a protease or a carnitine acyltransferase. Arch. Biochem. Biophys. 323:397–403. [PUBMED], [INFOTRIEVE], [CSA]
  • Bourdi, M., Chen, W., Peter, R. M., Martin, J. L., Buters, J. T. M., Nelson, S. D., Pohl, L. R. (1996). Human P4502E1 is a major autoantigen associated with halothane hepatitis and the epitopes are conformational. Chem. Res. Toxicol. 9:1159–1166. [PUBMED], [INFOTRIEVE], [CSA]
  • Boutaud, O., Aronoff, D. M., Richardson, J. H., Marnett, L. J., Oates, J. A. (2002). Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc. Natl. Acad. Sci. U. S. A. 99:7130–7135., [PUBMED], [INFOTRIEVE], [CSA]
  • Braun, A. G., Harding, F. A., Weinreb, S. L. (1986). Teratogen metabolism: thalidomide activation is mediated by cytochrome P450. Toxicol. Appl. Pharmacol. 82:175–179. [PUBMED], [INFOTRIEVE], [CSA]
  • Braun, W., Kallen, J., Mikol, V., Walkinshaw, M. D., Wütherich, K. (1995). Three-dimensional structure and actions of immunosuppressants and their immunophilins. FASEB J. 9:63–72. [PUBMED], [INFOTRIEVE], [CSA]
  • Brittebo, E. B. (1987). Metabolic activation of phenacetin in rat nasal mucosa: dose-dependent binding to the glands of Bowman. Cancer Res. 47:1449–1456. [PUBMED], [INFOTRIEVE]
  • Brøsen, K., Gram, L. F. (1988). First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 43:400–406.
  • Brøsen, K., Zeugin, T., Meyer, U. A. (1991). Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther. 49:609–617.
  • Brouwer, M. (1996). Role of metallothionein in intracellular metal metabolism and in activation of copper- and zinc-dependent proteins. Adv. Inorg. Biochem. 11:235–260.
  • Brown, A. P., Gandolfi, A. J. (1994). Glutathione-S-transferase is a target for covalent modification by a halothane reactive intermediate in the guinea pig liver. Toxicology 89:35–47. [PUBMED], [INFOTRIEVE], [CSA]
  • Brown, A. P., Hastings, K. L., Gandolfi, A. J., Liebler, D. C., Brendel, K. (1992). Formation and identification of protein adducts to cytosolic proteins in guinea pig liver slices exposed to halothane. Toxicology 73:281–295. [PUBMED], [INFOTRIEVE], [CSA]
  • Brune, K. (1986). Comparative pharmacology of ‘non-opioid’ analgesics. Med. Toxicol. 1:1–9. [PUBMED], [INFOTRIEVE]
  • Bruni, J., Gallo, J. M., Lee, C. S., Perchalski, R. J., Wilder, B. J. (1980a). Interactions of valproic acid with phenytoin. Neurology 30:1233–1236. [PUBMED], [INFOTRIEVE]
  • Bruni, J., Wilder, B. J., Perchalski, R. J., Hammond, E. J., Villarreal, H. J. (1980b). Valproic acid and plasma levels of phenobarbital. Neurology 30:94–97. [PUBMED], [INFOTRIEVE]
  • Bryant, M. S., Simmons, H. F., Harrell, R. E., Hinson, J. A. (1994). 2,6-Dimethylaniline-hemoglobin adducts from lidocaine in humans. Carcinogenesis 15:2287–2290. [PUBMED], [INFOTRIEVE]
  • Budavari, S. (1996). The Merck Index 12th Ed. Merck Research Laboratories. Whitehouse Station, NJ: Merck & Co., Inc.
  • Budinsky, R. A., Roberts, S. M., Coats, E. A., Adams, L., Hess, E. V. (1987). The formation of procainamide hydroxylamine by rat and human liver microsomes. Drug Metab. Dispos. 15:37–43. [PUBMED], [INFOTRIEVE]
  • Buehler, B. A., Rao, V., Finnell, R. H. (1994). Biochemical and molecular teratology of fetal hydantoin syndrome. Neurol. Clin. 12:741–748. [PUBMED], [INFOTRIEVE]
  • Bulera, S. J., Birge, R. B., Cohen, S. D., Khairallah, E. A. (1995). Identification of the mouse liver 44-kDa acetaminophen-binding protein as a subunit of glutamine synthetase. Toxicol. Appl. Pharmacol. 134:313–320. [PUBMED], [INFOTRIEVE], [CSA]
  • Bunchman, T., Navarro, M., Broyer, M., Sherbotie, J., Chavers, B., Tonshoff, B., Birk, P., Lerner, G., Lirenman, D., Greenbaum, L., Walker, R., Zimmerhackl, L. B., Blowey, D., Clark, G., Ettenger, R., Arterburn, S., Klamerus, K., Fong, A., Tang, H., Thomas, S., Ramos, E. (2001). The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr. Nephrol. 16:978–984. [PUBMED], [INFOTRIEVE], [CSA]
  • Buratti, S., Lavine, J. E. (2002). Drugs and the liver: advances in metabolism, toxicity, and therapeutics. Curr. Opin. Pediatr. 14:601–607. [PUBMED], [INFOTRIEVE], [CSA]
  • Burchell, B., Brierley, C. H., Monaghan, G., Clarke, D. J. (1998). The structure and function of the UDP-glucuronosyltransferase gene family. Adv. Pharmacol. 42:335–338. [PUBMED], [INFOTRIEVE]
  • Burkman, R. T., Collins, J. A., Shulman, L. P., Williams, J. K. (2001). Current perspectives on oral contraceptive use. Am. J. Obstet. Gynecol. 185:S4–S12. [PUBMED], [INFOTRIEVE], [CSA]
  • Burlingame, R. W. (1997). The clinical utility of antihistone antibodies. Autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus. Clin. Lab. Med. 17:367–378. [PUBMED], [INFOTRIEVE], [CSA]
  • Burlingame, R. W., Rubin, R. L. (1996). Autoantibody to the nucleosome subunit (H2A-H2B)-DNA is an early and ubiquitous feature of lupus-like conditions. Mol. Biol. Rep. 23:159–166. [PUBMED], [INFOTRIEVE], [CSA]
  • Burrows, G. D., Kremer, C. M. (1997). Mirtazapine: clinical advantages in the treatment of depression. J. Clin. Psychopharmacol. 17:S34–S39.
  • Butler, L. E., Thomassen, D., Martin, J. L., Martin, B. M., Kenna, J. G., Pohl, L. R. (1992). The calcium-binding protein calreticulin is covalently modified in rat liver by a reactive metabolite of the inhalation anesthetic halothane. Chem. Res. Toxicol. 5:406–410. [PUBMED], [INFOTRIEVE]
  • CaJacob, C. A., Chan, W. K., Shephard, E., Ortiz de Montellano, P. R. (1988). The catalytic site of rat hepatic lauric acid omega-hydroxylase. Protein versus prosthetic heme alkylation in the omega-hydroxylation of acetylenic fatty acids. J. Biol. Chem. 263:18640–18649. [PUBMED], [INFOTRIEVE]
  • Calabrese, J. R., Markovitz, P. J., Kimmel, S. E., Wagner, S. C. (1992). Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J. Clin. Psychopharmacol. 12:S53–S56.
  • Calder, I. C., Hart, S. J., Healey, K., Ham, K. N. (1981). N-hydroxyacetaminophen: a postulated toxic metabolite of acetaminophen. J. Med. Chem. 24:988–993. [PUBMED], [INFOTRIEVE]
  • Calleman, C. J., Ehrenberg, L., Jansson, B., Osterman-Golkar, S., Segerback, D., Svensson, K., Wachtmeister, C. A. (1978). Monitoring and risk assessment by means of alkyl groups in hemoglobin in persons occupationally exposed to ethylene oxide. J. Environ. Pathol. Toxicol. 2:427–442. [PUBMED], [INFOTRIEVE]
  • Cameron, H. A., Ramsay, L. E. (1984). The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br. Med. J. (Clin. Res. Ed.) 289:410–412.
  • Campiani, G., Ramunno, A., Maga, G., Nacci, V., Fattorusso, C., Catalanotti, B., Morelli, E., Novellino, E. (2002). Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr. Pharm. Des. 8:615–657. [PUBMED], [INFOTRIEVE], [CSA]
  • Camu, F., Vanlersberghe, C. (2002). Pharmacology of systemic analgesics. Best Pract. Res. Clin. Anaesthesiol. 16:475–488. [PUBMED], [INFOTRIEVE]
  • Canal, P., Gay, C., Dezeuze, A., Douillard, J. Y., Bugat, R., Brunet, R., Adenis, A., Herait, P., Lokiec, F., Mathieu-Boue, A. (1996). Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 14:2688–2695. [PUBMED], [INFOTRIEVE]
  • Cannell, G. R., Vesey, D. A., Dickinson, R. G. (2001). Inhibition of proliferation of HT-29 colon adenocarcinoma cells by carboxylate NSAIDs and their acyl glucuronides. Life Sci. 70:37–48. [PUBMED], [INFOTRIEVE]
  • Cannell, G. R., Bailey, M. J., Dickinson, R. G. (2002). Inhibition of tubulin assembly and covalent binding to microtubular protein by valproic acid glucuronide in vitro. Life Sci. 71:2633–2643. [PUBMED], [INFOTRIEVE]
  • Carriere, V., Berthou, F., Baird, S., Belloc, C., Beaune, P., de Waziers, I. (1996). Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 6:203–211. [PUBMED], [INFOTRIEVE], [CSA]
  • Cashman, J. R. (2002). Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism. Pharmacogenomics 3:325–339. [PUBMED], [INFOTRIEVE], [CSA]
  • Cashman, J. R., Proudfoot, J., Pate, D. W., Hogberg, T. (1988). Stereoselective N-oxygenation of zimeldine and homozimeldine by the flavin-containing monooxygenase. Drug Metab. Dispos. 16:616–622. [PUBMED], [INFOTRIEVE], [CSA]
  • Cashman, J. R., Yang, Z. C., Hogberg, T. (1990). Oxidation of N-hydroxynorzimeldine to a stable nitrone by hepatic monooxygenases. Chem. Res. Toxicol. 3:428–432. [PUBMED], [INFOTRIEVE]
  • Casini, A., Scozzafava, A., Supuran, C. T. (2002). Cysteine-modifying agents: a possible approach for effective anticancer and antiviral drugs. Environ. Health Perspect. 110:801–806. [PUBMED], [INFOTRIEVE], [CSA]
  • Castagnoli, N. Jr., Rimoldi, J. M., Bloomquist, J., Castagnoli, K. P. (1997). Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes. Chem. Res. Toxicol. 10:924–940., [PUBMED], [INFOTRIEVE], [CSA]
  • Castillo, M., Smith, P. C. (1995). Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Drug Metab. Dispos. 23:566–572. [PUBMED], [INFOTRIEVE], [CSA]
  • Castillo, M., Lam, Y. W.F., Dooley, M. A., Stahl, E., Smith, P. C. (1995). Disposition and covalent binding of ibuprofen and its acyl glucuronide in the elderly. Clin. Pharmacol. Ther. 57:636–644. [PUBMED], [INFOTRIEVE], [CSA]
  • Castot, A., Larrey, D. (1992). Hepatitis observed during a treatment with a drug or tea containing wild germander. Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance. Gastroenterol. Clin. Biol. 16:916–922. [PUBMED], [INFOTRIEVE]
  • Chan, S. (2002). A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Semin. Oncol. 29:129–133. [PUBMED], [INFOTRIEVE]
  • Chan, W. K., Delucchi, A. B. (2000). Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci. 67:3103–3112. [PUBMED], [INFOTRIEVE]
  • Chan, W. K., Nguyen, L. T., Miller, V. P., Harris, R. Z. (1998). Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci. 62:135–142.
  • Chen, Y. Z., Ung, C. Y. (2001). Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. J. Mol. Graph. Model 20:199–218. [PUBMED], [INFOTRIEVE], [CSA]
  • Chen, X. G., Liu, H. Y., Lei, X. H., Fu, Z. D., Li, Y., Tao, L. H., Han, R. (1998). Cancer chemopreventive and therapeutic activities of red ginseng. J. Ethnopharmacol. 60:71–78. [CSA]
  • Chen, W., Shockcor, J. P., Tonge, R., Hunter, A., Gartner, C., Nelson, S. D. (1999). Protein and nonprotein cysteinyl thiol modification by N-acetyl-p-benzoquinone imine via a novel ipso adduct. Biochemistry 38:8159–8166. [PUBMED], [INFOTRIEVE]
  • Chen, L. J., Lebetkin, E. H., Burka, L. T. (2001). Metabolism of (R)-(+)-pulegone in F344 rats. Drug Metab. Dispos. 29:1567–1577. [PUBMED], [INFOTRIEVE], [CSA]
  • Chen, G., Yin, S., Maiti, S., Shao, X. (2002a). 4-Hydroxytamoxifen sulfation metabolism. J. Biochem. Mol. Toxicol. 16:279–285. [PUBMED], [INFOTRIEVE], [CSA]
  • Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., Tang, W. (2002b). Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15:907–914. [PUBMED], [INFOTRIEVE], [CSA]
  • Cheng, C. L., Smith, D. E., Carver, P. L., Cox, S. R., Watkins, P. B., Blake, D. S., Kauffman, C. A., Meyer, K. M., Amidon, G. L., Stetson, P. L. (1997). Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin. Pharmacol. Ther. 61:531–543. [PUBMED], [INFOTRIEVE], [CSA]
  • Chiba, M., Nishime, J. A., Lin, J. H. (1995). Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J. Pharmacol. Exp. Ther. 275:1527–1534. [PUBMED], [INFOTRIEVE], [CSA]
  • Chiba, M., Hensleigh, M., Nishime, J. A., Balani, S. K., Lin, J. H. (1996). Role of cytochrome P450 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:307–314. [PUBMED], [INFOTRIEVE], [CSA]
  • Chiou, Y., Tomer, K. B., Smith, P. C. (1999). Effect of nonenzymatic glycation of albumin and superoxide dismutase by glucuronic acid and suprofen acyl glucuronide on their functions in vitro. Chem.-Biol. Interact. 121:141–159. [PUBMED], [INFOTRIEVE], [CSA]
  • Chitturi, S., Farrell, G. C. (2000). Herbal hepatotoxicity: an expanding but poorly defined problem. J. Gastroenterol. Hepatol. 15:1093–1099. [PUBMED], [INFOTRIEVE], [CSA]
  • Chitturi, S., George, J. (2002). Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin. Liver Dis. 22:169–183. [PUBMED], [INFOTRIEVE], [CSA]
  • Chitwood, K. K., Abdul-Haqq, A. J., Heim-Duthoy, K. L. (1993). Cyclosporine-amiodarone interaction. Ann. Pharmacother. 27:569–571., [PUBMED], [INFOTRIEVE]
  • Choquet-Kastylevsky, G., Vial, T., Descotes, J. (2002). Allergic adverse reactions to sulfonamides. Curr. Allergy Asthma Rep. 2:16–25. [PUBMED], [INFOTRIEVE], [CSA]
  • Chouinard, G., Lefko-Singh, K., Teboul, E. (1999). Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell. Mol. Neurobiol. 19:533–552. [PUBMED], [INFOTRIEVE], [CSA]
  • Chow, T., Hiroi, T., Imaoka, S., Chiba, K., Funae, Y. (1999). Isoform-selective metabolism of mianserin by cytochrome P-450 2D. Drug Metab. Dispos. 27:1200–1204. [PUBMED], [INFOTRIEVE], [CSA]
  • Christ, D. D., Kenna, J. G., Kammerer, W., Satoh, H., Pohl, L. R. (1988a). Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 69:833–888. [PUBMED], [INFOTRIEVE]
  • Christ, D. D., Satoh, H., Kenna, J. G., Pohl, L. R. (1988b). Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab. Dispos. 16:135–140. [PUBMED], [INFOTRIEVE]
  • Christians, U., Sewing, K. F. (1995). Alternative cyclosporine metabolic pathways and toxicity. Clin. Biochem. 28:547–559. [PUBMED], [INFOTRIEVE]
  • Christians, U., Braun, F., Kosian, N., Schmidt, M., Schiebel, M., Ernst, L., Kruse, C., Winkler, M., Holze, I., Linck, A., Sewing, K. F. R. (1991). High performance liquid chromatography/mass spectrometry of FK-506 and its metabolites in blood, bile and urine of liver-grafted patients. Transplant. Proc. 23:2741–2744. [PUBMED], [INFOTRIEVE]
  • Christie, G., Breckenridge, A. M., Park, B. K. (1989). Drug-protein conjugates—XVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. Biochem. Pharmacol. 38:1451–1458. [PUBMED], [INFOTRIEVE], [CSA]
  • Chu, X. Y., Kato, Y., Niinuma, K., Sudo, K. I., Hakusui, H., Sugiyama, Y. (1997). Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther. 281:304–314. [PUBMED], [INFOTRIEVE], [CSA]
  • Chu, X. Y., Kato, Y., Ueda, K., Susuki, H., Niinuma, K., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E., Sugiyama, Y. (1998). Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 58:5137–5143. [PUBMED], [INFOTRIEVE]
  • Chu, X. Y., Suzuki, H., Ueda, K., Kato, Y., Akiyama, S., Sugiyama, Y. (1999). Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J. Pharmacol. Exp. Ther. 288:735–741. [PUBMED], [INFOTRIEVE], [CSA]
  • Clarke, C. E., Guttman, M. (2002). Dopamine agonist monotherapy in Parkinson's disease. Lancet 360:1767–1769. [PUBMED], [INFOTRIEVE]
  • Clarke, J. B., Maggs, J. L., Kitteringham, N. R., Park, B. K. (1990). Immunogenicity of amodiaquine in the rat. Int. Arch. Allergy Appl. Immunol. 91:335–342. [PUBMED], [INFOTRIEVE], [CSA]
  • Clarke, J. B., Thomas, C., Chen, M., Hastings, K. L., Gandolfi, A. J. (1995). Halogenated anesthetics form liver adducts and antigens that cross-react with halothane-induced antibodies. Int. Arch. Allergy Immunol. 108:24–32. [PUBMED], [INFOTRIEVE], [CSA]
  • Clay, P. G. (2002). The abacavir hypersensitivity reaction: a review. Clin. Ther. 24:1502–1514. [PUBMED], [INFOTRIEVE], [CSA]
  • Clemett, D., Spencer, C. M. (2000). Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 60:379–411. [PUBMED], [INFOTRIEVE]
  • Clemons, M., Danson, S., Howell, A. (2002). Tamoxifen (“Nolvadex”): a review. Cancer Treat. Rev. 28:165–180. [PUBMED], [INFOTRIEVE], [CSA]
  • Clink, H. M. (1983). Mianserin and blood dyscrasias. Br. J. Clin. Pharmacol. 15:S291–S293.
  • Clissold, S. P. (1986). Paracetamol and phenacetin. Drugs 32:46–59. [PUBMED], [INFOTRIEVE]
  • Cohen, S. M. (2002). Current immunosuppression in liver transplantation. Am. J. Ther. 9:119–125. [PUBMED], [INFOTRIEVE], [CSA]
  • Cohen, S. D., Khairallah, E. A. (1997). Selective protein arylation and acetaminophen-induced hepatotoxicity. Drug Metab. Rev. 29:59–77. [PUBMED], [INFOTRIEVE], [CSA]
  • Cohen, S. D., Pumford, N. R., Khairallah, E. A., Boekelheide, K., Pohl, L. R., Amouzadeh, H. R., Hinson, J. A. (1997). Selective protein covalent binding and target organ toxicity. Toxicol. Appl. Pharmacol. 143:1–12., [PUBMED], [INFOTRIEVE], [CSA]
  • Coleman, M. D. (2001). Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology 162:53–60. [PUBMED], [INFOTRIEVE], [CSA]
  • Coleman, M. D., Tingle, M. D. (1992). Use of a metabolic inhibitor to reduce dapsone-dependent haematological toxicity. Drug Dev. Res. 25:1–16. [CSA]
  • Coleman, M. D., Breckenridge, A. M., Park, B. K. (1989). Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br. J. Clin. Pharmacol. 28:389–395. [PUBMED], [INFOTRIEVE]
  • Coles, B., Wilson, I., Wardman, P., Hinson, J. A., Nelson, S. D., Ketterer, B. (1988). The spontaneous and enzymatic reaction of N-acetyl-p-benzoquinonimine with glutathione: a stopped-flow kinetic study. Arch. Biochem. Biophys. 264:253–260. [PUBMED], [INFOTRIEVE], [CSA]
  • Conaway, C. C., Jiao, D., Chung, F.-L. (1996). Inhibition of rat liver cytochrome P450 isozymes by isothiocyanates and their conjugates: a structure activity relationship study. Carcinogenesis 17:2423–2427. [PUBMED], [INFOTRIEVE]
  • Correia, J. J., Lobert, S. (2001). Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr. Pharm. Des. 7:1213–1228. [PUBMED], [INFOTRIEVE], [CSA]
  • Cosyns, J. P. (2003). Aristolochic acid and ‘Chinese herbs nephropathy’: a review of the evidence to date. Drug Safety 26:33–48. [PUBMED], [INFOTRIEVE], [CSA]
  • Couch, D. B. (1996). Carcinogenesis: basic principles. Drug Chem. Toxicol. 19:133–148. [PUBMED], [INFOTRIEVE], [CSA]
  • Court, M. H., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Patten, C. J., Miners, J. O., Mackenzie, P. I. (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J. Pharmacol. Exp. Ther. 299:998–1006. [PUBMED], [INFOTRIEVE], [CSA]
  • Coyle, J. D., Boudoulas, H., Mackichan, J. J., Lima, J. J. (1985). Concentration-dependent clearance of procainamide in normal subjects. Biopharm. Drug Dispos. 6:159–165. [PUBMED], [INFOTRIEVE]
  • Crewe, H. K., Ellis, S. W., Lennard, M. S., Tucker, G. T. (1997). Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53:171–178. [PUBMED], [INFOTRIEVE], [CSA]
  • Crewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S., Gillam, E. M. (2002). Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30:869–874. [PUBMED], [INFOTRIEVE], [CSA]
  • Cribb, A. E., Spielberg, S. P. (1990). Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab. Dispos. 18:784–787. [PUBMED], [INFOTRIEVE]
  • Cribb, A. E., Miller, M., Tesoro, A., Spielberg, S. P. (1990). Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol. Pharmacol. 38:744–751. [PUBMED], [INFOTRIEVE], [CSA]
  • Cribb, A. E., Spielberg, S. P., Griffin, G. P. (1995). N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Dispos. 23:406–414. [PUBMED], [INFOTRIEVE], [CSA]
  • Cribb, A. E., Nuss, C. E., Alberts, D. W., Lamphere, D. B., Grant, D. M., Grossman, S. J., Spielberg, S. P. (1996). Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem. Res. Toxicol. 9:500–507. [PUBMED], [INFOTRIEVE], [CSA]
  • Cunningham, R. F., Israili, Z. H., Dayton, P. G. (1981). Clinical pharmacokinetics of probenecid. Clin. Pharmacokinet. 6:135–151. [PUBMED], [INFOTRIEVE]
  • Cunningham, M. L., Pippin, L. L., Anderson, N. L., Wenk, M. L. (1995). The hepatocarcinogen methapyrilene but not the analog pyrilamine induces sustained hepatocellular replication and protein alterations in F344 rats in a 13-week feed study. Toxicol. Appl. Pharmacol. 131:216–223. [PUBMED], [INFOTRIEVE], [CSA]
  • Curson, D. A., Hale, A. S. (1979). Mianserin and agranulocytosis. Br. Med. J. 1:378–379. [PUBMED], [INFOTRIEVE]
  • Cuttle, L., Munns, A. J., Hogg, N. A., Scott, J. R., Hooper, W. D., Dickinson, R. G., Gillam, E. M. (2000). Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2Cforms in secondary metabolism and drug-protein adduct formation. Drug Metab. Dispos. 28:945–950. [PUBMED], [INFOTRIEVE], [CSA]
  • Dahl, M. L., Voortman, G., Alm, C., Elwin, C. E., Delbressine, L., Vos, R., Bogaards, J. J. P., Bertilsson, L., Moonen, M. E. G., Kaspersen, F. M. (1997). In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin. Drug Investig. 13:37–46.
  • Dain, J. G., Jaffe, J. M. (1988). Effect of diet and gavage on the absorption and metabolism of fluperlapine in the rat. Drug Metab. Dispos. 16:238–242. [PUBMED], [INFOTRIEVE]
  • Daluge, S. M., Good, S. S., Faletto, M. B., Miller, W. H., St. Clair, M. H., Boone, L. R., Tisdale, M., Parry, N. R., Reardon, J. E., Dornsife, R. E., Averett, D. R., Krenitsky, T. A. (1997). 159U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082–1093. [PUBMED], [INFOTRIEVE], [CSA]
  • D'Amato, R. J., Loughnan, M. S., Flynn, E., Gague, M. (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 91:4082–4085. [PUBMED], [INFOTRIEVE], [CSA]
  • Dansette, P. M., Amar, C., Smith, C., Pons, C., Mansuy, D. (1990). Oxidative activation of the thiophene ring by hepatic enzymes. Hydroxylation and formation of electrophilic metabolites during metabolism of tienilic acid and its isomer by rat liver microsomes. Biochem. Pharmacol. 39:911–918. [PUBMED], [INFOTRIEVE], [CSA]
  • Dansette, P. M., Amar, C., Valadon, P., Beaune, P., Mansuy, D. (1991). Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes: catalysis by a cytochrome P450 2C different from that responsible for mephenytoin hydroxylation. Biochem. Pharmacol. 41:553–560. [PUBMED], [INFOTRIEVE], [CSA]
  • Dao, T., Peytier, A., Galateau, F., Valla, A. (1993). Chronic cirrhogenic hepatitis induced by germander. Gastroenterol. Clin. Biol. 17:609–610. [PUBMED], [INFOTRIEVE], [CSA]
  • Darke, P. L., Nutt, R. F., Brady, S. F., Garsky, V. M., Ciccarone, T. M., Leu, C.-T., Lumma, P. K., Freidinger, R. M., Veber, D., Sigal, I. S. (1988). HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem. Biophys. Res. Commun. 156:297–303. [PUBMED], [INFOTRIEVE], [CSA]
  • Davila, J. C., Pumford, N. R., Martin, B. M., Thomassen, D., Martin, J. L. (1991). A trifluroacetylated 82 kDa stress protein appears to be a neoantigen associated with halothane hepatitis. Toxicologist 11:268.
  • Davis, R., Peters, D. H., McTavish, D. (1994). Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47:332–372. [PUBMED], [INFOTRIEVE]
  • Davis, W., Venitt, S., Phillips, D. H. (1998). The metabolic activation of tamoxifen and hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis 19:861–866. [PUBMED], [INFOTRIEVE]
  • De Berardinis, V., Moulis, C., Maurice, M., Beaune, P., Pessayre, D., Pompon, D., Loeper, J. (2000). Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol. Pharmacol. 58:542–551. [PUBMED], [INFOTRIEVE], [CSA]
  • De Gowin, R. L., Eppes, R. B., Powell, R. D., Carson, P. E. (1966). The haemolytic effects of diaphenylsulphone (DDS) in normal subjects and in those with glucose 6-phosphate dehydrogenase deficiency. Bull. W.H.O. 35:165–179.
  • De Sousa, M., Pirmohamed, M., Kitteringham, N. R., Woolf, T., Park, B. K. (1998). No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease. Pharmacogenetics 8:353–355. [PUBMED], [INFOTRIEVE], [CSA]
  • de Villiers, E. M. (2003). Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int. J. Cancer 103:705–708. [PUBMED], [INFOTRIEVE]
  • de Vries, J. (1981). Hepatotoxic metabolic activation of paracetamol and its derivatives phenacetin and benorilate: oxygenation or electron transfer? Biochem. Pharmacol. 30:399–402. [PUBMED], [INFOTRIEVE], [CSA]
  • Decker, C. J., Laitinen, L. M., Bridson, G. W., Raybuck, S. A., Tung, R. D., Chaturvedi, P. R. (1998). Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. Sci. 87:803–807., [PUBMED], [INFOTRIEVE]
  • Dehal, S. S., Kupfer, D. (1996). Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res. 56:1283–1290. [PUBMED], [INFOTRIEVE]
  • Dehal, S. S., Kupfer, D. (1999). Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab. Dispos. 27:681–688. [PUBMED], [INFOTRIEVE], [CSA]
  • Dekant, W. (2001). Chemical-induced nephrotoxicity mediated by glutathione S-conjugate formation. Toxicol. Lett. 124:21–36. [PUBMED], [INFOTRIEVE], [CSA]
  • Delaforge, M., Jaouen, M., Mansuy, D. (1983). Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite-complexes: a structure-activity relationship. Biochem. Pharmacol. 32:2309–2318. [PUBMED], [INFOTRIEVE]
  • Delbressine, L. P. C., Moonen, M. E. G., Kaspersen, F. M., Wagenaars, G. N., Jacobs, P. L., Timmer, C. J., Paanakker, J. E., van Hal, H. J. M., Voortman, G. (1998). Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin. Drug Investig. 15:45–55.
  • Deleu, D., Northway, M. G., Hanssens, Y. (2002). Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacokinet. 41:261–309. [PUBMED], [INFOTRIEVE], [CSA]
  • Deng, J. F. (2002). Clinical and laboratory investigations in herbal poisonings. Toxicology 27:571–576.
  • Desta, Z., Zhao, X., Shin, J. G., Flockhart, D. A. (2002). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41:913–958. [PUBMED], [INFOTRIEVE], [CSA]
  • Dexter, S. L. (1984). Zimeldine induced neuropathies. Human Toxicol. 3:141–143.
  • Dhillon, S., Richens, A. (1982). Valproic acid and diazepam interaction in vivo. Br. J. Clin. Pharmacol. 13:553–560. [PUBMED], [INFOTRIEVE]
  • Dickinson, D. A., Forman, H. J. (2002). Glutathione in defense and signaling: lessons from a small thiol. Ann. N.Y. Acad. Sci. 973:488–504. [PUBMED], [INFOTRIEVE]
  • Dickinson, R. G., King, A. R. (1993). Studies on the reactivity of acyl glucuronides. 5. Glucuronide-derived covalent binding of diflunisal to bladder tissue of rats and its modulation by urinary pH and beta-glucuronidase. Biochem. Pharmacol. 46:1175–1182. [PUBMED], [INFOTRIEVE], [CSA]
  • Dickinson, R. G., Baker, P. V., King, A. R. (1994). Studies on the reactivity of acyl glucuronides. 7. Salicylic acyl glucuronide reactivity in vitro and covalent binding of salicylic acid to plasma protein of humans taking aspirin. Biochem. Pharmacol. 47:469–476. [PUBMED], [INFOTRIEVE], [CSA]
  • Ding, X., Kaminsky, L. S. (2003). Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43:149–173. [PUBMED], [INFOTRIEVE], [CSA]
  • Ding, A., Ojingwa, J. C., McDonagh, A. F., Burlingame, A. L., Benet, L. Z. (1993). Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc. Natl. Acad. Sci. U. S. A. 90:3797–3801. [PUBMED], [INFOTRIEVE], [CSA]
  • Ding, A., Zia-Amirhosseini, P., McDonagh, A. F., Burlingame, A. L., Benet, L. Z. (1995). Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab. Dispos. 23:369–376. [PUBMED], [INFOTRIEVE], [CSA]
  • Donahue, S. R., Flockhart, D. A., Abernethy, D. R., Ko, J. W. (1997). Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin. Pharmacol. Ther. 62:572–577. [PUBMED], [INFOTRIEVE], [CSA]
  • Dorner, A. J., Wasley, L. C., Raney, P., Haugejorden, S., Green, M., Kaufman, R. J. (1990). The stress response in Chinese hamster ovary cells: regulation of ERp72 and protein disulfide isomerase expression and secretion. J. Biol. Chem. 265:22029–22034. [PUBMED], [INFOTRIEVE]
  • Dourakis, S. P., Papanikolaou, I. S., Tzemanakis, E. N., Hadziyannis, S. J. (2002). Acute hepatitisassociated with herb (Teucrium capitatum L.) administration. Eur. J. Gastroenterol. Hepatol. 14:693–695. [PUBMED], [INFOTRIEVE], [CSA]
  • Dresser, G. K., Spence, J. D., Bailey, D. G. (2000). Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38:41–57. [PUBMED], [INFOTRIEVE], [CSA]
  • Drukarch, B., van Muiswinkel, F. L. (2000). Drug treatment of Parkinson's disease. Time for phase II. Biochem. Pharmacol. 59:1023–1031. [PUBMED], [INFOTRIEVE], [CSA]
  • du Souich, P., Erill, S. (1977). Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease. Clin. Pharmacol. Ther. 22:588–595. [PUBMED], [INFOTRIEVE]
  • du Souich, P., Verges, J., Erill, S. (1993). Plasma protein binding and pharmacological response. Clin. Pharmacokinet. 24:435–440. [PUBMED], [INFOTRIEVE]
  • Ducharme, M. P., Warbasse, L. H., Edwards, D. J. (1995). Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther. 57:485–491. [PUBMED], [INFOTRIEVE], [CSA]
  • Duggin, G. G. (1996). Combination analgesic-induced kidney disease: the Australian experience. Am. J. Kidney Dis. 28:S39–S47. [PUBMED], [INFOTRIEVE], [CSA]
  • Dumontet, C., Sikic, B. I. (1999). Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17:1061–1070. [PUBMED], [INFOTRIEVE]
  • Dundaroz, R., Turkbay, T., Surer, I., Gok, F., Denli, M., Baltaci, V. (2002). DNA damage in children treated with imipramine for primary nocturnal enuresis. Pediatr. Int. 44:617–621. [PUBMED], [INFOTRIEVE], [CSA]
  • Durrant, S., Read, D. (1982). Fatal aplastic anaemia associated with mianserin. Br. Med. J. (Clin. Res. Ed.). 285:437.
  • Dwivedy, I., Devanesan, P., Cremonesi, P., Rogan, E., Cavalieri, E. (1992). Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. Chem. Res. Toxicol. 5:828–833. [PUBMED], [INFOTRIEVE]
  • Dybing, E., Nelson, S. D., Mitchell, J. R., Sasame, H. A., Gillette, J. R. (1976). Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis. Mol. Pharmacol.Nov. 12 (6):911–920. [PUBMED], [INFOTRIEVE]
  • Ebner, T., Heinzel, G., Prox, A., Beschke, K., Wachsmuth, H. (1999). Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab. Dispos. 27:1143–1149. [PUBMED], [INFOTRIEVE], [CSA]
  • Eddington, N. D., Young, D. (1990). Biliary excretion of reduced haloperidol glucuronide. Psychopharmacology (Berl.). 100:46–48.
  • Edelson, R., Berger, C., Gasparro, F., Jegasothy, B., Heald, P., Wintroub, B., Vonderheid, E., Knobler, R., Wolff, K., Plewig, G., McKiernan, G., Christiansen, L., Oster, M., Honigsman, H., Wilford, H., Kokoschka, E., Rehle, T., Perez, M. D., Stingl, G., Laroche, L. (1987). Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N. Engl. J. Med. 316:297–303. [PUBMED], [INFOTRIEVE]
  • Eisen, T. (2002). Thalidomide in solid malignancies. J. Clin. Oncol. 20:2607–2609. [PUBMED], [INFOTRIEVE]
  • Eliasson, E., Kenna, J. G. (1996). Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol. Pharmacol. 50:573–582. [PUBMED], [INFOTRIEVE], [CSA]
  • Eliasson, E., Gardner, I., Hume-Smith, H., de Waziers, I., Beaune, P., Kenna, J. G. (1998). Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis. Chem.-Biol. Interact. 116:123–141. [PUBMED], [INFOTRIEVE], [CSA]
  • Eling, T. E., Mason, R. P., Sivarajah, K. (1985). The formation of aminopyrine cation radical by the peroxidase activity of prostaglandin H synthase and subsequent reactions of the radical. J. Biol. Chem. 260:1601–1607. [PUBMED], [INFOTRIEVE]
  • Emdadul Haque, M., Asanuma, M., Higashi, Y., Miyazaki, I., Tanaka, K., Ogawa, N. (2003). Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim. Biophys. Acta. 1619:39–52. [PUBMED], [INFOTRIEVE]
  • Endresen, L., Bakka, A., Rugstad, H. E. (1983). Increased resistance to chlorambucil in cultured cells with a high concentration of cytoplasmic metallothionein. Cancer Res. 43:2918–2926., [PUBMED], [INFOTRIEVE]
  • Epe, B., Hegler, J., Metzler, M. (1987). Site-specific covalent binding of stilbene-type and steroidal estrogens to tubulin following metabolic activation in vitro. Carcinogenesis 8:1271–1275. [PUBMED], [INFOTRIEVE]
  • Epe, B., Harttig, U., Stopper, H., Metzler, M. (1990). Covalent binding of reactive estrogen metabolites to microtubular protein as a possible mechanism of aneuploidy induction and neoplastic cell transformation. Environ. Health Perspect. 88:123–127. [PUBMED], [INFOTRIEVE], [CSA]
  • Eriksson, T., Bjorkman, S., Roth, B., Fyge, A., Hoglund, P. (1995). Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7:44–52. [PUBMED], [INFOTRIEVE], [CSA]
  • Eriksson, T., Bjorkman, S., Roth, B., Bjork, H., Hoglund, P. (1998). Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man. J. Pharm. Pharmacol. 50:1409–1416. [PUBMED], [INFOTRIEVE]
  • Ernst, E. (2000). Adverse effects of herbal drugs in dermatology. Br. J. Dermatol. 143:923–929. [PUBMED], [INFOTRIEVE]
  • Ernst, E., Pittler, M. H. (2002). Herbal medicine. Med. Clin. North Am. 86:149–161. [PUBMED], [INFOTRIEVE], [CSA]
  • Escudier, B., Lassau, N., Couanet, D., Angevin, E., Mesrati, F., Leborgne, S., Garofano, A., Leboulaire, C., Dupouy, N., Laplanche, A. (2002). Phase II trial of thalidomide in renal-cell carcinoma. Ann. Oncol. 13:1029–1035. [PUBMED], [INFOTRIEVE]
  • Evans, W. E., Johnson, J. A. (2001). Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2:9–39. [PUBMED], [INFOTRIEVE], [CSA]
  • Evans, G. H., Shand, D. G. (1973). Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin. Pharmacol. Ther. 14:487–493. [PUBMED], [INFOTRIEVE]
  • Eyles, D. W., McGrath, J. J., Pond, S. M. (1996). Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacologia 125:214–219. [CSA]
  • Eyles, D. W., Avent, K. M., Stedman, T. J., Pond, S. M. (1997). Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci. 60:529–534. [PUBMED], [INFOTRIEVE]
  • Fabre, G., Julian, B., Saint-Aubert, B., Joyeux, H., Berger, Y. (1993). Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab. Dispos. 21:978–985. [PUBMED], [INFOTRIEVE], [CSA]
  • Faed, E. M. (1984). Properties of acyl glucuronide: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev. 15:1213–1249. [PUBMED], [INFOTRIEVE]
  • Fagius, J., Osterman, P. O., Siden, A., Wiholm, B. E. (1985). Guillain-Barre syndrome following zimeldine treatment. J. Neurol. Neurosurg. Psychiatry. 48:65–69. [PUBMED], [INFOTRIEVE]
  • Faigle, J. W., Keverly, H., Reiss, W., Schmid, K. (1962). The metabolic fate of thalidomide. Experientia 18:389–432.
  • Fan, P. W., Bolton, J. L. (2001). Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA. Drug Metab. Dispos. 29:891–896. [PUBMED], [INFOTRIEVE], [CSA]
  • Fang, J., Gorrod, J. W. (1993). An HPLC system for the analysis of haloperidol and seven of its metabolites in microsomal preparations. J. Chromatogr. 614:267–273. [PUBMED], [INFOTRIEVE]
  • Fang, J., Baker, G. B., Coutts, R. T. (1966). Determination of 4-(4-chlorophenyl)-4-hydroxypiperidine, a metabolite of haloperidol, by gas chromatography with electron-capture detection. J. Chromatogr., Biomed. Appl. 682:283–288.
  • Fang, J., Baker, G. B., Silverstone, P. H., Coutts, R. T. (1997). Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell. Mol. Neurobiol. 17:227–233. [PUBMED], [INFOTRIEVE], [CSA]
  • Fang, J., McKay, G., Song, J., Remillrd, A., Li, X., Midha, K. (2001). In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab. Dispos. 29:1638–1643. [PUBMED], [INFOTRIEVE], [CSA]
  • Fau, D., Lekehal, M., Farrell, G., Moreau, A., Moulis, C., Feldmann, G., Haouzi, D., Pessayre, D. (1997). Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology 113:1334–1346. [PUBMED], [INFOTRIEVE], [CSA]
  • Fava, M., Dunner, D. L., Greist, J. H., Preskorn, S. H., Trivedi, M. H., Zajecka, J., Cohen, M. (2001). Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J. Clin. Psychiatry. 62:413–420., [PUBMED], [INFOTRIEVE]
  • Fehr, C., Grunder, G., Hiemke, C., Dahmen, N. (2000). Increase in serum clomipramine concentrations caused by valproate. J. Clin. Psychopharmacol. 20:493–494. [PUBMED], [INFOTRIEVE], [CSA]
  • Feierman, D. E., Melnikov, Z. (1997). Cytochrome P-4502E1-dependent formation of trifluoroacetyl adducts from halothane by transduced HepG2 cells. Alcohol Clin. Exp. Res. 21:1606–1611. [PUBMED], [INFOTRIEVE], [CSA]
  • Felson, D. T., Zhang, Y., Hannan, M., Kiel, D. P., Wilson, P. W. F., Anderson, J. J. (1993). The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329:1141–1146. [PUBMED], [INFOTRIEVE]
  • Ferrari, P., Sansonnens, A., Dick, B., Frey, F. J. (2001). In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice. Hypertension 38:1330–1336. [PUBMED], [INFOTRIEVE]
  • Fichtenbaum, C. J., Gerber, J. G. (2002). Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet. 41:1195–1211. [PUBMED], [INFOTRIEVE], [CSA]
  • Figg, W. D., Dahut, W., Duray, P., Hamilton, M., Tompkins, A., Steinberg, S. M., Jones, E., Premkumar, A., Linehan, W. M., Floeter, M. K., Chen, C. C., Dixon, S., Kohler, D. R., Kruger, E. A., Gubish, E., Pluda, J. M., Reed, E. (2001). A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 7:1888–1893. [PUBMED], [INFOTRIEVE], [CSA]
  • Fischer, V., Wiebel, F. J. (1990). Metabolism of fluperlapine by cytochrome P450-dependent and flavin-dependent monooxygenases in continuous cultures of rat and human cells. Biochem. Pharmacol. 39:1327–1333. [PUBMED], [INFOTRIEVE]
  • Fischer, V., Haar, J. A., Greiner, L., Lloyd, R. V., Mason, R. P. (1991). Possible role of free radical formation in clozapine (Clozaril)-induced agranulocytosis. Mol. Pharmacol. 40:846–853. [PUBMED], [INFOTRIEVE], [CSA]
  • Fischer, V., Vogels, B., Maurer, G., Tynes, R. E. (1992). The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J. Pharmacol. Exp. Ther. 260:1355–1360. [PUBMED], [INFOTRIEVE], [CSA]
  • Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., Cronin, W. M. (1994). Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86:527–537. [PUBMED], [INFOTRIEVE]
  • Fisher, B., Constantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., Wolmark, N. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1371–1388. [PUBMED], [INFOTRIEVE]
  • Fisher, M. B., Paine, M. F., Strelevitz, T. J., Wrighton, S. A. (2001). The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. 33:273–297. [PUBMED], [INFOTRIEVE], [CSA]
  • Fitzsimmons, M. E., Collins, J. M. (1997). Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P450 3A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25:256–266. [PUBMED], [INFOTRIEVE], [CSA]
  • Forsman, A., Larsson, M. (1978). Metabolism of haloperidol. Curr. Ther. Res. 24:567–568.
  • Fort, D. J., Stover, E. L., Bantle, J. A., Finch, R. A. (2000). Evaluation of the developmental toxicity of thalidomide using frog embryo teratogenesis assay-xenopus (FETAX): biotransformation and detoxification. Teratog. Carcinog. Mutagen. 20:35–47. [PUBMED], [INFOTRIEVE], [CSA]
  • Forte, A. J., Wilson, J. M., Slattery, J. T., Nelson, S. D. (1984). The formation and toxicity of catechol metabolites of acetaminophen in mice. Drug Metab. Dispos. 12:484–491. [PUBMED], [INFOTRIEVE]
  • Foster, R. H., Faulds, D. (1998). Abacavir. Drugs 55:729–736. [PUBMED], [INFOTRIEVE]
  • Foster, B. C., Foster, M. S., Vandenhoek, S., Krantis, A., Budzinski, J. W., Arnason, J. T., Gallicano, K. D., Choudri, S. (2001). An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J. Pharm. Pharm. Sci. 4:176–184., [PUBMED], [INFOTRIEVE], [CSA]
  • Fouin-Fortunet, H., Tinel, M., Descatoire, V., Letteron, P., Larrey, D., Geneve, J., Pessayre, D. (1986). Inactivation of cytochrome P-450 by the drug methoxsalen. J. Pharmacol. Exp. Ther. 236:237–247. [PUBMED], [INFOTRIEVE]
  • Frantzen, F. (1997). Chromatographic and electrophoretic methods for modified hemoglobins. J. Chromatogr., B, Biomed. Sci. Appl. 699:269–286.
  • Freeman, R. W., Uetrecht, J. P., Woosley, R. L., Oates, J. A., Harbison, R. D. (1981). Covalent binding of procainamide in vitro and in vivo to hepatic protein in mice. Drug Metab. Dispos. 9:188–192. [PUBMED], [INFOTRIEVE]
  • Frisch, J. M. (1973). Clinical experience with adverse reactions to trimethoprimsulfamethoxazole. J. Infect. Dis. 128:607–612. [PUBMED], [INFOTRIEVE]
  • Fujisawa, Y., Sakamoto, M., Matsushita, M., Fujita, T., Nishioka, K. (2000). Glycyrrhizin inhibits the lytic pathway of complement—possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis. Microbiol. Immunol. 44:799–804. [PUBMED], [INFOTRIEVE], [CSA]
  • Fujiwara, T., Yoshioka, S., Yoshida, T., Ushiyama, I., Horikoshi, H. (1998). Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zuker fatty rats. Diabetes 37:1549–1558.
  • Fukutake, M., Yokota, S., Kamamura, H., Iizuka, A., Amagaya, S., Fukuda, K., Komatsu, Y. (1998). Inhibitory effect of Coptidis rhizoma and Scutellariae radix on azoxymethane-induced aberrant crypt foci formation in rat colon. Biol. Pharm. Bull. 21:814–817. [PUBMED], [INFOTRIEVE], [CSA]
  • Fukutake, M., Miura, N., Yamamoto, M., Fukuda, K., Iijima, O., Ishikawa, H., Kubo, M., Okada, M., Komatsu, Y., Sasaki, H., Wakabayashi, K., Ishige, A., Amagaya, S. (2000). Suppressive effect of the herbal medicine Oren-gedoku-to on cyclooxygenase-2 activity and azoxymethane-induced aberrant crypt foci development in rats. Cancer Lett. 157:9–14. [PUBMED], [INFOTRIEVE], [CSA]
  • Fulton, B., Goa, K. L. (1997). Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281–298. [PUBMED], [INFOTRIEVE]
  • Funch-Brentano, C., Becquemont, L., Kroemer, K. H., Kerstin, B., Knebel, N. G., Eichelbaum, M., Jaillon, P. (1994). Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin. Pharmacol. Ther. 55:256–269. [CSA]
  • Furr, B. J. A., Jordan, V. C. (1984). The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25:127–205. [PUBMED], [INFOTRIEVE]
  • Furst, S. M., Uetrecht, J. P. (1993). Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem. Pharmacol. 45:1267–1275. [PUBMED], [INFOTRIEVE]
  • Furst, S. M., Uetrecht, J. P. (1995). The effect of carbamazepine and its reactive metabolite, 9-acridine carboxaldehyde, on immune cell function in vitro. Int. J. Immunopharmacol. 17:445–452. [PUBMED], [INFOTRIEVE], [CSA]
  • Furst, S. M., Sukhai, P., McClelland, R. A., Uetrecht, J. P. (1995). Covalent binding of carbamazepine oxidative metabolites to neutrophils. Drug Metab. Dispos. 23:590–594. [PUBMED], [INFOTRIEVE], [CSA]
  • Furst, S. M., Luedke, D., Gandolfi, A. J. (1997). Kupffer cells from halothane-exposed guinea pig carry trifluoroacetylated protein adducts. Toxicology 120:119–132. [PUBMED], [INFOTRIEVE], [CSA]
  • Gale, E. A. (2001). Lessons from the glitazones: a story of drug development. Lancet 357:1870–1875. [PUBMED], [INFOTRIEVE]
  • Gall, W. E., Zawada, G., Mojarrabi, B., Tephly, T. R., Green, M. D., Coffman, B. L., Mackenzie, P. I., Radominska-Pandya, A. (1999). Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7. J. Steroid Biochem. Mol. Biol. 70:101–108. [PUBMED], [INFOTRIEVE], [CSA]
  • Gan, L. S., Acebo, A. L., Alworth, W. L. (1984). 1-Ethynylpyrene, a suicide inhibitor of cytochrome P-450 dependent benzo[a]pyrene hydroxylase activity in liver microsomes. Biochemistry 23:3827–3836. [PUBMED], [INFOTRIEVE]
  • Gan, J., Kipper, P. L., Tannenbaum, S. R. (2001). Oxidation of 2,6-dimethylaniline by recombinant human cytochrome P450s and human liver microsomes. Chem. Res. Toxicol. 14:672–677., [PUBMED], [INFOTRIEVE], [CSA]
  • Ganer, A., Knobel, B., Fryd, C. H., Rachmilewitz, E. A. (1981). Dapsone-induced methaemoglobinaemia and hemolysis in the presence of familial hemoglobinopathy hasharon and familial methaemoglobin reductase deficiency. Isr. J. Med. Sci. 17:703–704. [PUBMED], [INFOTRIEVE]
  • Gannett, M., Iversen, P., Lawson, T. (1990). The mechanism of inhibition of cytochrome P450IIE1 by dihydrocapsaicin. Bioorg. Chem. 18:185–198.
  • Gardiner, C. S., Reed, D. J. (1995). Glutathione redox cycle-driven recovery of reduced glutathione after oxidation by tertiary-butyl hydroperoxide in preimplantation mouse embryos. Arch. Biochem. Biophys. 321:6–12. [PUBMED], [INFOTRIEVE], [CSA]
  • Gardiner, C. S., Salmen, J. J., Brandt, C. J., Stover, S. K. (1998). Glutathione is present in reproductive tract secretions and improves development of mouse embryos after chemically induced glutathione depletion. Biol. Reprod. 59:431–436. [PUBMED], [INFOTRIEVE], [CSA]
  • Gardner, I., Leeder, J. S., Chin, T., Zahid, N., Uetrecht, J. P. (1998). A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 53:999–1008. [PUBMED], [INFOTRIEVE], [CSA]
  • Garte, S. J., Trachman, J., Crofts, F., Toniolo, P., Buxbaum, J., Bayo, S., Taioli, E. (1996). Distribution of composite CYP1A1 genotypes in Africans, African–Americans and Caucasians. Hum. Hered. 46:121–127. [PUBMED], [INFOTRIEVE], [CSA]
  • Gemborys, M. W., Mudge, G. H. (1981). Formation and disposition of the minor metabolites of acetaminophen in the hamster. Drug Metab. Dispos. 9:340–351. [PUBMED], [INFOTRIEVE], [CSA]
  • Geneve, J., Degott, C., Letteron, P., Tinel, M., Descatoire, V., Larrey, D., Amouyal, G., Pessayre, D. (1987a). Metabolic activation of the tricyclic antidepressant amineptine—II. Protective role of glutathione against in vitro and in vivo covalent binding. Biochem. Pharmacol. 36:331–337. [PUBMED], [INFOTRIEVE]
  • Geneve, J., Larrey, D., Letteron, P., Descatoire, V., Tinel, M., Amouyal, G., Pessayre, D. (1987b). Metabolic activation of the tricyclic antidepressant amineptine—I. Cytochrome P-450-mediated in vitro covalent binding. Biochem. Pharmacol. 36:323–329. [PUBMED], [INFOTRIEVE], [CSA]
  • Georges, H., Presle, N., Buronfosse, T., Fournel-Gigleux, S., Netter, P., Magdalou, J., Lapicque, F. (2000). In vitro stereoselective degradation of carprofen glucuronide by human serum albumin. Characterization of sites and reactive amino acids. Chirality 12:53–62. [PUBMED], [INFOTRIEVE], [CSA]
  • Gibson, J. E., Becker, B. A. (1968). Teratogenic effects of diphenylhydantoin in Swiss-Webster and A-J mice. Proc. Soc. Exp. Biol. Med. 128:905–909. [PUBMED], [INFOTRIEVE]
  • Gill, J., Heel, R. C., Fitton, A. (1992). Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 43:69–110. [PUBMED], [INFOTRIEVE]
  • Gill, H. J., Tingle, M. D., Park, B. K. (1995). N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br. J. Clin. Pharmacol. 40:531–538. [PUBMED], [INFOTRIEVE], [CSA]
  • Gill, H. J., Hough, S. J., Naisbitt, D. J., Maggs, J. L., Kitteringham, N. R., Pirmohamed, M., Park, B. K. (1997). The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J. Pharmacol. Exp. Ther. 282:795–801. [PUBMED], [INFOTRIEVE], [CSA]
  • Girard, P.-M., Landman, R., Gaudebout, C., Olivares, R., Saimot, A. G., Jelazko, P., Gaudebout, C., Certain, A., Bouõ, F., Bouvet, E., Lecompte, T., Coulaud, J.-P. (1993). Dapsone-pmethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii and toxoplasmosis in HIV infection. N. Engl. J. Med. 328:1514–1520. [PUBMED], [INFOTRIEVE], [CSA]
  • Gisbert, J. P., Gomollon, F., Mate, J., Pajares, J. M. (2002). Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig. Dis. Sci. 47:471–488. [PUBMED], [INFOTRIEVE], [CSA]
  • Glader, B. F., Conrad, M. E. (1973). Haemolysis by diphenylsulfones: comparative effects of DDS and hydroxylamine-DDS. J. Lab. Clin. Med. 81:267–272. [PUBMED], [INFOTRIEVE]
  • Glatt, H. (1997). Sulfation and sulfotransferases. 4. Bioactivation of mutagens via sulfation. FASEB J. 11:314–321. [PUBMED], [INFOTRIEVE], [CSA]
  • Glatt, H. (2000). Sulfotransferases in the bioactivation of xenobiotics. Chem.-Biol. Interact. 129:141–170., [PUBMED], [INFOTRIEVE], [CSA]
  • Glatt, H., Engelke, C. E., Pabel, U., Teubner, W., Jones, A. L., Coughtrie, M. W., Andrae, U., Falany, C. N., Meinl, W. (2000). Sulfotransferase: genetics and role in toxicology. Toxicol. Lett. 112–113:341–348.
  • Glatt, H., Boeing, H., Engelke, C. E., Ma, L., Kuhlow, A., Pabel, U., Pomplun, D., Teubner, W., Meinl, W. (2001). Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat. Res. 482:27–40. [PUBMED], [INFOTRIEVE]
  • Goebel, C., Vogel, C., Wulferink, M., Mittmann, S., Sachs, B., Schraa, S., Abel, J., Degen, G., Uetrecht, J., Gleichmann, E. (1999). Procainamide, a drug causing lupus, induces prostaglandin H synthase-2 and formation of T cell-sensitizing drug metabolites in mouse macrophages. Chem. Res. Toxicol. 12:488–500. [PUBMED], [INFOTRIEVE], [CSA]
  • Good, S. S., Daluge, S. M., Ching, S. V., Ayers, M. M., Mahony, W. B., Falletto, M. B., Domin, B. A., Owens, B. S., Dornsife, R. E., McDowell, J. A., LaFon, S. W., Symonds, W. T. (1995). 1592U89 succinate-preclinical toxicological and disposition studies and preliminary clinical pharmacokinetics. Antivir. Res. 26:A229.
  • Goodman, Z. D. (2002). Drug hepatotoxicity. Clin. Liver Dis. 6:381–397. [PUBMED], [INFOTRIEVE], [CSA]
  • Goodwin, D. C., Grover, T. A., Aust, S. D. (1996). Redox mediation in the peroxidase-catalyzed oxidation of aminopyrine: possible implications for drug–drug interactions. Chem. Res. Toxicol. 9:476–483. [PUBMED], [INFOTRIEVE], [CSA]
  • Goosen, T. C., Kent, U. M., Brand, L., Hollenberg, P. F. (2000). Inactivation of cytochrome P4502B1 by benzyl isothiocyanate, a chemopreventive agent from cruciferous vegetables. Chem. Res. Toxicol. 13:1349–1359. [PUBMED], [INFOTRIEVE], [CSA]
  • Goosen, T. C., Mills, D. E., Hollenberg, P. F. (2001). Effects of benzyl isothiocyanate on rat and human cytochromes P450: identification of metabolites formed by P450 2B1. J. Pharmacol. Exp. Ther. 296:198–206. [PUBMED], [INFOTRIEVE], [CSA]
  • Gopaul, S. V., Farrell, K., Abbott, F. S. (2000). Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab. Dispos. 28:823–832. [PUBMED], [INFOTRIEVE], [CSA]
  • Gordon, G. B., Spielberg, S. P., Blake, D. A., Jet, L. (1981). Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acid. Sci. U. S. A. 78:2545–2548. [CSA]
  • Gordon, W. P., Forte, A. J., McMurtry, R. J., Gal, J., Nelson, S. D. (1982). Hepatotoxicity and pulmonary toxicity of pennyroyal oil and its constituent terpenes in the mouse. Toxicol. Appl. Pharmacol. 65:413–424. [PUBMED], [INFOTRIEVE], [CSA]
  • Gordon, W. P., Huitric, A. C., Seth, C. L., McClanahan, R. H., Nelson, S. D. (1987). The metabolism of the abortifacient terpene, (R)-(+)-pulegone, to a proximate toxin, menthofuran. Drug Metab. Dispos. 15:589–594. [PUBMED], [INFOTRIEVE], [CSA]
  • Gorrod, J. W., Fang, J. (1993). On the metabolism of haloperidol. Xenobiotica 23:495–508. [PUBMED], [INFOTRIEVE]
  • Gottlinger, H. G., Sodroski, J. G., Haseltine, W. A. (1989). Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 86:5781–5785. [PUBMED], [INFOTRIEVE], [CSA]
  • Graham, D. G., Tiffany, S. M., Bell, W. R. Jr., Gutknecht, W. F. (1978). Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14:644–653. [PUBMED], [INFOTRIEVE]
  • Grant, D. M., Hughes, N. C., Janezic, S. A., Goodfellow, G. H., Chen, H. J., Gaedigk, A., Yu, V. L., Grewal, R. (1997). Human acetyltransferase polymorphisms. Mutat. Res. 376:61–70. [PUBMED], [INFOTRIEVE]
  • Greco, A., Ajmone-Cat, M. A., Nicolini, A., Sciulli, M. G., Minghetti, L. (2003). Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase. J. Neurosci. Res. 71:844–852. [PUBMED], [INFOTRIEVE], [CSA]
  • Green, M. D., Bishop, W. P., Tephly, T. R. (1995a). Expressed human UGT1.4 protein catalyzesthe formation of quaternary ammonium-linked glucuronides. Drug Metab. Dispos. 23:299–302. [PUBMED], [INFOTRIEVE], [CSA]
  • Green, V. J., Pirmohamed, M., Kitteringham, N. R., Knapp, M. J., Park, B. K. (1995b). Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. Br. J. Clin. Pharmacol. 39:411–415. [PUBMED], [INFOTRIEVE], [CSA]
  • Greensfelder, L. (2000). Alternative medicine. Herbal product linked to cancer. Science 288:1946. [PUBMED], [INFOTRIEVE]
  • Groth, U., Neumann, H. G. (1972). The relevance of chemico-biological interactions for the toxic and carcinogenic effects of aromatic amines. V. The pharmacokinetics of related aromatic amines in blood. Chem.-Biol. Interact. 4:409–419. [PUBMED], [INFOTRIEVE]
  • Grubb, N., Weil, A., Caldwell, J. (1993). Studies on the in vitro reactivity of clofibryl and fenofibryl glucuronides. Evidence for protein binding via a Schiff's base mechanism. Biochem. Pharmacol. 46:357–364. [PUBMED], [INFOTRIEVE]
  • Grundschober, F. (1979). Literature review of pulegone. Perfum. Flavor. 4:15–17.
  • Gruol, D. J., Zee, M. C., Trotter, J., Bourgeois, S. (1994). Reversal of multidrug resistance by RU486. Cancer Res. 54:3088–3091. [PUBMED], [INFOTRIEVE]
  • Guan, X., Davis, M. R., Tang, C., Jochheim, C. M., Jin, L., Baillie, T. A. (1999). Identification of S-(n-butylcarbamoyl)glutathione, a reactive carbamoylating metabolite of tolbutamide in the rat, and evaluation of its inhibitory effects on glutathione reductase in vitro. Chem. Res. Toxicol. 12:1138–1143. [PUBMED], [INFOTRIEVE], [CSA]
  • Guengerich, F. P. (1990a). Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3:363–371. [PUBMED], [INFOTRIEVE]
  • Guengerich, F. P. (1990b). Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci. 47:1981–1988. [PUBMED], [INFOTRIEVE]
  • Guengerich, F. P. (1993). Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3:363–371.
  • Guengerich, F. P. (2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14:611–650. [PUBMED], [INFOTRIEVE], [CSA]
  • Guengerich, F. P., Liebler, D. C. (1985). Enzymatic activation of chemicals to toxic metabolites. Crit. Rev. Toxicol. 14:259–307. [PUBMED], [INFOTRIEVE]
  • Guengerich, F. P., Cai, H., Johnson, W. W., Parikh, A. (2001). Reactive intermediates in biological systems: what have we learned and where are we going? Adv. Exp. Med. Biol. 500:639–650. [PUBMED], [INFOTRIEVE], [CSA]
  • Guillouzo, A., Begue, J. M., Maurer, G., Koch, P. (1988). Identification of metabolic pathways of pindolol and fluperlapine in adult human hepatocyte cultures. Xenobiotica 18:131–139. [PUBMED], [INFOTRIEVE]
  • Guleria, R., Behera, D., Jindal, S. K. (1990). Systemic lupus erythematosus during isoniazid therapy. Indian J. Chest Dis. Allied Sci. 32:55–58. [PUBMED], [INFOTRIEVE]
  • Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., Ratain, M. J. (1994). Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54:3723–3725. [PUBMED], [INFOTRIEVE]
  • Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., Ratain, M. J. (1997a). Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J. Clin. Oncol. 15:1502–1510. [PUBMED], [INFOTRIEVE]
  • Gupta, S., Rogers, L. K., Taylor, S. K., Smith, C. V. (1997b). Inhibition of carbamyl phosphate synthetase-I and glutamine synthetase by hepatotoxic doses of acetaminophen in mice. Toxicol. Appl. Pharmacol. 146:317–327. [PUBMED], [INFOTRIEVE], [CSA]
  • Haas, I. G. (1994). BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum. Experientia 50:1012–1020. [PUBMED], [INFOTRIEVE]
  • Haaz, M. C., Rivory, L., Riche, C., Vernillet, L., Robert, J. (1998). Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 58:468–472. [PUBMED], [INFOTRIEVE]
  • Ha-Duong, N. T., Dijols, S., Macherey, A. C., Dansette, P. M., Mansuy, D. (2001a). Inhibition byticlopidine and its derivatives of human liver cytochrome p450. Mechanism-based inactivation of CYP 2C19 by ticlopidine. Adv. Exp. Med. Biol. 500:145–148. [PUBMED], [INFOTRIEVE], [CSA]
  • Ha-Duong, N. T., Dijols, S., Macherey, A. C., Goldstein, J. A., Dansette, P. M., Mansuy, D. (2001b). Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112–12122. [PUBMED], [INFOTRIEVE]
  • Hales, B. F., Brown, H. (1991). The effect of in vivo glutathione depletion with buthionine sulfoximine on rat embryo development. Teratology 44:251–257. [PUBMED], [INFOTRIEVE]
  • Hall, R. L., Oser, B. L. (1965). Recent progress in the consideration of flavoring ingredients under the food additives amendment III GRAS substances. Food Technol. 19:253–271.
  • Haller, C. A., Benowitz, N. L. (2000). Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N. Engl. J. Med. 343:1833–1838. [PUBMED], [INFOTRIEVE], [CSA]
  • Halmes, N. C., Hinson, J. A., Martin, B. M., Pumford, N. R. (1996). Glutamate dehydrogenase covalently binds to a reactive metabolite of acetaminophen. Chem. Res. Toxicol. 9:541–546. [PUBMED], [INFOTRIEVE], [CSA]
  • Hamdan, M., Galvani, M., Righetti, P. G. (2001). Monitoring 2-D gel-induced modifications of proteins by MALDI-TOF mass spectrometry. Mass Spectrom. Rev. 20:121–141. [PUBMED], [INFOTRIEVE], [CSA]
  • Hamer, D. H. (1986). Metallothionein. Annu. Rev. Biochem. 55:913–951. [PUBMED], [INFOTRIEVE], [CSA]
  • Hanioka, N., Ozawa, S., Jinno, H., Ando, M., Saito, Y., Sawada, J. (2001). Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 31:687–699. [PUBMED], [INFOTRIEVE], [CSA]
  • Hanioka, N., Ozawa, S., Jinno, H., Tanaka-Kagawa, T., Nishimura, T., Ando, M., Sawada, J. I. (2002). Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab. Dispos. 30:391–396. [PUBMED], [INFOTRIEVE], [CSA]
  • Hanna, I. H., Dawling, S., Roodi, N., Guengerich, F. P., Parl, F. F. (2000). Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 60:3440–3444. [PUBMED], [INFOTRIEVE]
  • Hansen, J. M., Harris, K. K., Philbert, M. A., Harris, C. (2002). Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb. J. Pharmacol. Exp. Ther. 300:768–776. [PUBMED], [INFOTRIEVE], [CSA]
  • Hansen-Moller, J., Schmit, U. (1991). Rapid high-performance liquid chromatographic assay for the simultaneous determination of probenecid and its glucuronide in urine. Irreversible binding of probenecid to serum albumin. J. Pharm. Biomed. Anal. 9:65–73. [PUBMED], [INFOTRIEVE]
  • Harbison, R. D., Becker, B. A. (1972). Diphenylhydantoin teratogenicity in rats. Toxicol. Appl. Pharmacol. 22:193–200. [PUBMED], [INFOTRIEVE]
  • Hargus, S. J., Martin, B. M., George, J. W., Pohl, L. R. (1995). Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac. Chem. Res. Toxicol. 8:993–996. [PUBMED], [INFOTRIEVE], [CSA]
  • Harris, J. W., Pohl, L. R., Martin, J. L., Anders, M. W. (1991). Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trifluoroethane. Proc. Natl. Acad. Sci. U. S. A. 88:1407–1410. [PUBMED], [INFOTRIEVE], [CSA]
  • Harris, J. W., Jones, J. P., Martin, J. L., LaRosa, A. C., Olson, M. J., Pohl, L. R., Anders, M. W. (1992). Pentahaloethane-based chlorofluorocarbon substitutes and halothane: correlation of in vivo hepatic protein trifluoroacetylation and urinary trifluoroacetic acid excretion with calculated enthalpies of activation. Chem. Res. Toxicol. 5:720–725. [PUBMED], [INFOTRIEVE]
  • Harris, R. Z., Benet, L. Z., Schwartz, J. B. (1995). Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50:222–392. [PUBMED], [INFOTRIEVE]
  • Harrison, A. C., Kitteringham, N. R., Clarke, J. B., Park, B. K. (1992). The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem. Pharmacol. 43:1421–1430. [PUBMED], [INFOTRIEVE]
  • Hartmann, G., Cheung, A. K., Piquette-Miller, M. (2002). Inflammatory cytokines, but not bileacids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. 303:273–281. [PUBMED], [INFOTRIEVE], [CSA]
  • Haruda, F. (1997). Phenytoin hypersensitivity: 38 cases. Neurology 29:1480–1485.
  • Hasegawa, J., Smith, P. C., Benet, L. Z. (1982). Apparent intramolecular acyl migration of zomepirac glucuronide. Drug Metab. Dispos. 10:469–473. [PUBMED], [INFOTRIEVE]
  • Haslett, P. A. J., Klausner, J. D., Makonkawkeyoon, S., Jet, L. (1999). Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res. Hum. Retrovir. 15:1169–1179. [PUBMED], [INFOTRIEVE], [CSA]
  • Hass, W. K., Easton, J. D., Adams, H. P. Jr., Pryse-Phillips, W., Molony, B. A., Anderson, S., Kamm, B. (1989). A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med. 321:501–507. [PUBMED], [INFOTRIEVE]
  • Hawkins, T., Carter, J. M., Romeril, K. R., Jackson, S. R., Green, G. J. (1993). Severe trimethoprim induced neutropenia and thrombocytopenia. N.Z. Med. J. 106:251–252. [PUBMED], [INFOTRIEVE]
  • He, K., Iyer, K. R., Hayes, R. N., Sinz, M. W., Woolf, T. F., Hollenberg, P. F. (1998). Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 11:252–259. [PUBMED], [INFOTRIEVE], [CSA]
  • He, K., Woolf, T. F., Hollenberg, P. F. (1999). Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J. Pharmacol. Exp. Ther. 288:791–797. [PUBMED], [INFOTRIEVE], [CSA]
  • Hecht, J. R. (1998). Gastrointestinal toxicity or irinotecan. Oncology (Huntingt.). 12:72–78. [CSA]
  • Hedaya, M. A., Elmquist, W. F., Sawchuk, R. J. (1990). Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. Pharm. Res. 7:411–417. [PUBMED], [INFOTRIEVE]
  • Heel, R. C., Morley, P. A., Brogden, R. N., Carmine, A. A., Speight, T. M., Avery, G. S. (1982). Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 24:169–206. [PUBMED], [INFOTRIEVE]
  • Heimark, L. D., Wienkers, L., Kunze, K., Gibaldi, M., Eddy, A. C., Trager, W. F., O'Reilly, R. A., Goulart, D. A. (1992). The mechanism of the interaction between amiodarone and warfarin in humans. Clin. Pharmacol. Ther. 51:398–407. [PUBMED], [INFOTRIEVE]
  • Heimpel, H. (1988). Drug-induced agranulocytosis. Med. Toxicol. Adverse Drug Exp. 3:449–462. [PUBMED], [INFOTRIEVE]
  • Hein, D. W. (2002). Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 30:65–77.
  • Henderson, C. J., Wolf, C. R., Kitteringham, N., Powell, H., Otto, D., Park, B. K. (2000). Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc. Natl. Acad. Sci. U. S. A. 97:12741–12745. [PUBMED], [INFOTRIEVE], [CSA]
  • Henry, R. R. (1997). Thiazolidinones. Endocrinol. Metab. Clin. North Am. 26:553–573. [PUBMED], [INFOTRIEVE], [CSA]
  • Hermansson, J., Glaumann, H., Karlen, B., von Bahr, C. (1980). Metabolism of lidocaine in human liver in vitro. Acta Pharm. Toxicol. (Copenh.). 47:49–52.
  • Hermening, A., Grafe, A. K., Baktir, G., Mutschler, E., Spahn-Langguth, H. (2000). Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies. J. Chromatogr. B. 741:129–144. [CSA]
  • Hinson, J. A., Forkert, P. G. (1995). Phase II enzymes and bioactivation. Can. J. Physiol. Pharm. 73:1407–1413.
  • Hinson, J. A., Mays, J. B. (1986a). Covalent binding of the phenacetin metabolite p-nitrosophenetole to protein. J. Pharmacol. Exp. Ther. 238:106–112. [PUBMED], [INFOTRIEVE], [CSA]
  • Hinson, J. A., Mays, J. B. (1986b). p-Nitrosophenetole: a reactive intermediate of phenacetin that binds to protein. Adv. Exp. Med. Biol. 197:691–696. [PUBMED], [INFOTRIEVE]
  • Hinson, J. A., Nelson, S. D., Gillette, J. R. (1979a). Metabolism of [p-18O]-phenacetin: the mechanism of activation of phenacetin to reactive metabolites in hamsters. Mol. Pharmacol. 15:419–427. [PUBMED], [INFOTRIEVE]
  • Hinson, J. A., Pohl, L. R., Gillette, J. R. (1979b). N-Hydroxyacetaminophen: a microsomalmetabolite of N-hydroxyphenacetin but apparently not of acetaminophen. Life Sci. 24:2133–2138. [PUBMED], [INFOTRIEVE]
  • Hinson, J. A., Pohl, L. R., Monks, T. J., Gillette, J. R., Guengerich, F. P. (1980). 3-Hydroxyacetaminophen: a microsomal metabolite of acetaminophen. Evidence against an epoxide as the reactive metabolite of acetaminophen. Drug Metab. Dispos. 8:289–294. [PUBMED], [INFOTRIEVE]
  • Hinson, J. A., Pohl, L. R., Monks, T. J., Gillette, T. J. (1981). Acetaminophen-induced hepatotoxicity. Life Sci. 29:107–116. [PUBMED], [INFOTRIEVE]
  • Hinson, J. A., Pumford, N. R., Roberts, D. W. (1995). Mechanisms of acetaminophen toxicity: immunochemical detection of drug-protein adducts. Drug Metab. Rev. 27:72–92.
  • Hinson, J. A., Roberts, D. W., Halmes, N. C., Gibson, J. D., Pumford, N. R. (1996). Immunochemical detection of drug-protein adducts in acetaminophen hepatotoxicity. Adv. Exp. Med. Biol. 387:47–55. [PUBMED], [INFOTRIEVE], [CSA]
  • Hinson, J. A., Michael, S. L., Ault, S. G., Pumford, N. R. (2000). Western blot analysis for nitrotyrosine protein adducts in livers of saline-treated and acetaminophen-treated mice. Toxicol. Sci. 53:467–473. [PUBMED], [INFOTRIEVE], [CSA]
  • Hirsch, A., Saccar, C., McGeady, S. J., Pjila, P. A. (1993). Interaction between theophylline and amiodarone. Ann. Allergy 70:68.
  • Hjelm, M., De Verdier, C. H. (1965). Biochemical effects of aromatic amines. I. Methaemoglobinaemia, haemolysis and Heinz-body formation induced by 4,4-diaminodiphenylsulphone. Biochem. Pharmacol. 14:1119–1128. [PUBMED], [INFOTRIEVE]
  • Hlavica, P. (2002). N-oxidative transformation of free and n-substituted amine functions by cytochrome P450 as means of bioactivation and detoxication. Drug Metab. Rev. 34:451–477. [PUBMED], [INFOTRIEVE], [CSA]
  • Hlavica, P., Golly, I., Lehnerer, M., Schulze, J. (1997). Primary aromatic amines: their N-oxidative bioactivation. Human Exp. Toxicol. 16:441–448. [CSA]
  • Ho, P. C., Yu, N. E.H., Tang, O. S. (2002). Mifepristone: contraceptive and non-contraceptive uses. Curr. Opin. Obstet. Gynecol. 14:325–330. [PUBMED], [INFOTRIEVE], [CSA]
  • Hoffmann, K. J., Axworthy, D. B., Baillie, T. A. (1990). Mechanistic studies on the metabolic activation of acetaminophen in vivo. Chem. Res. Toxicol. 3:204–211. [PUBMED], [INFOTRIEVE]
  • Hofstra, A. H., Uetrecht, J. P. (1993a). Myeloperoxidase-mediated activation of xenobiotics by human leukocytes. Toxicology 82:221–242. [PUBMED], [INFOTRIEVE], [CSA]
  • Hofstra, A. H., Uetrecht, J. P. (1993b). Reactive intermediates in the oxidation of hydralazine by HOCl: the major oxidant generated by neutrophils. Chem.-Biol. Interact. 89:183–196. [PUBMED], [INFOTRIEVE], [CSA]
  • Hofstra, A. H., Matassa, L. C., Uetrecht, J. P. (1991). Metabolism of hydralazine by activated leukocytes: implications for hydralazine induced lupus. J. Rheumatol. 18:1673–1680. [PUBMED], [INFOTRIEVE]
  • Hofstra, A. H., Li-Muller, S. M., Uetrecht, J. P. (1992). Metabolism of isoniazid by activated leukocytes. Possible role in drug-induced lupus. Drug Metab. Dispos. 20:205–210. [PUBMED], [INFOTRIEVE]
  • Hoivik, D. J., Manautou, J. E., Tveit, A., Mankowski, D. C., Khairallah, E. A., Cohen, S. D. (1996). Evidence suggesting the 58-kDa acetaminophen binding protein is a preferential target for acetaminophen electrophile. Fundam. Appl. Toxicol. 32:79–86. [PUBMED], [INFOTRIEVE], [CSA]
  • Holm, K. J., Markham, A. (1999). Mirtazapine: a review of its use in major depression. Drugs 57:607–631. [PUBMED], [INFOTRIEVE]
  • Holtzman, J. L. (1995). The role of covalent binding to microsomal proteins in the hepatotoxicity of acetaminophen. Drug Metab. Rev. 27:277–297. [PUBMED], [INFOTRIEVE], [CSA]
  • Homberg, J. C., Andre, C., Abuaf, N. (1984). A new anti-liver-kidney-microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin. Exp. Immunol. 55:561–570. [PUBMED], [INFOTRIEVE], [CSA]
  • Hood, K. A., Zarembski, D. G. (1997). Mycophenolate mofetil: a unique immunosuppressive agent. Am. J. Health Syst. Pharm. 54:285–294. [PUBMED], [INFOTRIEVE], [CSA]
  • Horikawa, M., Kato, Y., Sugiyama, Y. (2002). Reduced gastrointestinal toxicity followinginhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm. Res. 19:1345–1353. [PUBMED], [INFOTRIEVE]
  • Horowitz, R. S., Feldhaus, K., Dart, R. C., Stermitz, F. R., Beck, J. J. (1996). The clinical spectrum of Jin Bu Huan toxicity. Arch. Intern. Med. 156:899–903. [PUBMED], [INFOTRIEVE], [CSA]
  • Huang, Z., Fasco, M. J., Figge, H. L., Keyomarsi, K., Kaminsky, L. S. (1996). Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab. Dispos. 24:899–905. [PUBMED], [INFOTRIEVE], [CSA]
  • Huang, L. Y., Wring, S., Woolley, J. L., Brouwer, K. R., Serabjit-Singh, C., Polli, J. W. (2001). Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 29:754–760. [PUBMED], [INFOTRIEVE], [CSA]
  • Huang, Y. S., Chern, H. D., Su, W. J., Wu, J. C., Lai, S. L., Yang, S. Y., Chang, F. Y., Lee, S. D. (2002). Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883–889. [PUBMED], [INFOTRIEVE]
  • Hukkanen, J., Mantyla, M., Kangas, L., Wirta, P., Hakkola, J., Paakki, P., Evisalmi, S., Pelkonen, O., Raunio, H. (1998). Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol. Toxicol. 82:93–97. [PUBMED], [INFOTRIEVE], [CSA]
  • Humerickhouse, R., Lohrbach, K., Li, L., Bosron, W. F., Dolan, M. E. (2000). Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60:1189–1192. [PUBMED], [INFOTRIEVE]
  • Hutchins, G. M. (2002). Ma huang toxicity. Mayo Clin. Proc. 77:733. [PUBMED], [INFOTRIEVE], [CSA]
  • Huupponen, R., Pyykko, K. (1995). Stability of thalidomide in human plasma. Clin. Chem. 41:1199. [PUBMED], [INFOTRIEVE], [CSA]
  • Hyneck, M. L., Munafo, A., Benet, L. Z. (1988a). Effect of pH on acyl migration and hydrolysis of tolmetin glucuronide. Drug Metab. Dispos. 16:322–324. [PUBMED], [INFOTRIEVE]
  • Hyneck, M. L., Smith, P. C., Munafo, A., McDonagh, F. A., Benet, L. Z. (1988b). Disposition and irreversible plasma protein binding of Tolmetin in humans. Clin. Pharmacol. Ther. 44:107–114. [PUBMED], [INFOTRIEVE]
  • Igarashi, K., Kasuya, F., Fukui, M., Usuki, E., Castagnoli, N. Jr. (1995). Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP + found in rat brain following ip administration of HP. Life Sci. 57:2439–2446. [PUBMED], [INFOTRIEVE]
  • Imaoka, S., Enomoto, K., Oda, Y., Asada, A., Fujimori, M., Shimada, T., Fujita, S., Guengerich, F. P., Funae, Y. (1990). Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J. Pharmacol. Exp. Ther. 255:1385–1391. [PUBMED], [INFOTRIEVE]
  • Inman, W. H. (1988). Safety of mianserin. Lancet 2:683–684. [PUBMED], [INFOTRIEVE]
  • Iverson, S. L., Shen, L., Anlar, N., Bolton, J. L. (1996). Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes. Chem. Res. Toxicol. 9:492–499. [PUBMED], [INFOTRIEVE], [CSA]
  • Iwahashi, K., Anemo, K., Nakamura, K., Yoshihara, E., Igarashi, K. (2000). Analysis of the metabolism of haloperidol (HP) and its neurotoxic pyridinium metabolite (HPP +) in patients with drug-induced parkinsonism. Clin. Chim. Acta 298:193–195. [PUBMED], [INFOTRIEVE], [CSA]
  • Iwakawa, S., Spahn, H., Benet, L. Z., Lin, E. T. (1990). Stereoselective binding of the glucuronide conjugates of carprofen enantiomers to human serum albumin. Biochem. Pharmacol. 39:949–953. [PUBMED], [INFOTRIEVE], [CSA]
  • Iwaki, M., Ogiso, T., Inagawa, S., Kakehi, K. (1999). In vitro regioselective stability of beta-1-O and 2-O-acyl glucuronides of naproxen and their covalent binding to human serum albumin. J. Pharm. Sci. 88:52–57. [PUBMED], [INFOTRIEVE]
  • Iwasaki, K., Shiraga, T., Matsuda, H., Nagase, K., Tokuda, Y., Hata, T., Fugii, Y., Sakuma, S., Fujitsu, T., Fujikawa, A., Shimatani, K., Sato, A., Fujioka, M. (1995). Further metabolism of FK506 (Tacrolimus): identification and biological activities of the metabolites oxidized at multiple sites of FK-506. Drug Metab. Dispos. 23:28–34., [PUBMED], [INFOTRIEVE], [CSA]
  • Izumi, T., Hoshiyama, K., Enomoto, S., Sasahara, K., Sugiyama, Y. (1997). Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. J. Pharmacol. Exp. Ther. 280:1392–1400. [PUBMED], [INFOTRIEVE], [CSA]
  • Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., Berthou, F. (1991). Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41:1911–1919. [PUBMED], [INFOTRIEVE], [CSA]
  • Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D., Lemasters, J. J. (2002). Mechanisms of hepatotoxicity. Toxicol. Sci. 65:166–176. [PUBMED], [INFOTRIEVE], [CSA]
  • Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C., Pezzuto, J. M. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220. [PUBMED], [INFOTRIEVE]
  • Jann, M. W., Shirley, K. L., Small, G. W. (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 41:719–739. [PUBMED], [INFOTRIEVE], [CSA]
  • Jean, P., Lopez-Garcia, P., Dansette, P., Mansuy, D., Goldstein, J. L. (1996). Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur. J. Biochem. 241:797–804. [PUBMED], [INFOTRIEVE]
  • Jenner, P. G., Brin, M. F. (1998). Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology 50:S39–S43. [PUBMED], [INFOTRIEVE], [CSA]
  • Jewell, H., Maggs, J. L., Harrison, A. C., O'Neill, P. M., Ruscoe, J. E., Park, B. K. (1995). Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica 25:199–217. [PUBMED], [INFOTRIEVE], [CSA]
  • Jiang, X., Khursigara, G., Rubin, R. L. (1994). Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 266:810–813. [PUBMED], [INFOTRIEVE]
  • Jin, J. X., Baillie, T. A. (1997). Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Chem. Res. Toxicol. 10:318–327. [PUBMED], [INFOTRIEVE], [CSA]
  • Jin, C., Miners, J. O., Lillywhite, K. J., Mackenzie, P. I. (1993). Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J. Pharmacol. Exp. Ther. 264:475–479. [PUBMED], [INFOTRIEVE]
  • Jochheim, C. M., Davis, M. R., Baillie, K. M., Ehlhardt, W. J., Baillie, T. A. (2002). Glutathione-dependent metabolism of the antitumor agent sulofenur. Evidence for the formation of p-chlorophenyl isocyanate as a reactive intermediate. Chem. Res. Toxicol. 15:240–248. [PUBMED], [INFOTRIEVE], [CSA]
  • Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., Brodie, B. B. (1973). Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther. 187:195–202. [PUBMED], [INFOTRIEVE]
  • Jones, A. (2002). Over-the-counter analgesics: a toxicology perspective. Am. J. Ther. 9:245–257. [PUBMED], [INFOTRIEVE], [CSA]
  • Jones, K. L., Lacro, R. V., Johnson, K. A., Adams, J. (1989). Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 320:1661–1666. [PUBMED], [INFOTRIEVE], [CSA]
  • Jones, D. R., Gorski, J. C., Hamman, M. A., Mayhew, B. S., Rider, S., Hall, S. D. (1999). Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther. 290:1116–1125. [PUBMED], [INFOTRIEVE], [CSA]
  • Jones, D. C., Gunasekar, P. G., Borowitz, J. L., Isom, G. E. (2000). Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells. J. Neurochem. 74:2296–2304. [PUBMED], [INFOTRIEVE]
  • Jonsson, N. A. (1972a). Chemical structure and teratogenic properties. 3. A review of available data on structure–activity relationships and mechanism of action of thalidomide analogues. Acta Pharm. Suec. 9:521–542. [PUBMED], [INFOTRIEVE]
  • Jonsson, N. A. (1972b). Chemical structure and teratogenic properties. IV. An outline of a chemical hypothesis for the teratogenic action of thalidomide. Acta Pharm. Suec. 9:543–562., [PUBMED], [INFOTRIEVE]
  • Jordan, A., Hadfield, J. A., Lawrence, N. J., McGown, A. T. (1998). Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. 18:259–296. [PUBMED], [INFOTRIEVE]
  • Jorde, U. P., Horowitz, H. W., Wormser, G. P. (1993). Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulphamethoxazole-intolerant, HIV-infected individuals. AIDS 7:354–359.
  • Jorga, K. M., Sedek, G., Fotteler, B., Zürcher, G., Nielsen, T., Aitken, J. W. (1997). Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin. Pharmacol. Ther. 62:300–310. [PUBMED], [INFOTRIEVE], [CSA]
  • Jorga, K., Fotteler, B., Heizmann, P., Gasser, R. (1999). Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br. J. Clin. Pharmacol. 48:513–520. [PUBMED], [INFOTRIEVE], [CSA]
  • Ju, C., Uetrecht, J. P. (1998). Oxidation of a metabolite of indomethacin (Desmethyldeschlorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system. Drug Metab. Dispos. 26:676–680. [PUBMED], [INFOTRIEVE], [CSA]
  • Ju, C., Uetrecht, J. P. (1999). Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J. Pharmacol. Exp. Ther. 288:51–56. [PUBMED], [INFOTRIEVE], [CSA]
  • Ju, C., Uetrecht, J. P. (2002). Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr. Drug Metab. 3:367–377. [PUBMED], [INFOTRIEVE]
  • Kaakkola, S. (2000). Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59:1233–1250. [PUBMED], [INFOTRIEVE]
  • Kagi, J. H. R. (1991). Overview of metallothionein. Methods Enzymol. 205:613–626. [PUBMED], [INFOTRIEVE]
  • Kagimoto, N., Masubuchi, Y., Fujita, S., Narimatsu, S., Suzuki, T. (1994). Kinetic analysis of propranolol-induced impairment of its own metabolism in rats. J. Pharm. Pharmacol. 46:528–530. [PUBMED], [INFOTRIEVE]
  • Kalgutkar, A. S., Dalvie, D. K., O'Donnell, J. P., Taylor, T. J., Sahakian, D. C. (2002). On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics. Curr. Drug Metab. 3:378–424.
  • Kalgutkar, A. S., Taylor, T. J., Venkatakrishnan, K., Isin, E. M. (2003). Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab. Dispos. 31:243–249. [PUBMED], [INFOTRIEVE], [CSA]
  • Kalyanaraman, B., Sohnle, P. G. (1985). Generation of free radical intermediates from foreign compounds by neutrophil-derived oxidants. J. Clin. Invest. 75:1618–1622. [PUBMED], [INFOTRIEVE]
  • Kamali, F. (1993). The effect of probenecid on paracetamol metabolism and pharmacokinetics. Eur. J. Clin. Pharmacol. 45:551–553. [PUBMED], [INFOTRIEVE], [CSA]
  • Kane, G. C., Lipsky, J. J. (2000). Drug-grapefruit juice interactions. Mayo Clin. Proc. 75:933–942. [PUBMED], [INFOTRIEVE], [CSA]
  • Kane, J. A., Kane, S. P., Jain, S. (1995). Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut 36:146–147. [PUBMED], [INFOTRIEVE]
  • Kaplan, G. (2000). Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions. Lepr. Rev. 71:S117–S120. [PUBMED], [INFOTRIEVE]
  • Kaplowitz, N. (2001). Drug-induced liver disorders: implications for drug development and regulation. Drug Safety 24:483–490. [PUBMED], [INFOTRIEVE], [CSA]
  • Kaptchuk, T. J. (1995). Acute hepatitis associated with jin bu huan. Ann. Intern. Med. 122:636. [PUBMED], [INFOTRIEVE], [CSA]
  • Karanam, B. V., Vincent, S. H., Newton, D. J., Wang, R. W., Chiu, S. H. (1994). FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug Metab. Dispos. 22:811–814. [PUBMED], [INFOTRIEVE], [CSA]
  • Karplus, P. A., Krauth-Siegel, R. L., Schirmer, R. H., Schulz, G. E. (1988). Inhibition of human glutathione reductase by the nitrosourea drugs 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea. A crystallographic analysis. Eur. J. Biochem. 171:193–198., [PUBMED], [INFOTRIEVE]
  • Karrow, N. A., McCay, J. A., Brown, R. D., Jet, L. (2000). Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. Toxicol. Appl. Pharmacol. 165:237–244. [PUBMED], [INFOTRIEVE], [CSA]
  • Kasahara, M., Suzuki, H., Komiya, I. (2000). Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms. Drug Metab. Dispos. 28:409–417. [PUBMED], [INFOTRIEVE], [CSA]
  • Kassahun, K., Abbott, F. (1993). In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid. Drug Metab. Dispos. 21:1098–1106. [PUBMED], [INFOTRIEVE], [CSA]
  • Kassahun, K., Baillie, T. A. (1993). Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically active metabolite of valproic acid, in rat liver microsomal preparations. Drug Metab. Dispos. 21:242–248. [PUBMED], [INFOTRIEVE]
  • Kassahun, K., Farrell, K., Abbott, F. (1991). Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab. Dispos. 19:525–535. [PUBMED], [INFOTRIEVE]
  • Kassahun, K., Hu, P., Grillo, M. P., Davis, M. R., Jin, L., Baillie, T. A. (1994). Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem.-Biol. Interact. 90:253–275. [PUBMED], [INFOTRIEVE]
  • Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., Baillie, T. A. (2001). Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14:62–70. [PUBMED], [INFOTRIEVE], [CSA]
  • Kastelova, A., Yanev, S. (2002). Propranolol as an inhibitor of some cytochrome P450-dependent monooxygenase activities in native and induced rat liver microsomes. Methods Find. Exp. Clin. Pharmacol. 24:189–194. [PUBMED], [INFOTRIEVE], [CSA]
  • Katayama, H., Watanabe, M., Yoshitomi, H., Yoshida, H., Kimoto, H., Kamiya, A., Hayashi, T., Akimura, T. (1998). Urinary metabolites of valproic acid in epileptic patients. Biol. Pharm. Bull. 21:304–307. [PUBMED], [INFOTRIEVE], [CSA]
  • Katayama, H., Nagasu, T., Oda, Y. (2001). Improvement of in-gel digestion protocol for peptide mass fingerprinting by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 15:1416–1421. [PUBMED], [INFOTRIEVE], [CSA]
  • Kato, R., Yamazoe, Y. (1992). Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicol. Lett. 64–65:661–667.
  • Katsutani, N., Shionoya, H. (1992). Drug-specific immune responses induced by procainamide, hydralazine and isoniazid in guinea-pigs. Int. J. Immunopharmacol. 14:673–679. [PUBMED], [INFOTRIEVE]
  • Kaur, I., Mehta, M., Agnihotri, N., Dogra, S., Ganguly, N. K. (2001). Dapsone-induced methemoglobinemia in leprosy patients. Int. J. Lepr. Other Mycobact. Dis. Sep. 69(3):247–249. [PUBMED], [INFOTRIEVE], [CSA]
  • Kavallaris, M., Verrills, N. M., Hill, B. T. (2001). Anticancer therapy with novel tubulin-interacting drugs. Drug Resist. Updat. 4:392–401. [PUBMED], [INFOTRIEVE], [CSA]
  • Kawai, K., Odaka, T., Tsuruta, F., Tokui, T., Ikeda, T., Nakamura, K. (1998). Stereoselective metabolism of new oral anti-diabetic agent troglitazone stereoisomers in liver. Xenobiol. Metab. Dispos. 13:362–368. [CSA]
  • Kelder, J., Funke, C., De Boer, T., Delbressin, L., Leysen, D., Nickolson, V. (1997). A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J. Pharm. Pharmacol. 49:403–411. [PUBMED], [INFOTRIEVE]
  • Kelly, P., Kahan, B. D. (2002). Review: metabolism of immunosuppressant drugs. Curr. Drug Metab. 3:275–287., [PUBMED], [INFOTRIEVE]
  • Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., Sun, E., Pizzuti, D., Plattner, J. J., Norbeck, D. W., Leonard, J. M. (1997). Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654–660. [PUBMED], [INFOTRIEVE], [CSA]
  • Kendall, M. J. (2000). Clinical trial data on the cardioprotective effects of beta-blockade. Basic Res. Cardiol. 95:I25–I30. [PUBMED], [INFOTRIEVE]
  • Kenna, J. G., Neuberger, J., Williams, R. (1987). Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. J. Pharmacol. Exp. Ther. 242:733–740. [PUBMED], [INFOTRIEVE]
  • Kenna, J. G., Neuberger, J., Williams, R. (1988a). Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology 8:1635–1641. [PUBMED], [INFOTRIEVE]
  • Kenna, J. G., Satoh, H., Christ, D. D., Pohl, L. R. (1988b). Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 245:1103–1109. [PUBMED], [INFOTRIEVE]
  • Kenna, J. G., Martin, J. L., Satoh, H., Pohl, L. R. (1990). Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab. Dispos. 18:788–793. [PUBMED], [INFOTRIEVE]
  • Kent, U. M., Aviram, M., Rosenblat, M., Hollenberg, P. F. (2002a). The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab. Dispos. 30:709–715. [PUBMED], [INFOTRIEVE], [CSA]
  • Kent, U. M., Mills, D. E., Rajnarayanan, R. V., Alworth, W. L., Hollenberg, P. F. (2002b). Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J. Pharmacol. Exp. Ther. 300:549–558. [PUBMED], [INFOTRIEVE], [CSA]
  • Kenyon, B. M., Browne, F., D'Amato, R. J. (1997). Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64:971–978. [PUBMED], [INFOTRIEVE], [CSA]
  • Kessler, D. A. (2000). Cancer and herbs. N. Engl. J. Med. 342:1742–1743. [PUBMED], [INFOTRIEVE], [CSA]
  • Kessler, F. K., Kessler, M. R., Auyeung, D. J., Ritter, J. K. (2002). Glucuronidation of acetaminophen catalyzed by multiple rat phenol UDP-glucuronosyltransferases. Drug Metab. Dispos. 30:324–330. [PUBMED], [INFOTRIEVE], [CSA]
  • Kesterson, J. W., Granneman, G. R., Machinist, J. M. (1984). The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 4:1143–1152. [PUBMED], [INFOTRIEVE]
  • Khan, F. H., Saha, M., Chakrabarti, S. (2001). Dopamine induced protein damage in mitochondrial-synaptosomal fraction of rat brain. Brain Res. 895:245–249. [PUBMED], [INFOTRIEVE]
  • Kharasch, E. D., Hankins, D. C., Fenstamaker, K., Cox, K. (2000). Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. Eur. J. Clin. Pharmacol. 55:853–859. [PUBMED], [INFOTRIEVE], [CSA]
  • Khojasteh-Bakht, S. C., Koenigs, L. L., Peter, R. M., Trager, W. F., Nelson, S. D. (1998). (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab. Dispos. 26:701–704. [PUBMED], [INFOTRIEVE], [CSA]
  • Kickler, T. S., Buck, S., Ness, P., Shirey, R. S., Sholar, P. W. (1986). Probenecid induced immune hemolytic anemia. J. Rheumatol. 13:208–209. [PUBMED], [INFOTRIEVE]
  • King, A. R., Dickinson, R. G. (1993). Studies on the reactivity of acyl glucuronides—IV. Covalent binding of diflunisal to tissues of the rat. Biochem. Pharmacol. 45:1043–1047. [PUBMED], [INFOTRIEVE]
  • Kingsley, E., Gray, P., Tolman, K. G., Tweedale, R. (1983). The toxicity of metabolites of sodium valproate in cultured hepatocytes. J. Clin. Pharmacol. 23:178–185. [PUBMED], [INFOTRIEVE]
  • Kishi, Y., Oki, Y., Machida, U. (2000). Thalidomide in multiple myeloma. N. Engl. J. Med. 342:975.
  • Kitamura, K., Kanasashi, M., Suga, C., Saito, S., Yoshida, S., Ikezawa, Z. (1993). Cutaneous reactions induced by calcium channel blocker: high frequency of psoriasiform eruptions. J. Dermatol. 20:279–286. [PUBMED], [INFOTRIEVE]
  • Kitteringham, N. R., Lambert, C., Maggs, J. L., Colbert, J., Park, B. K. (1988). A comparative study of the formation of chemically reactive drug metabolites by human liver microsomes. Br. J. Clin. Pharmacol. 26:13–21. [PUBMED], [INFOTRIEVE]
  • Kitteringham, N. R., Kenna, J. G., Park, B. K. (1995). Detection of autoantibodies directed against human hepatic endoplasmic reticulum in sera from patients with halothane-associated hepatitis. Br. J. Clin. Pharmacol. 40:379–386. [PUBMED], [INFOTRIEVE], [CSA]
  • Klaassen, S. L. (1998). Ticlopidine-induced phenytoin toxicity. Ann. Pharmacother. 32:1295–1298. [PUBMED], [INFOTRIEVE], [CSA]
  • Klausner, J. D., Freedman, V. H., Kaplan, G. (1996). Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin. Immunol. Immunopathol. 81:219–223. [PUBMED], [INFOTRIEVE], [CSA]
  • Klepser, T. B., Klepser, M. E. (1999). Unsafe and potentially safe herbal therapies. Am. J. Health-Syst. Pharm. 56:125–138. [PUBMED], [INFOTRIEVE], [CSA]
  • Ko, J. W., Desta, Z., Soukhova, N. V., Tracy, T., Flockhart, D. A. (2000). In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br. J. Clin. Pharmacol. 49:343–351. [PUBMED], [INFOTRIEVE], [CSA]
  • Kobrin, I., Charlon, V., Lindberg, E., Pordy, R. (1997). Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. Am. J. Cardiol. 80:C40–C46.
  • Koch, H., Kohler, F. (1976). Teratology study of two isoglutamine derivatives. Arch. Toxicol. 35:63–68. [PUBMED], [INFOTRIEVE]
  • Koenigs, L. L., Trager, W. F. (1998a). Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. Biochemistry 37:13184–13193. [PUBMED], [INFOTRIEVE]
  • Koenigs, L. L., Trager, W. F. (1998b). Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 37:10047–10061. [PUBMED], [INFOTRIEVE]
  • Koenigs, L. L., Peter, R. M., Thompson, S. J., Rettie, A. E., Trager, W. F. (1997). Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Dispos. 25:1407–1415. [PUBMED], [INFOTRIEVE], [CSA]
  • Koenigs, L. L., Peter, R. M., Hunter, A. P., Haining, R. L., Rettie, A. E., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., Trager, W. F. (1999). Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry 38:2312–2319. [PUBMED], [INFOTRIEVE]
  • Kohita, H., Matsushita, Y., Moriguchi, I. (1994). Binding of carprofen to human and bovine serum albumins. Chem. Pharm. Bull. 42:937–940. [PUBMED], [INFOTRIEVE], [CSA]
  • Komatsu, T., Yamazaki, H., Asahi, S., Gillam, E. M. J., Guengerich, F. P., Nakajima, M., Yokoi, T. (2000). Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P4502C9, 2C19, and 3A4. Drug Metab. Dispos. 28:1361–1368. [PUBMED], [INFOTRIEVE], [CSA]
  • Komatsu, T., Yamazaki, H., Nakajima, M., Yokoi, T. (2002). Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes. Biochem. Pharmacol. 63:2081–2090. [PUBMED], [INFOTRIEVE], [CSA]
  • Koopmans, P. P., van der Ven, A. J., Vree, T. B., van der Meer, J. W. (1995). Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? AIDS 9:217–222. [PUBMED], [INFOTRIEVE]
  • Korczyn, A. D. (2003). Dopaminergic drugs in development for Parkinson's disease. Adv. Neurol. 91:267–271. [PUBMED], [INFOTRIEVE], [CSA]
  • Korsmeyer, K. K., Davoll, S., Figueiredo-Pereira, M. E., Correia, M. A. (1999). Proteolytic degradation of heme-modified hepatic cytochromes P450: a role for phosphorylation, ubiquitination, and the 26S proteasome?. Arch. Biochem. Biophys. 365:31–44., [PUBMED], [INFOTRIEVE], [CSA]
  • Kostrubsky, V. E., Szakacs, J. G., Jeffery, E. H., Wood, S. G., Bement, W. J., Wrighton, S. A., Sinclair, P. R., Sinclair, J. F. (1997). Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity. Toxicol. Appl. Pharmacol. 143:315–323. [PUBMED], [INFOTRIEVE], [CSA]
  • Kostrzewa, R. M., Kostrzewa, J. P., Brus, R. (2002). Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids 23:57–63. [PUBMED], [INFOTRIEVE], [CSA]
  • Kotsonis, F. N., Klaassen, C. D. (1979). Increase in hepatic metallothionein in rats treated with alkylating agents. Toxicol. Appl. Pharmacol. 51:19–27. [PUBMED], [INFOTRIEVE]
  • Koudriakova, T., Iatsimirskaia, E., Utkin, I., Gangl, E., Vouros, P., Storozhuk, E., Orza, D., Marinina, J., Gerber, N. (1998). Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26:552–561. [PUBMED], [INFOTRIEVE], [CSA]
  • Koujitani, T., Yasuhara, K., Kobayashi, H., Shimada, A., Onodera, H., Takagi, H., Hirose, M., Mitsumori, K. (1999). Tumor-promoting activity of 2,6-dimethylaniline in a two-stage nasal carcinogenesis model in N-bis(2-hydroxypropyl)nitrosamine-treated rats. Cancer Lett. 142:161–171. [PUBMED], [INFOTRIEVE], [CSA]
  • Kouzi, S. A., McMurtry, R. J., Nelson, S. D. (1994). Hepatotoxicity of germander (Teucrium chamaedrys L.) and one of its constituent neoclerodane diterpenes teucrin A in the mouse. Chem. Res. Toxicol. 7:850–856. [PUBMED], [INFOTRIEVE], [CSA]
  • Koyama, E., Chiba, K., Tani, M., Ishizaki, T. (1997). Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J. Pharmacol. Exp. Ther. 281:1199–1210. [PUBMED], [INFOTRIEVE], [CSA]
  • Koymans, L., van Lenthe, J. H., van de Straat, R., Donne-Op den Kelder, G. M., Vermeulen, N. P. (1989). A theoretical study on the metabolic activation of paracetamol by cytochrome P-450: indications for a uniform oxidation mechanism. Chem. Res. Toxicol. 2:60–66. [PUBMED], [INFOTRIEVE]
  • Koymans, L., Van Lenthe, J. H., Donne-Op Den Kelder, G. M., Vemeulen, N. P. (1990). Mechanisms of activation of phenacetin to reactive metabolites by cytochrome P-450: a theoretical study involving radical intermediates. Mol. Pharmacol. 37:452–460. [PUBMED], [INFOTRIEVE], [CSA]
  • Koymans, L., Donne-Op den Kelder, G. M., te Koppele, J. M., Vermeulen, N. P. (1993). Generalized cytochrome P450-mediated oxidation and oxygenation reactions in aromatic substrates with activated N–H, O–H, C–H, or S–H substituents. Xenobiotica 23:633–648. [PUBMED], [INFOTRIEVE], [CSA]
  • Kretz-Rommel, A., Boelsterli, U. A. (1994). Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins—retention of the glucuronic acid moiety in the adduct. Drug Metab. Dispos. 22:956–961. [PUBMED], [INFOTRIEVE], [CSA]
  • Krishna, D. R., Klotz, U. (1994). Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinet. 26:144–160. [PUBMED], [INFOTRIEVE], [CSA]
  • Kroemer, H. K., Klotz, U. (1992). Glucuronidation of drugs: a re-evaluation of the pharmacological significance of the conjugates and modulation factors. Clin. Pharmacokinet. 23:292–310. [PUBMED], [INFOTRIEVE]
  • Krupp, P., Barnes, P. (1989). Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 99:S118–S121. [PUBMED], [INFOTRIEVE]
  • Kubow, S., Wells, P. G. (1989). In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase. Mol. Pharmacol. 35:504–511. [PUBMED], [INFOTRIEVE], [CSA]
  • Kudo, S., Ishizaki, T. (1999). Pharmacokinetics of haloperidol: an update. Clin. Pharmacokinet. 37:435–456. [PUBMED], [INFOTRIEVE], [CSA]
  • Kudoh, S., Fujiwara, Y., Takada, Y., Yamamoto, H., Kinoshita, A., Ariyoshi, Y., Furuse, K., Fukuoka, M. (1998). Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J. Clin. Oncol. 16:1068–1074., [PUBMED], [INFOTRIEVE]
  • Kuhn, D. M., Arthur, R. E. J. (1999). L-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein. Brain Res. Mol. Brain Res. 73:78–84. [PUBMED], [INFOTRIEVE], [CSA]
  • Kuhn, D. M., Arthur, R. E. J., Thomas, D. M., Elferink, L. A. (1999). Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem. 73:1309–1317. [PUBMED], [INFOTRIEVE]
  • Kumar, G. N., Rodrigues, A., Buko, A. M., Dennison, J. F. (1996). Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423–431. [PUBMED], [INFOTRIEVE], [CSA]
  • Kumar, S., Wong, H., Yeung, S. A., Riggs, K. W., Abbott, F. S., Rurak, D. W. (2000). Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination. Drug Metab. Dispos. 28:857–864. [PUBMED], [INFOTRIEVE], [CSA]
  • La Vecchia, C., Altieri, A., Franceschi, S., Tavani, A. (2001). Oral contraceptives and cancer: an update. Drug Safety 24:741–754. [PUBMED], [INFOTRIEVE], [CSA]
  • Labbe, G., Descatoire, V., Beaune, P., Letteron, P., Larrey, D., Pessayre, D. (1989). Suicide inactivation of cytochrome P-450 by methoxsalen: evidence for the covalent binding of a reactive intermediate to the protein moiety. J. Pharmacol. Exp. Ther. 250:1034–1042. [PUBMED], [INFOTRIEVE], [CSA]
  • LaCagnin, L. B., Colby, H. D., Dalal, N. S., O'Donnell, J. P. (1987). Metabolic activation of hydralazine by rat liver microsomes. Biochem. Pharmacol. 36:2667–2672. [PUBMED], [INFOTRIEVE], [CSA]
  • Lahiri-Chatterjee, M., Katiyar, S. K., Mohan, R. R., Agarwal, R. (1999). A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 59:622–632. [PUBMED], [INFOTRIEVE]
  • Lai, M. L., Huang, J. D. (1993). Dual effect of valproic acid on the pharmacokinetics of phenytoin. Biopharm. Drug Dispos. 14:365–370. [PUBMED], [INFOTRIEVE]
  • Lai, W. G., Zahid, N., Uetrecht, J. P. (1999). Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J. Pharmacol. Exp. Ther. 291:292–299. [PUBMED], [INFOTRIEVE], [CSA]
  • Lai, W. G., Gardner, I., Zahid, N., Uetrecht, J. P. (2000). Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: implications for fluperlapine-induced agranulocytosis. Drug Metab. Dispos. 28:255–263. [PUBMED], [INFOTRIEVE], [CSA]
  • Lalezari, J. P., Lawrence Drew, W., Glutzer, E., Miner, D., Safrin, S., Owen, W. F. Jr., Davidson, J. M., Fisher, P. E., Jaffe, H. S. (1994). Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J. Infect. Dis. 170:570–572. [PUBMED], [INFOTRIEVE]
  • Laliberte, L., Villeneuve, J. P. (1996). Hepatitis after the use of germander, a herbal remedy. CMAJ 154:1689–1692. [PUBMED], [INFOTRIEVE], [CSA]
  • Lambert, C., Park, B. K., Kitteringham, N. R. (1989). Activation of mianserin and its metabolites by human liver microsomes. Biochem. Pharmacol. 38:2853–2858. [PUBMED], [INFOTRIEVE]
  • Landi, M. T., Zocchetti, C., Bernucci, I., Kadlubar, F. F., Tannenbaum, S., Skipper, P., Bartsch, H., Malaveille, C., Shields, P., Caporaso, N. E., Vineis, P. (1996). Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol. Biomarkers Prev. 5:693–698. [PUBMED], [INFOTRIEVE], [CSA]
  • Landi, M. T., Sinha, R., Lang, N. P., Kadlubar, F. F. (1999). Human cytochrome P4501A2. In: Ryder, W., ed. Metabolic Polymorphisms and Susceptibility to Cancer. Lyon: IARC Scientific Publications, pp. 173–195.
  • Landin, J. S., Cohen, S. D., Khairallah, E. A. (1996). Identification of a 54-kDa mitochondrial acetaminophen-binding protein as aldehyde dehydrogenase. Toxicol. Appl. Pharmacol. 141:299–307. [PUBMED], [INFOTRIEVE], [CSA]
  • Lang, D. M. (1995). Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers. Drug Safety 12:299–304. [PUBMED], [INFOTRIEVE], [CSA]
  • Larrey, D., Pageaux, G. P. (1997). Genetic predisposition to drug-induced hepatotoxicity. J. Hepatol. 26:12–21., [PUBMED], [INFOTRIEVE]
  • Larrey, D., Tinel, M., Pessayre, D. (1983). Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem. Pharmacol. 32:1487–1493. [PUBMED], [INFOTRIEVE]
  • Larrey, D., Vial, T., Pauwels, A., Castot, A., Biour, M., David, M., Michel, H. (1992). Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann. Intern. Med. 117:129–132. [PUBMED], [INFOTRIEVE]
  • Larry, D., Funk-Brentano, C., Breil, P., Vitaux, J., Theodore, C., Babany, G., Pessayre, D. (1983). Effect of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem. Pharmacol. 32:1063–1068.
  • Lawson, D. H., Jick, H. (1977). Adverse reactions to procainamide. Br. J. Clin. Pharmacol. 4:507–511. [PUBMED], [INFOTRIEVE]
  • Lecoeur, S., Bonierbale, E., Challine, D., Gautier, J. C., Valadon, P., Dansette, P. M., Catinot, R., Ballet, F., Mansuy, D., Beaune, P. H. (1994). Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem. Res. Toxicol. 7:434–442. [PUBMED], [INFOTRIEVE], [CSA]
  • Lecoeur, S., Andre, C., Beaune, P. H. (1996). Tienilic acid-induced autoimmune hepatitis: anti-liver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol. Pharmacol. 50:326–333. [PUBMED], [INFOTRIEVE], [CSA]
  • Lecureur, V., Fardel, O., Guilouzo, A. (1994). The antiprogestin drug RU486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett. 355:187–191. [PUBMED], [INFOTRIEVE], [CSA]
  • Lee, S. S., Buters, J. T., Pineau, T., Fernandez-Salguero, P., Gonzalez, F. J. (1996). Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 271:12063–12067. [PUBMED], [INFOTRIEVE]
  • Lee, C. R., Goldstein, J. A., Pieper, J. A. (2002). Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251–263. [PUBMED], [INFOTRIEVE], [CSA]
  • Leeder, J. S. (1998). Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia. 39:S8–S16. [PUBMED], [INFOTRIEVE]
  • Leeder, J. S., Dosch, H. M., Spielberg, S. P. (1991). Cellular toxicity of sulfamethoxazole reactive metabolite. I: inhibition of intracellular esterase activity prior to cell death. Biochem. Pharmacol. 41:567–574. [PUBMED], [INFOTRIEVE], [CSA]
  • Leeder, J. S., Gaedigk, A., Lu, X., Cook, V. A. (1996). Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol. Pharmacol. 49:234–243. [PUBMED], [INFOTRIEVE], [CSA]
  • Leeder, J. S., Lu, X., Timsit, Y., Gaedigk, A. (1998). Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions. Pharmacogenetics 8:211–225. [PUBMED], [INFOTRIEVE], [CSA]
  • Lekehal, M., Pessayre, D., Lereau, J. M., Moulis, C., Fouraste, I., Fau, D. (1996). Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology 24:212–218. [PUBMED], [INFOTRIEVE]
  • Leleu, X., Magro, L., Fawaz, A., Bauters, F., Facon, T., Yakoub-Agha, I. (2002). Efficacy of a low dose of thalidomide in advanced multiple myeloma. Blood 100:1519–1520. [PUBMED], [INFOTRIEVE], [CSA]
  • Lenz, W. (1962). Thalidomide and congenital abnormalities [editorial]. Lancet I:45.
  • Lertratanangkoon, K., Horning, M. G. (1982). Metabolism of carbamazepine. Drug Metab. Dispos. 10:1–10. [PUBMED], [INFOTRIEVE]
  • Lessard, E., Fortin, A., Belanger, P. M., Beaune, P., Hamelin, B. A., Turgeon, J. (1997). Role of CYP2D6 in the N-hydroxylation of procainamide. Pharmacogenetics 7:381–390. [PUBMED], [INFOTRIEVE], [CSA]
  • Lessard, E., Hamelin, B. A., Labbe, L., O'Hara, G., Belanger, P. M., Turgeon, J. (1999). Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics 9:683–696. [PUBMED], [INFOTRIEVE], [CSA]
  • Letteron, P., Descatoire, V., Larrey, D., Tinel, M., Geneve, J., Pessayre, D. (1986). Inactivation andinduction of cytochrome P-450 by various psoralen derivatives in rats. J. Pharmacol. Exp. Ther. 238:685–692. [PUBMED], [INFOTRIEVE], [CSA]
  • Letteron, P., Descatoire, V., Tinel, M., Maurel, P., Labbe, G., Loeper, J., Larrey, D., Freneaux, E., Pessayre, D. (1989). Metabolic activation of the antidepressant tianeptine. I. Cytochrome P-450-mediated in vitro covalent binding. Biochem. Pharmacol. 38:3241–3246. [PUBMED], [INFOTRIEVE]
  • Levy, R. H., Rettenmeier, A. W., Anderson, G. A., Wilensky, A. J., Friel, P. N., Baillie, T. A., Acheampong, A., Tor, J., Guyot, M., Loiseau, P. (1990). Effects of polytherapy with phenytoin carbamazepine and stiripentol on formation of 4 ene-valproate, a hepatotoxic metabolite of valproic acid. Clin. Pharmacol. Ther. 48:225–235. [PUBMED], [INFOTRIEVE]
  • Lewis, R. V., Lofthouse, C. (1993). Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Safety 9:272–279. [PUBMED], [INFOTRIEVE], [CSA]
  • Lhoest, G., Dieden, R., Verbeeck, R. K., Maton, N., Ingendoh, A., Latinne, D. (1998). In vitro immunosuppressive activity, isolation from pig liver microsomes and identification by electrospray ms–ms of a new FK-506 C19–C20 epoxide metabolite. J. Pharmacol. Exp. Ther. 284:1074–1081. [PUBMED], [INFOTRIEVE], [CSA]
  • Li, A. P. (2002). A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem.-Biol. Interact. 142:7–23. [PUBMED], [INFOTRIEVE], [CSA]
  • Li, D. N., Seidel, A., Pritchard, M. P., Wolf, C. R., Friedberg, T. (2000). Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 10:343–353. [PUBMED], [INFOTRIEVE], [CSA]
  • Liebler, D. C. (2002). Proteomic approaches to characterize protein modifications: new tools to study the effects of environmental exposures. Environ. Health Perspect. 110:3–9. [PUBMED], [INFOTRIEVE], [CSA]
  • Liégeois, J. F., Rogister, F., Delarge, J., Pincemail, J. (1995). Peroxidase-catalysed oxidation of different dibenzapine derivatives. Arch. Pharm. (Weinh.) 328:109–112. [CSA]
  • Lightning, L. K., Jones, J. P., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., Trager, W. F. (2000). Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394. Biochemistry 39:4276–4287. [PUBMED], [INFOTRIEVE]
  • Lillibridge, J. H., Amore, B. M., Slattery, J. T., Kalhorn, T. F., Nelson, S. D., Finnell, R. H., Bennett, G. D. (1996). Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab. Dispos. 24:509–514. [PUBMED], [INFOTRIEVE], [CSA]
  • Lillibridge, J. H., Liang, B. H., Kerr, B. M., Webber, S., Quart, B., Shetty, B. V., Lee, C. A. (1998). Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab. Dispos. 26:609–616. [PUBMED], [INFOTRIEVE], [CSA]
  • Lin, J. H., Yamazaki, M. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 41:59–98. [CSA]
  • Lin, J. K., Yen, J. Y., Chang, H. W., Lin-Shiau, S. Y. (1984). N-nitrosophenacetin: its synthesis, characterization, mutagenicity, and teratogenicity. J. Natl. Cancer Inst. 72:863–869. [PUBMED], [INFOTRIEVE]
  • Lin, J. H., Chiba, M., Chen, I. W., Vastag, K. J., Nishime, J. A., Dorsey, B. D., Michelson, S. R., McDaniel, S. L. (1995). Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. J. Pharmacol. Exp. Ther. 274:264–269. [PUBMED], [INFOTRIEVE], [CSA]
  • Lin, J. H., Chen, I. W., Chiba, M., Nishime, J. A., Deluna, F. A. (2000). Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: involvement of enzyme inactivation. Drug Metab. Dispos. 28:460–466. [PUBMED], [INFOTRIEVE], [CSA]
  • Lin, H. L., Kent, U. M., Hollenberg, P. F. (2002). Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J. Pharmacol. Exp. Ther. 301:160–167. [PUBMED], [INFOTRIEVE], [CSA]
  • Litwin, A., Adams, L. E., Zimmer, H., Foad, B., Loggie, J. H., Hess, E. V. (1981). Prospective study of immunologic effects of hydralazine in hypertensive patients. Clin. Pharmacol. Ther. 29:447–456., [PUBMED], [INFOTRIEVE], [CSA]
  • Liu, Z. C., Uetrecht, J. P. (1995). Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J. Pharmacol. Exp. Ther. 275:1476–1483. [PUBMED], [INFOTRIEVE], [CSA]
  • Liu, Z. C., Uetrecht, J. P. (2000). Metabolism of ticlopidine by activated neutrophils: implications for ticlopidine-induced agranulocytosis. Drug Metab. Dispos. 28:726–730. [PUBMED], [INFOTRIEVE], [CSA]
  • Liu, L., Wells, P. G. (1995a). DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2′-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Radic. Biol. Med. 19:639–648. [PUBMED], [INFOTRIEVE], [CSA]
  • Liu, L., Wells, P. G. (1995b). Potential molecular targets mediating chemical teratogenesis: in vitro peroxidase-catalyzed phenytoin metabolism and oxidative damage to proteins and lipids in murine maternal hepatic microsomes and embryonic 9000g supernatant. Toxicol. Appl. Pharmacol. 134:71–80. [PUBMED], [INFOTRIEVE], [CSA]
  • Liu, Z. C., McClelland, R. A., Uetrecht, J. P. (1995). Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases. Drug Metab. Dispos. 23:246–250. [PUBMED], [INFOTRIEVE], [CSA]
  • Lo, A., Addison, R. S., Hooper, W. D., Dickinson, R. G. (2001). Disposition of naproxen, naproxen acyl glucuronide and its rearrangement isomers in the isolated perfused rat liver. Xenobiotica 31:309–319. [PUBMED], [INFOTRIEVE], [CSA]
  • Loeper, J., Descatoire, V., Letteron, P., Moulis, C., Degott, C., Dansette, P., Fau, D., Pessayre, D. (1994). Hepatotoxicity of germander in mice. Gastroenterology 106:464–472. [PUBMED], [INFOTRIEVE], [CSA]
  • Loeper, J., De Berardinis, V., Moulis, C., Beaune, P., Pessayre, D., Pompon, D. (2001). Human epoxide hydrolase is the target of germander autoantibodies on the surface of human hepatocytes: enzymatic implications. Adv. Exp. Med. Biol. 500:121–124. [PUBMED], [INFOTRIEVE], [CSA]
  • Lohr, J. W., Willsky, G. R., Acara, M. A. (1998). Renal drug metabolism. Pharmacol. Rev. 50:107–141. [PUBMED], [INFOTRIEVE]
  • Loi, C. M., Alvey, C. W., Vassos, A. B., Randinitis, E. J., Sedman, A., Koup, J. (1999). Steady-state pharmacokinetic and dose proportionality of troglitazone and its metabolites. J. Clin. Pharmacol. 39:920–926. [PUBMED], [INFOTRIEVE], [CSA]
  • Lopez-Carillo, L., Avila, M. H., Dubrow, R. (1994). Chili pepper consumption and gastric cancer in Mexico: a case control study. Am. J. Epidemiol. 139:263–271. [CSA]
  • Lopez-Garcia, M. P., Dansette, P. M., Valadon, P., Amar, C., Beaune, P. H., Guengerich, F. P., Mansuy, D. (1993). Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Eur. J. Biochem. 213:223–232. [PUBMED], [INFOTRIEVE]
  • Lopez-Garcia, M. P., Dansette, P. M., Mansuy, D. (1994). Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 33:166–175. [PUBMED], [INFOTRIEVE]
  • Lord, G. M., Cook, T., Arlt, V. M., Schmeiser, H. H., Williams, G., Pusey, C. D. (2001). Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358:1515–1516. [PUBMED], [INFOTRIEVE]
  • Love, B. B., Biller, J., Gent, M. (1998). Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Safety 19:89–98. [PUBMED], [INFOTRIEVE], [CSA]
  • Ludden, T. M. (1985). Pharmacokinetic interactions of the macrolide antibiotics. Clin. Pharmacokinet. 10:63–79. [PUBMED], [INFOTRIEVE]
  • Luduena, R. F., Roach, M. C. (1991). Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmacol. Ther. 49:133–152. [PUBMED], [INFOTRIEVE]
  • Lum, J. T., Wells, P. G. (1986). Pharmacological studies on the potentiation of phenytoin teratogenicity by acetaminophen. Teratology 33:53–72. [PUBMED], [INFOTRIEVE], [CSA]
  • Lundstrom, J., Hogberg, T., Gosztonyi, T., de Paulis, T. (1981). Metabolism of zimelidine in rat, dog and man. Identification and synthesis of the principal metabolites. Arzneimittelforschung 31:486–494. [PUBMED], [INFOTRIEVE]
  • Lytton, S. D., Berg, U., Nemeth, A., Ingelman-Sundberg, M. (2002). Autoantibodies againstcytochrome P450s in sera of children treated with immunosuppressive drugs. Clin. Exp. Immunol. 127:293–302. [PUBMED], [INFOTRIEVE], [CSA]
  • Ma, B., Prueksaritanont, T., Lin, J. H. (2000). Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos. 28:125–130. [PUBMED], [INFOTRIEVE], [CSA]
  • Macdonald, J. I., Wallace, S. M., Herman, R. J., Verbeeck, R. K. (1995). Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. Eur. J. Clin. Pharmacol. 47:519–523. [PUBMED], [INFOTRIEVE], [CSA]
  • Mackenzie, P. I. (2000). Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther. Drug Monit. 22:10–13. [PUBMED], [INFOTRIEVE], [CSA]
  • Mackenzie, P. I., Miners, J. O., McKinnon, R. A. (2000). Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin. Chem. Lab. Med. 38:889–892. [PUBMED], [INFOTRIEVE], [CSA]
  • Madan, A., Parkinson, A. (1996). Characterization of the NADPH-dependent covalent binding of [14C]halothane to human liver microsomes: a role for cytochrome P4502E1 at low substrate concentrations. Drug Metab. Dispos. 24:1307–1313. [PUBMED], [INFOTRIEVE], [CSA]
  • Madden, S., Woolf, T. F., Pool, W. F., Park, B. K. (1993). An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem. Pharmacol. 46:13–20. [PUBMED], [INFOTRIEVE]
  • Madden, S., Spaldin, V., Hayes, R. N., Woolf, T. F., Pool, W. F., Park, B. K. (1995). Species variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica 25:103–116. [PUBMED], [INFOTRIEVE], [CSA]
  • Madden, S., Maggs, J. L., Park, B. K. (1996). Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). Drug Metab. Dispos. 24:469–479. [PUBMED], [INFOTRIEVE], [CSA]
  • Madyastha, K. M., Gaikwad, N. W. (1999). Metabolic disposition of a monoterpene ketone, piperitenone, in rats: evidence for the formation of a known toxin, p-cresol. Drug Metab. Dispos. 27:74–80. [PUBMED], [INFOTRIEVE], [CSA]
  • Madyastha, K. M., Raj, C. P. (1990). Biotransformations of R-(+)-pulegone and menthofuran in vitro: chemical basis for toxicity. Biochem. Biophys. Res. Commun. 173:1086–1092. [PUBMED], [INFOTRIEVE]
  • Madyastha, K. M., Raj, C. P. (1992). Metabolic fate of menthofuran in rats. Novel oxidative pathways. Drug Metab. Dispos. 20:295–301. [PUBMED], [INFOTRIEVE]
  • Madyastha, K. M., Raj, C. P. (1993). Studies on the metabolism of a monoterpene ketone (R)-(+)-pulegone hepatotoxin in rat: isolation and characterization of new metabolites. Xenobiotica 23:509–518. [PUBMED], [INFOTRIEVE], [CSA]
  • Madyastha, K. M., Raj, C. P. (2002). Stereoselective hydroxylation of 4-methyl-2-cyclohexenone in rats: its relevance to R-(+)-pulegone-mediated hepatotoxicity. Biochem. Biophys. Res. Commun. 297:202–205. [PUBMED], [INFOTRIEVE], [CSA]
  • Maenpaa, J., Sigusch, H., Raunio, H., Syngelma, T., Vuorela, P., Vuorela, H., Pelkonen, O. (1993). Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem. Pharmacol. 45:1035–1042. [PUBMED], [INFOTRIEVE], [CSA]
  • Maggs, J. L., Williams, D., Pirmohamed, M., Park, B. K. (1995). The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J. Pharmacol. Exp. Ther. 275:1463–1475. [PUBMED], [INFOTRIEVE], [CSA]
  • Maggs, J. L., Pirmohamed, M., Kitteringham, N. R., Park, B. K. (1997). Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry. Drug Metab. Dispos. 25:275–280. [PUBMED], [INFOTRIEVE], [CSA]
  • Maguire, J. H. (1988). Quantitative estimation of catechol/methylcatechol pathways in human phenytoin metabolism. Epilepsia 29:753–759. [PUBMED], [INFOTRIEVE]
  • Manchanda, T., Hess, D., Dale, L., Ferguson, S. G., Rieder, M. J. (2002). Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol. Pharmacol. 62:1011–1026. [PUBMED], [INFOTRIEVE], [CSA]
  • Mani, C., Pearce, R., Parkinson, A., Kupfer, D. (1994). Involvement of cytochrome P4503A incatalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 15:2715–2720. [PUBMED], [INFOTRIEVE]
  • Mann, K., Bartels, M., Gartner, H. J., Schied, H. W., Wagner, W., Heimann, H. (1987). Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol results of an open and crossover study. Pharmacopsychiatry 20:155–159. [PUBMED], [INFOTRIEVE]
  • Mansuy, D. (1997). Molecular structure and hepatotoxicity: compared data about two closely related thiophene compounds. J. Hepatol. 26:22–25. [PUBMED], [INFOTRIEVE]
  • Manyike, P. T., Kharasch, E. D., Kalhorn, T. F., Slattery, J. T. (2000). Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin. Pharmacol. Ther. 67:275–282. [PUBMED], [INFOTRIEVE], [CSA]
  • Marks, M. G., Shi, J. D., Fry, M. O., Xiao, Z. L., Trzyna, M., Pokala, V., Ihnat, M. A., Li, P. K. (2002). Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol. Pharm. Bull. 25:597–604. [PUBMED], [INFOTRIEVE], [CSA]
  • Marshall, J. K., Irvine, E. J. (2000). Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am. J. Gastroenterol. 95:1628–1636. [PUBMED], [INFOTRIEVE]
  • Martin, J. L., Pumford, N. R., LaRosa, A. C., Martin, B. M., Gonzaga, H. M., Beaven, M. A., Pohl, L. R. (1991). A metabolite of halothane covalently binds to an endoplasmic reticulum protein that is highly homologous to phosphatidylinositol-specific phospholipase C-alpha but has no activity. Biochem. Biophys. Res. Commun. 178:679–685. [PUBMED], [INFOTRIEVE], [CSA]
  • Martin, J. L., Kenna, J. G., Martin, B. M., Thomassen, D., Reed, G. F., Pohl, L. R. (1993). Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. Hepatology 18:858–863. [PUBMED], [INFOTRIEVE]
  • Massarella, J. W., Nazareno, L. A., Passe, S., Min, B. (1996). The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. Pharm. Res. 13:449–452. [PUBMED], [INFOTRIEVE]
  • Masubuchi, Y., Horie, T. (1998). Dihydralazine-induced inactivation of cytochrome P450 enzymes in rat liver microsomes. Drug Metab. Dispos. 26:338–342. [PUBMED], [INFOTRIEVE], [CSA]
  • Masubuchi, Y., Horie, T. (1999). Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem. Res. Toxicol. 12:1028–1032. [PUBMED], [INFOTRIEVE], [CSA]
  • Masubuchi, Y., Araki, J., Narimatsu, S., Suzuki, T. (1992). Metabolic activation of lidocaine and covalent binding to rat liver microsomal protein. Biochem. Pharmacol. 43:2551–2557. [PUBMED], [INFOTRIEVE]
  • Masubuchi, Y., Umeda, S., Igarashi, S., Fujita, S., Narimatsu, S., Suzuki, T. (1993). Participation of the CYP2D subfamily in lidocaine 3-hydroxylation and formation of a reactive metabolite covalently bound to liver microsomal protein in rats. Biochem. Pharmacol. 46:1867–1869. [PUBMED], [INFOTRIEVE], [CSA]
  • Masubuchi, Y., Narimatsu, S., Hosokawa, S., Suzuki, T. (1994). Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats. Biochem. Pharmacol. 48:1891–1898. [PUBMED], [INFOTRIEVE], [CSA]
  • Masubuchi, Y., Igarashi, S., Suzuki, T., Horie, T., Narimatsu, S. (1996). Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate. J. Pharmacol. Exp. Ther. 279:724–733. [PUBMED], [INFOTRIEVE], [CSA]
  • Masubuchi, Y., Nakano, T., Ose, A., Horie, T. (2001a). Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver. Arch. Toxicol. 75:538–543. [PUBMED], [INFOTRIEVE]
  • Masubuchi, Y., Ose, A., Horie, T. (2001b). Mechanism-based inactivation of CYP2C11 by diclofenac. Drug Metab. Dispos. 29:1190–1195. [PUBMED], [INFOTRIEVE], [CSA]
  • Masubuchi, Y., Masuda, E., Horie, T. (2002a). Multiple mechanisms in indomethacin-induced impairment of hepatic cytochrome P450 enzymes in rats. Gastroenterology 122:774–783. [PUBMED], [INFOTRIEVE], [CSA]
  • Masubuchi, Y., Ose, A., Horie, T. (2002b). Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab. Dispos. 30:1143–1148., [PUBMED], [INFOTRIEVE], [CSA]
  • Mathijssen, R. H.J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., Sparreboom, A. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7:2182–2194. [PUBMED], [INFOTRIEVE], [CSA]
  • Mattei, A., Bizollon, T., Charles, J. D., Debat, P., Fontanges, T., Chevallier, M., Trepo, C. (1992). Liver damage induced by the ingestion of a product of phytotherapy containing wild germander. Four cases. Gastroenterol. Clin. Biol. 16:798–800. [PUBMED], [INFOTRIEVE]
  • Mayhew, B. S., Jones, D. R., Hall, S. D. (2000). An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28:1031–1037. [PUBMED], [INFOTRIEVE], [CSA]
  • Mays, D. C., Hilliard, J. B., Wong, D. D., Chambers, M. A., Park, S. S., Gelboin, H. V., Gerber, N. (1990). Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome P-450 in mouse liver microsomes: modification by monoclonal antibodies, inhibition of drug metabolism and distribution of covalent adducts. J. Pharmacol. Exp. Ther. 254:720–731. [PUBMED], [INFOTRIEVE]
  • Mays, D. C., Pawluk, L. J., Apseloff, G., Davis, W. B., She, Z. W., Sagone, A. L., Gerber, N. (1995). Metabolism of phenytoin and covalent binding of reactive intermediates in activated human neutrophils. Biochem. Pharmacol. 50:367–380. [PUBMED], [INFOTRIEVE], [CSA]
  • Mazzarella, R. A., Green, M. (1987). ERp99, an abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to the 90-kDa heat shock protein (hsp90) and the 94-kDa glucose regulated protein (GRP94). J. Biol. Chem. 262:8875–8883. [PUBMED], [INFOTRIEVE]
  • Mazzarella, R. A., Srinivasan, M., Haugejorden, S. M., Green, M. (1990). ERp72, an abundant luminal endoplasmic reticulum protein, contains three copies of the active site sequences of protein disulfide isomerase. J. Biol. Chem. 265:1094–1101. [PUBMED], [INFOTRIEVE]
  • McBride, W. G. (1968). Thalidomide and congenital abnormalities. Lancet 2:1358.
  • McClain, R. M., Langhoff, L. (1980). Teratogenicity of diphenylhydantoin in the New Zealand white rabbit. Teratology 21:371–379. [PUBMED], [INFOTRIEVE]
  • McClanahan, R. H., Thomassen, D., Slattery, J. T., Nelson, S. D. (1989). Metabolic activation of (R)-(+)-pulegone to a reactive enonal that covalently binds to mouse liver proteins. Chem. Res. Toxicol. 2:349–355. [PUBMED], [INFOTRIEVE]
  • McHarg, A. M., McHarg, J. F. (1979). Leucopenia in association with mianserin treatment. Br. Med. J. 1:623–624. [PUBMED], [INFOTRIEVE]
  • McHugh, S. M., Rowland, T. L. (1997). Thalidomide and derivatives—immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation. Clin. Exp. Immunol. 110:151–154. [PUBMED], [INFOTRIEVE], [CSA]
  • McKinnon, G. E., Dickinson, R. G. (1989). Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. Res. Commun. Chem. Pathol. Pharmacol. 66:339–354. [PUBMED], [INFOTRIEVE]
  • McLaughlin, J. K., Blot, W. J., Mehl, E. S., Fraumeni, J. F. Jr. (1985). Relation of analgesic use to renal cancer: population-based findings. Natl. Cancer Inst. Monogr. 69:217–222. [PUBMED], [INFOTRIEVE]
  • McLaughlin, J. K., Lipworth, L., Chow, W. H., Blot, W. J. (1998). Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. Kidney Int. 54:679686.
  • McLeod, H. L. (2001). Pharmacogenetics: more than skin deep. Nat. Genet. 29:247–248. [PUBMED], [INFOTRIEVE]
  • McLeod, H. L., Evans, W. E. (2001). Pharmacogenomics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41:101–121. [PUBMED], [INFOTRIEVE], [CSA]
  • McRae, C. A., Agarwal, K., Mutimer, D., Bassendine, M. F. (2002). Hepatitis associated with Chinese herbs. Eur. J. Gastroenterol. Hepatol. 14:559–562. [PUBMED], [INFOTRIEVE], [CSA]
  • Medina, I., Mills, J., Leoung, G., Hopewell, P. C., Lee, B., Modin, G., Benowitz, N., Wofsy, C. B. (1990). Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N. Engl. J. Med. 323:776–778. [PUBMED], [INFOTRIEVE], [CSA]
  • Meffin, P. J., Zilm, D. M., Veenendaal, J. R. (1983). A renal mechanism for the clofibric acid-probenecid interaction. J. Pharmacol. Exp. Ther. 227:739–742., [PUBMED], [INFOTRIEVE]
  • Melamed, E., Offen, D., Shirvan, A., Djaldetti, R., Barzilai, A., Ziv, I. (1998). Levodopa toxicity and apoptosis. Ann. Neurol. 44:S149–S154. [PUBMED], [INFOTRIEVE], [CSA]
  • Melamed, E., Offen, D., Shirvan, A., Ziv, I. (2000). Levodopa—an exotoxin or a therapeutic drug? J. Neurol. 247:II135–II139. [PUBMED], [INFOTRIEVE]
  • Melet, A., Assrir, N., Jean, P., Pilar Lopez-Garcia, M., Marques-Soares, C., Jaouen, M., Dansette, P. M., Sari, M. A., Mansuy, D. (2003). Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch. Biochem. Biophys. 409:80–91. [PUBMED], [INFOTRIEVE], [CSA]
  • Melethil, S., Conway, W. D. (1976). Urinary excretion of probenecid and its metabolites in humans as a function of dose. J. Pharm. Sci. 65:861–865. [PUBMED], [INFOTRIEVE]
  • Menendez-Arias, L. (2002). Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 23:381–388. [PUBMED], [INFOTRIEVE]
  • Meyer, U. A., Gut, J. (2002). Genomics and the prediction of xenobiotic toxicity. Toxicology 27:463–466.
  • Michalets, E. L., Williams, C. R. (2000). Drug interactions with cisapride: clinical implications. Clin. Pharmacokinet. 39:49–75. [PUBMED], [INFOTRIEVE], [CSA]
  • Miller, J. A. (1994). Brief history of chemical carcinogenesis. Cancer Lett. 83:9–14. [PUBMED], [INFOTRIEVE], [CSA]
  • Miller, E. C., Miller, J. A. (1981). Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer 47:2327–2345. [PUBMED], [INFOTRIEVE]
  • Miller, J. L., Trepanier, L. A. (2002). Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation. Eur. J. Clin. Pharmacol. 58:69–72. [PUBMED], [INFOTRIEVE], [CSA]
  • Miller, J. W., Skerjanec, A., Knadler, M. P., Ghosh, A., Allerheiligen, S. R. (2001). Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin. Pharm. Res. 18:1024–1028. [PUBMED], [INFOTRIEVE]
  • Min, H., Shane, B., Stokstad, E. L. (1998). Identification of 10-formyltetrahydrofolate dehydrogenase-hydrolase as a major folate binding protein in liver cytosol. Biochim. Biophys. Acta 967:348–353.
  • Miner, D. J., Kissinger, P. T. (1979). Evidence for the involvement of N-acetyl-p-quinoneimine in acetaminophen metabolism. Biochem. Pharmacol. 28:3285–3290. [PUBMED], [INFOTRIEVE]
  • Mingatto, F. E., dos Santos, A. C., Rodrigues, T., Pigoso, A. A., Uyemura, S. A., Curti, C. (2000). Effects of nimesulide and its reduced metabolite on mitochondria. Br. J. Pharmacol. 131:1154–1160. [PUBMED], [INFOTRIEVE], [CSA]
  • Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., Jollow, H. R., Keiser, H. R. (1975). Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin. Pharmacol. Ther. 18:70–79. [PUBMED], [INFOTRIEVE]
  • Mitra, A. K., Thummel, K. E., Kalhorn, T. F., Kharasch, E. D., Unadkat, J. D., Slattery, J. T. (1995). Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin. Pharmacol. Ther. 58:556–566. [PUBMED], [INFOTRIEVE], [CSA]
  • Miura, T., Iwasaki, M., Komori, M., Ohi, H., Kitada, M., Mitsui, H., Kamataki, T. (1989). Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics. J. Antimicrob. Chemother. 24:551–559. [PUBMED], [INFOTRIEVE], [CSA]
  • Miura, T., Muraoka, S., Fujimoto, Y., Zhao, K. (2000). DNA damage induced by catechol derivatives. Chem.-Biol. Interact. 126:125–131. [PUBMED], [INFOTRIEVE], [CSA]
  • Miyamoto, G., Zahid, N., Uetrecht, J. P. (1997). Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem. Res. Toxicol. 10:414–419. [PUBMED], [INFOTRIEVE], [CSA]
  • Miyata, M., Tamura, E., Motoki, K., Nagata, K., Yamazoe, Y. (2003). Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation. Drug Metab. Dispos. 31:469–475. [PUBMED], [INFOTRIEVE], [CSA]
  • Mizuma, T., Benet, L. Z., Lin, E. T. (1999a). Interaction of human serum albumin with furosemide glucuronide: a role of albumin in isomerization, hydrolysis, reversible binding andirreversible binding of a 1-O-acyl glucuronide metabolite. Biopharm. Drug Dispos. 20:131–136. [PUBMED], [INFOTRIEVE], [CSA]
  • Mizuma, T., McDonagh, A. F., Lin, E. T., Benet, L. Z. (1999b). Photoinduced covalent binding of frusemide and frusemide glucuronide to human serum albumin. Br. J. Clin. Pharmacol. 48:79–87. [PUBMED], [INFOTRIEVE], [CSA]
  • Moder, K. G. (2003). Mycophenolate mofetil: new applications for this immunosuppressant. Ann. Allergy, Asthma, & Immun. 90:15–19. [CSA]
  • Mohri, K., Uesawa, Y. (2001). Effects of furanocoumarin derivatives in grapefruit juice on nifedipine pharmacokinetics in rats. Pharm. Res. 18:177–182. [PUBMED], [INFOTRIEVE]
  • Moldeus, P., Andersson, B., Rahimtula, A., Berggren, M. (1982). Prostaglandin synthetase catalyzed activation of paracetamol. Biochem. Pharmacol. 31:1363–1368. [PUBMED], [INFOTRIEVE]
  • Mongey, A. B., Hess, E. (2001). In vitro production of antibodies to histones in patients receiving chronic procainamide therapy. J. Rheumatol. 28:1992–1998. [PUBMED], [INFOTRIEVE]
  • Moorthy, B., Madyastha, P., Madyastha, K. M. (1989). Metabolism of a monoterpene ketone (R)-(+)-pulegonea hepatotoxin in rat. Xenobiotica 19:217–224. [PUBMED], [INFOTRIEVE], [CSA]
  • Mor, Z., Caspi, E. (1997). Cutaneous complications of hormonal replacement therapy. Clin. Dermatol. 15:147–154. [PUBMED], [INFOTRIEVE], [CSA]
  • Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., Kaplan, G. (1993). Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177:1675–1680. [PUBMED], [INFOTRIEVE]
  • Moreno, R. L., Kent, U. M., Hodge, K., Hollenberg, P. F. (1999). Inactivation of cytochrome P450 2E1 by benzyl isothiocyanate. Chem. Res. Toxicol. 12:582–587. [PUBMED], [INFOTRIEVE], [CSA]
  • Morgan, K. T., Ni, H., Brown, H. R., Yoon, L., Qualls, C. W.Jr., Crosby, L. M., Reynolds, R., Gaskill, B., Anderson, S. P., Kepler, T. B., Brainard, T., Liv, N., Easton, M., Merrill, C., Creech, D., Sprenger, D., Conner, G., Johnson, P. R., Fox, T., Sartor, M., Richard, E., Kuruvilla, S., Casey, W., Benavides, G. (2002). Application of cDNA microarray technology to in vitro toxicology and the selection of genes for a real-time RT-PCR-based screen for oxidative stress in Hep-G2 cells. Toxicol. Pathol. 30:435–451. [PUBMED], [INFOTRIEVE], [CSA]
  • Morrow, P. L., Hardin, N. J., Bonadies, J. (1989). Hypersensitivity myocarditis and hepatitis associated with imipramine and its metabolite, desipramine. J. Forensic Sci. 34:1016–1020. [PUBMED], [INFOTRIEVE]
  • Mostefa-Kara, N., Pauwels, A., Pines, E., Biour, M., Levy, V. G. (1992). Fatal hepatitis after herbal tea. Lancet 340:674. [PUBMED], [INFOTRIEVE]
  • Motzer, R. J., Berg, W., Ginsberg, M., Russo, P., Vuky, J., Yu, R., Bacik, J., Mazumdar, M. (2002). Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J. Clin. Oncol. 20:302–306. [PUBMED], [INFOTRIEVE]
  • Moyle, G., Carr, A. (2002). HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin. Trials 3:89–98. [PUBMED], [INFOTRIEVE], [CSA]
  • Mulder, G. J., Kadlubar, F. F., Mays, J. B., Hinson, J. A. (1984). Reaction of mutagenic phenacetin metabolites with glutathione and DNA. Possible implications for toxicity. Mol. Pharmacol. 26:342–347. [PUBMED], [INFOTRIEVE]
  • Müller-Oerlinghausen, B. (1984). A short survey on untoward effects of fluperlapine. ArzneimForsch 34:131–134.
  • Munns, A. J., De Voss, J. J., Hooper, W. D., Dickinson, R. G., Gillam, E. M. (1997). Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. Chem. Res. Toxicol. 10:1049–1058. [PUBMED], [INFOTRIEVE], [CSA]
  • Muramatsu, M., Inoue, S. (2000). Estrogen receptors: how do they control reproductive and nonreproductive functions? Biochem. Biophys. Res. Commun. 270:1–10. [PUBMED], [INFOTRIEVE], [CSA]
  • Murray, B. P., Correia, M. A. (2001). Ubiquitin-dependent 26S proteasomal pathway: a role in the degradation of native human liver CYP3A4 expressed in Saccharomyces cerevisiae? Arch. Biochem. Biophys. 393:106–116., [PUBMED], [INFOTRIEVE], [CSA]
  • Myers, M. W., Jick, H. (1997). Hospitalization for serious blood and skin disorders following use of co-trimoxazole. Br. J. Clin. Pharmacol. 43:446–448. [PUBMED], [INFOTRIEVE], [CSA]
  • Myers, T. G., Thummel, K. E., Kalhorn, T. F., Nelson, S. D. (1994). Preferred orientations in the binding of 4′-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J. Med. Chem. 37:860–867. [PUBMED], [INFOTRIEVE], [CSA]
  • Myers, K. W., Katial, R. K., Engler, R. J. M. (1998). Probenecid hypersensitivity in AIDS: a case report. Ann. Allergy, Asthma, & Immun. 80:416–418. [CSA]
  • Mytilineou, C., Walker, R. H., JnoBaptiste, R., Olanow, C. W. (2003). Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J. Pharmacol. Exp. Ther. 304:792–800. [PUBMED], [INFOTRIEVE], [CSA]
  • Nadir, A., Agrawal, S., King, P. D., Marshall, J. B. (1996). Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am. J. Gastroenterol. 91:1436–1438. [PUBMED], [INFOTRIEVE]
  • Naganuma, M., Shiga, T., Nishikata, K., Tsuchiya, T., Kasanuki, H., Fujii, E. (2001). Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J. Cardiovasc. Pharmacol. Ther. 6:363–367. [PUBMED], [INFOTRIEVE], [CSA]
  • Naisbitt, D. J., Ruscoe, J. E., Williams, D., O'Neill, P. M., Pirmohamed, M., Park, B. K. (1997). Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. J. Pharmacol. Exp. Ther. 280:884–893. [PUBMED], [INFOTRIEVE], [CSA]
  • Naisbitt, D. J., Williams, D. P., O'Neill, P. M., Maggs, J. L., Willock, D. J., Pirmohamed, M., Park, B. K. (1998). Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antimalarial drugs. Chem. Res. Toxicol. 11:1586–1595. [PUBMED], [INFOTRIEVE], [CSA]
  • Naisbitt, D. J., Hough, S. J., Gill, H. J., Pirmohamed, M., Kitteringham, N. R., Park, B. K. (1999). Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br. J. Pharmacol. 126:1393–1407. [PUBMED], [INFOTRIEVE], [CSA]
  • Naisbitt, D. J., Williams, D. P., Pirmohamed, M., Kitteringham, N. R., Park, B. K. (2001). Reactive metabolites and their role in drug reactions. Curr. Opin. Allergy Clin. Immunol. 1:317–325. [PUBMED], [INFOTRIEVE], [CSA]
  • Naisbitt, D. J., Farrell, J., Gordon, S. F., Maggs, J. L., Burkhart, C., Pichler, W. J., Pirmohamed, M., Park, B. K. (2002). Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol. Pharmacol. 62:628–637. [PUBMED], [INFOTRIEVE], [CSA]
  • Naisbitt, D. J., Pirmohamed, M., Park, B. K. (2003). Immunopharmacology of hypersensitivity reactions to drugs. Curr. Allergy Asthma Rep. 3:222–229.
  • Nakajima, M., Tanaka, E., Kobayashi, T., Ohashi, N., Kume, T., Yokoi, T. (2002). Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metab. Dispos. 30:636–642. [PUBMED], [INFOTRIEVE], [CSA]
  • Namazy, J. A., Simon, R. A. (2002). Sensitivity to nonsteroidal anti-inflammatory drugs. Ann. Allergy, Asthma, & Immun. 89:542–550. [CSA]
  • Nappi, A. J., Vass, E. (2001). The effects of nitric oxide on the oxidations of L-dopa and dopamine mediated by tyrosinase and peroxidase. J. Biol. Chem. 276:11214–11222. [PUBMED], [INFOTRIEVE]
  • Narazaki, R., Harada, K., Sugii, A., Otagiri, M. (1997). Kinetic analysis of the covalent binding of captopril to human serum albumin. J. Pharm. Sci. 86:215–219. [PUBMED], [INFOTRIEVE]
  • Narazaki, R., Watanabe, H., Maruyama, T., Suenaga, A., Otagiri, M. (1998). An immunological method for the detection of captopril-protein conjugate. Arch. Toxicol. 72:203–206. [PUBMED], [INFOTRIEVE]
  • Narimatsu, S., Watanabe, T., Masubuchi, Y., Horie, T., Kumagai, Y., Cho, A. K., Imaoka, S., Funae, Y., Ishikawa, T., Suzuki, T. (1995). Characterization of a chemically reactive propranolol metabolite that binds to microsomal proteins of rat liver. Chem. Res. Toxicol. 8:721–728. [PUBMED], [INFOTRIEVE], [CSA]
  • Narimatsu, S., Arai, T., Watanabe, T., Masubuchi, Y., Horie, T., Suzuki, T., Ishikawa, T., Tsutsui, M., Kumagai, Y., Cho, A. K. (1997). Covalent binding of a reactive metabolite derived from propranolol and its active metabolite 4-hydroxypropranolol to hepatic microsomal proteins of the rat. Chem. Res. Toxicol. 10:289–295. [PUBMED], [INFOTRIEVE], [CSA]
  • Narimatsu, S., Yamamoto, S., Kato, R., Masubuchi, Y., Horie, T. (1999). Contribution of flavin-containing monooxygenase and cytochrome P450 to imipramine N-oxidation in rat hepatic microsomes. Biol. Pharm. Bull. 22:567–571. [PUBMED], [INFOTRIEVE], [CSA]
  • Narimatsu, S., Arai, T., Masubuchi, Y., Horie, T., Hosokawa, M., Ueno, K., Kataoka, H., Yamamoto, S., Ishikawa, T., Cho, A. K. (2001). Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol. Biol. Pharm. Bull. 24:988–994. [PUBMED], [INFOTRIEVE], [CSA]
  • Nelson, S. D., Mitchell, J. R., Timbrell, J. A., Snodgrass, W. R., Corcoran, G. B. III (1976). Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 193:901–903. [PUBMED], [INFOTRIEVE]
  • Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., Allan, J. D. (2002). Postmenopausal hormone replacement therapy: scientific review. JAMA. 288:872–881. [PUBMED], [INFOTRIEVE]
  • Neuberger, J., Williams, R. (1989). Immune mechanisms in tienilic acid associated hepatotoxicity. Gut 30:515–519. [PUBMED], [INFOTRIEVE]
  • Neubert, R., Hinz, N., Thiel, R., Neubert, D. (1996). Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci. 58:295–316. [PUBMED], [INFOTRIEVE]
  • Neuman, M. G., Shear, N. H., Jacobson-Brown, P. M., Katz, G. G., Neilson, H. K., Malkiewicz, I. M., Cameron, R. G., Abbott, F. (2001). CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity. Clin. Biochem. 34:211–218. [PUBMED], [INFOTRIEVE]
  • Ng, S. S. W., Brown, M., Figg, W. D. (2002). Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomed. Pharmacother. 56:194–199. [PUBMED], [INFOTRIEVE], [CSA]
  • Nicholson, J. K., Connelly, J., Lindon, J. C., Holmes, E. (2002). Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1:153–161. [PUBMED], [INFOTRIEVE], [CSA]
  • Nicolau, D. P., Uber, W. E., Crumbley, A. J. I., Strange, C. (1992). Amiodarone-cyclosporine interaction in a heart transplant patient. J. Heart Lung Transplant. 11:564–568. [PUBMED], [INFOTRIEVE]
  • Njoku, D., Laster, M. J., Gong, D. H., Reed, G. F., Martin, J. L. (1997). Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth. Analg. 84:173–178. [PUBMED], [INFOTRIEVE]
  • Njoku, D. B., Greenberg, R. S., Bourdi, M., Borkowf, C. B., Dake, E. M., Martin, J. L., Pohl, L. R. (2002). Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth. Analg. 94:243–249. [PUBMED], [INFOTRIEVE]
  • Nobata, S., Ohira, T., Nagae, H., Ushiyama, T., Suzuki, K., Fujita, K. (2001). Licorice-induced pseudoaldosteronism in a patient with a non-functioning adrenal tumor. Hinyokika Kiyo-Acta Urologica Japonica 47:633–635. [PUBMED], [INFOTRIEVE]
  • Nohmi, T., Mizokami, K., Kawano, S., Fukuhara, M., Ishidate, M. Jr. (1987). Metabolic activation of phenacetin and phenetidine by several forms of cytochrome P-450 purified from liver microsomes of rats and hamsters. Jpn. J. Cancer Res. 78:153–161. [PUBMED], [INFOTRIEVE]
  • Nolan, P. E., Marcus, F. I., Hoyer, G. L., Bliss, M., Gear, K. (1989). Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin. Pharmacol. Ther. 46:43–50. [PUBMED], [INFOTRIEVE]
  • Nolan, C. M., Goldberg, S. V., Buskin, S. E. (1999). Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 281:1014–1018. [PUBMED], [INFOTRIEVE]
  • Noort, D., Hulst, A. G., Jansen, R. (2002). Covalent binding of nitrogen mustards to the cysteine-34 residue in human serum albumin. Arch. Toxicol. 76:83–88. [PUBMED], [INFOTRIEVE]
  • Nortier, J. L., Vanherweghem, J. L. (2002). Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). Toxicology 181–182:577–580.
  • Notley, L. M., De Wolf, C. J., Wunsch, R. M., Lancaster, R. G., Gillam, E. M. (2002). Bioactivation of tamoxifen by recombinant human cytochrome p450 enzymes. Chem. Res. Toxicol. 15:614–622., [PUBMED], [INFOTRIEVE], [CSA]
  • Obermayer-Straub, P., Manns, M. P. (1996). Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Mol. Biol. Rep. 23:235–242. [PUBMED], [INFOTRIEVE], [CSA]
  • Obermayer-Straub, P., Strassburg, C. P., Manns, M. P. (2000a). Autoimmune hepatitis. J. Hepatol. 32:181–197. [PUBMED], [INFOTRIEVE]
  • Obermayer-Straub, P., Strassburg, C. P., Manns, M. P. (2000b). Target proteins in human autoimmunity: cytochromes P450 and UDP-glucuronosyltransferases. Can. J. Gastroenterol. 14:429–439. [PUBMED], [INFOTRIEVE], [CSA]
  • O'Brien, P. J. (2000). Peroxidases. Chem.-Biol. Interact. 129:113–139. [PUBMED], [INFOTRIEVE], [CSA]
  • Ohmori, S., Ishii, I., Kuriya, S., Taniguchi, T., Rikihisa, T., Hirose, S., Kanakubo, Y., M., K. (1993). Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rat. Drug Metab. Dispos. 21:358–363. [PUBMED], [INFOTRIEVE]
  • Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., Ito, M., Yamamoto, Y., Ogura, T., Maeda, K., Komuta, K., Igarashi, T., Azumam, J. (2000). Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 4:256–261. [PUBMED], [INFOTRIEVE], [CSA]
  • Ohyama, K., Nakajima, M., Nakamura, S., Shimada, N., Yamazaki, H., Yokoi, T. (2000a). A significant role of human cytochrome P4502C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab. Dispos. 28:1303–1310. [PUBMED], [INFOTRIEVE], [CSA]
  • Ohyama, K., Nakajima, M., Suzuki, M., Shimada, N., Yamazaki, H., Yokoi, T. (2000b). Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br. J. Clin. Pharmacol. 49:244–253. [PUBMED], [INFOTRIEVE], [CSA]
  • Ojingwa, J. C., Spahn-Langguth, H., Benet, L. Z. (1988). Studies of tolmetin reversible and irreversible binding to proteins via its glucuronide conjugates. Pharm. Res. 5:S214.
  • Ojingwa, J. C., Spahnlangguth, H., Benet, L. Z. (1994). Irreversible binding of tolmetin to macromolecules via its glucuronide—binding to blood constituent, tissue homogenates and subcellular fractions in vitro. Xenobiotica 24:495–506. [PUBMED], [INFOTRIEVE], [CSA]
  • Olanow, C. W. (2000). Tolcapone and hepatotoxic effects. Arch. Neurol. 57:263–267. [PUBMED], [INFOTRIEVE]
  • Olliaro, P., Mussano, P. (2000). Amodiaquine for treating malaria. Cochrane Database Syst. Rev. 2:CD000016.
  • Olliaro, P., Nevill, C., LeBras, J., Ringwald, P., Mussano, P., Garner, P., Brasseur, P. (1996). Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348:1196–1201. [PUBMED], [INFOTRIEVE]
  • Olsen, J., Bjornsdottir, I., Tjornelund, J., Honore Hansen, S. (2002). Chemical reactivity of the naproxen acyl glucuronide and the naproxen coenzyme A thioester towards bionucleophiles. J. Pharm. Biomed. Anal. 29:7–15. [PUBMED], [INFOTRIEVE], [CSA]
  • Olson, D. P., Scadden, D. T., D'Aquila, R. T., De Pasquale, M. P. (2002). The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 16:1743–1747. [PUBMED], [INFOTRIEVE]
  • Olyaei, A. J., de Mattos, A. M., Bennett, W. M. (2001). Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr. Opin. Crit. Care 7:384–389. [PUBMED], [INFOTRIEVE], [CSA]
  • Ono, K., Kurohara, K., Yoshihara, M., Shimamoto, Y., Yamaguchi, M. (1991). Agranulocytosis caused by ticlopidine and its mechanism. Am. J. Hematol. 37:239–242. [PUBMED], [INFOTRIEVE]
  • Ordi-Ros, J., Cortes, F., Cucurull, E., Jet, L. (2000). Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J. Rheumatol. 27:1429–1433. [PUBMED], [INFOTRIEVE]
  • O'Regan, R. M., Jordan, V. C. (2002). The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 3:207–214. [PUBMED], [INFOTRIEVE], [CSA]
  • O'Reilly, R. A., Tranger, W. F., Rettie, A. E., Goulart, D. A. (1987). Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in human. Clin. Pharmacol. Ther. 42:290–294. [PUBMED], [INFOTRIEVE], [CSA]
  • Ortiz de Montellano, P. R., Kunze, K. L. (1980). Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates. J. Biol. Chem. 255:5578–5585., [PUBMED], [INFOTRIEVE]
  • Ortiz de Montellano, P. R., Reich, N. O. (1984). Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids. J. Biol. Chem. 259:4136–4141. [PUBMED], [INFOTRIEVE]
  • Osterman-Golkar, S., Ehrenberg, L., Segerback, D., Hallstrom, I. (1976). Evaluation of genetic risks of alkylating agents. II. Haemoglobin as a dose monitor. Mutat. Res. 34:1–10. [PUBMED], [INFOTRIEVE]
  • Pai, V. B., Nahata, M. C. (1999). Nelfinavir mesylate: a protease inhibitor. Ann. Pharmacother. 33:325–339. [PUBMED], [INFOTRIEVE], [CSA]
  • Pan, L., Belpaire, F. M. (1999). In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur. J. Clin. Pharmacol. 55:599–604. [PUBMED], [INFOTRIEVE], [CSA]
  • Pan, L. P., Wijnant, P., De Vriendt, C., Rosseel, M. T., Belpaire, F. M. (1997). Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br. J. Clin. Pharmacol. 44:557–564. [PUBMED], [INFOTRIEVE], [CSA]
  • Pan, L. P., De Vriendt, C., Belpaire, F. M. (1998). In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 8:383–389. [PUBMED], [INFOTRIEVE], [CSA]
  • Pantarotto, C., Arboix, M., Sezzano, P., Abbruzzi, R. (1982). Studies on 5,5-diphenylhydantoin irreversible binding to rat liver microsomal proteins. Biochem. Pharmacol. 31:1501–1507. [PUBMED], [INFOTRIEVE]
  • Pariente, E. A., Pessayre, D., Bernuau, J., Degott, C., Benhamou, J. P. (1983). Dihydralazine hepatitis: report of a case and review of the literature. Digestion 27:47–52. [PUBMED], [INFOTRIEVE]
  • Park, B. K., Grabowski, P. S., Yeung, J. H., Breckenridge, A. M. (1982). Drug protein conjugates—I. A study of the covalent binding of [14C]captopril to plasma proteins in the rat. Biochem. Pharmacol. 31:1755–1760. [PUBMED], [INFOTRIEVE]
  • Park, K. K., Chun, K. S., Yook, J. I., Surh, Y. J. (1998). Lack of tumor promoting activity of capsaicin, a principal pungent ingredient of red peppers, in mouse skin carcinogens. Anticancer Res. 18:4201–4205. [PUBMED], [INFOTRIEVE], [CSA]
  • Park, G. J., Mann, S. P., Ngu, M. C. (2001). Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum. J. Gastroenterol. Hepatol. 16:115–117. [PUBMED], [INFOTRIEVE], [CSA]
  • Parker, R. J., Collins, J. M., Strong, J. M. (1996). Identification of 2,6-xylidine as a major lidocaine metabolite in human liver slices. Drug Metab. Dispos. 24:1167–1173. [PUBMED], [INFOTRIEVE], [CSA]
  • Parman, T., Chen, G., Wells, P. G. (1998). Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis. J. Biol. Chem. 273:25079–25088. [PUBMED], [INFOTRIEVE]
  • Parman, T., Wiley, J. M., Wells, P. G. (1999). Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. 5:582–585. [PUBMED], [INFOTRIEVE], [CSA]
  • Parrish, J. A., Fitzpatrick, T. B., Tanenbaum, L., Pathak, M. A. (1974). Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N. Engl. J. Med. 291:1207–1211. [PUBMED], [INFOTRIEVE]
  • Pascussi, J. M., Gerbal-Chaloin, S., Pichard-Garcia, L., Daujat, M., Fabre, J. M., Maurel, P., Vilarem, M. J. (2000). Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem. Biophys. Res. Commun. 274:707–713. [PUBMED], [INFOTRIEVE], [CSA]
  • Patel, I. H., Levy, R. H., Cutler, R. E. (1980). Phenobarbital-valproic acid interaction. Clin. Pharmacol. Ther. 27:515–521. [PUBMED], [INFOTRIEVE]
  • Patel, D. K., Notarianni, L. J., Bennett, P. N. (1990). Comparative metabolism of high doses of aspirin in man and rat. Xenobiotica 20:847–854. [PUBMED], [INFOTRIEVE]
  • Patel, M., Tang, B. K., Kalow, W. (1992). Variability of acetaminophen metabolism in Caucasians and Orientals. Pharmacogenetics 2:38–45. [PUBMED], [INFOTRIEVE]
  • Patsalos, P. N., Froscher, W., Pisani, F., van Rijn, C. M. (2002). The importance of drug interactions in epilepsy therapy. Epilepsia 43:365–385. [PUBMED], [INFOTRIEVE], [CSA]
  • Pearce, R. K., Owen, A., Daniel, S., Jenner, P., Marsden, C. D. (1997). Alterations in thedistribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104:661–677. [PUBMED], [INFOTRIEVE], [CSA]
  • Pearce, R. E., Vakkalagadda, G. R., Leeder, J. S. (2002). Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab. Dispos. 30:1170–1179. [PUBMED], [INFOTRIEVE], [CSA]
  • Pelkonen, O. (2002). Human CYPs: in vivo and clinical aspects. Drug Metab. Rev. 34:37–46. [PUBMED], [INFOTRIEVE], [CSA]
  • Pelkonen, O., Raunio, H. (1997). Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. Environ. Health Perspect. 105:767–774. [PUBMED], [INFOTRIEVE]
  • Pelkonen, O., Boobis, A. R., Kremers, P., Ingelman-Sundberg, M., Rane, A. (2001a). Interindividual variation of P450 enzymes in vitro and its causes. In: Pacifici, G. M., Pelkonen, O., Interindividual Variability in Human Drug Metabolism. London: Taylor & Francis Ltd., pp.269–332. [Article].
  • Pelkonen, O., Myllynen, P., Taavitsainen, P., Boobis, A. R., Watts, P., Lake, B. G., Price, R. J., Renwick, A. B., Gomez-Lechon, M. J., Castell, J. V., Ingelman-Sundberg, M., Hidestrand, M., Guillouzo, A., Corcos, L., Goldfarb, P. S., Lewis, D. F.V. (2001b). Carbamazepine: a ‘blind’ assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31:321–343. [PUBMED], [INFOTRIEVE], [CSA]
  • Pellock, J. M. (1987). Carbamazepine side effects in children and adults. Epilepsia 28:S64–S70. [PUBMED], [INFOTRIEVE]
  • Perez-Gilabert, M., Sanchez-Ferrer, A., Garcia-Carmona, F. (1997). Oxidation of aminopyrine by the hydroperoxidase activity of lipoxygenase: a new proposed mechanism of N-demethylation. Free Radic. Biol. Med. 23:548–555. [PUBMED], [INFOTRIEVE], [CSA]
  • Periti, P., Mazzei, T., Mini, E., Novelli, A. (1992). Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 23:106–131. [PUBMED], [INFOTRIEVE], [CSA]
  • Pershing, L. K., Franklin, M. R. (1982). Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics: a new class of agents. Xenobiotica 12:687–699. [PUBMED], [INFOTRIEVE]
  • Perucca, E. (2002). Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 16:695–714. [PUBMED], [INFOTRIEVE], [CSA]
  • Perucca, E., Hebdige, S., Frigo, G. M., Gatti, G., Lecchini, S., Crema, A. (1980). Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin. Pharmacol. Ther. 28:779–789. [PUBMED], [INFOTRIEVE]
  • Pessayre, D., Tinel, M., Larrey, D., Cobert, B., Funck-Brentano, C., Babany, G. (1983). Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione. J. Pharmacol. Exp. Ther. 224:685–691. [PUBMED], [INFOTRIEVE]
  • Peters, J. M., Morishima, H., Ward, J. M., Coakley, C. J., Kimura, S., Gonzalez, F. J. (1999). Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice. Toxicol. Sci. 50:82–89. [PUBMED], [INFOTRIEVE], [CSA]
  • Petersen, H. A., Foster, J. F. (1965). The microheterogeneity of plasma albumins. 3. Comparison of some physicochemical properties of subfractions. J. Biol. Chem. 240:3858–3865. [PUBMED], [INFOTRIEVE]
  • Petty, B. G., Kornhauser, D. M., Lietman, P. S. (1990). Zidovudine with probenecid: a warning. Lancet 335:1044–1045. [PUBMED], [INFOTRIEVE]
  • Pfau, W., Schmeiser, H. H., Wiessler, M. (1990). Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 11:313–319. [PUBMED], [INFOTRIEVE]
  • Picard-Fraire, C. (1984). Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. Agents Actions 15:68–75.
  • Picciotto, A., Campo, N., Brizzolara, R., Giusto, R., Guido, G., Sinelli, N., Lapertosa, G., Celle, G. (1998). Chronic hepatitis induced by Jin Bu Huan. J. Hepatol. 28:165–167. [PUBMED], [INFOTRIEVE]
  • Pirmohamed, M., Kitteringham, N. R., Guenthner, T. M., Breckenridge, A. M., Park, B. K. (1992). An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem. Pharmacol. 43:1675–1682. [PUBMED], [INFOTRIEVE], [CSA]
  • Pirmohamed, M., Williams, D., Madden, S., Templeton, E., Park, B. K. (1995). Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther. 272:984–990., [PUBMED], [INFOTRIEVE], [CSA]
  • Pirmohamed, M., Madden, S., Park, B. K. (1996). Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism. Clin. Pharmacokinet. 31:215–230. [PUBMED], [INFOTRIEVE], [CSA]
  • Pirmohamed, M., Naisbitt, D. J., Gordon, F., Park, B. K. (2002). The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology 181–182:55–63.
  • Pisciotta, V. (1978). Drug-induced agranulocytosis. Drugs 15:132–143. [PUBMED], [INFOTRIEVE]
  • Piver, B., Berthou, F., Dreano, Y., Lucas, D. (2001). Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol. Lett. 125:83–91. [PUBMED], [INFOTRIEVE], [CSA]
  • Pohl, L. R., Thomassen, D., Pumford, N. R., Butler, L. E., Satoh, H. (1990). Hapten carrier conjugates associated with halothane hepatitis. Adv. Exp. Med. Biol. 283:111–120.
  • Pohl, L. R., Pumford, N. R., Martin, J. L. (1996). Mechanisms, chemical structures, and drug metabolism. Eur. J. Haematol. 57:98–104.
  • Poirier, M. C., Santella, R. M., Weston, A. (2000). Carcinogen macromolecular adducts and their measurement. Carcinogenesis 21:353–359. [PUBMED], [INFOTRIEVE]
  • Poisson, D., Dupuis, A., Breteau, M., Bouquet, S., Poterre, M., Couet, W. (1997). Effect of tamoxifen on the pharmacokinetics of theophylline in rats. J. Pharm. Pharmacol. 49:40–42. [PUBMED], [INFOTRIEVE]
  • Pollock, B. G., Perel, J. M. (1992). Imipramine and 2-hydroxyimipramine: comparative cardiotoxicity and pharmacokinetics in swine. Psychopharmacology (Berl.). 109:57–62. [CSA]
  • Polymeros, D., Kamberoglou, D., Tzias, V. (2002). Acute cholestatic hepatitis caused by Teucrium polium (golden germander) with transient appearance of antimitochondrial antibody. J. Clin. Gastroenterol. 34:100–101. [PUBMED], [INFOTRIEVE], [CSA]
  • Pompeo, F., Brooke, E., Kawamura, A., Mushtaq, A., Sim, E. (2002). The pharmacogenetics of NAT: structural aspects. Pharmacogenomics 3:19–30. [PUBMED], [INFOTRIEVE], [CSA]
  • Pons, C., Dansette, P. M., Amar, C., Jaouen, M., Wolf, C. R. (1991). Detection of human hepatitis anti-liver kidney microsomes (LKM2) autoantibodies on rat liver sections is predominantly due to reactivity with rat liver P-450 IIC11. J. Pharmacol. Exp. Ther. 259:1328–1334. [PUBMED], [INFOTRIEVE]
  • Porubek, D. J., Grillo, M. P., Baillie, T. A. (1989). The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes. Drug Metab. Dispos. 17:123–130. [PUBMED], [INFOTRIEVE], [CSA]
  • Potter, D. W., Hinson, J. A. (1986). Reactions of N-acetyl-p-benzoquinone imine with reduced glutathione, acetaminophen, and NADPH. Mol. Pharmacol. 30:33–41. [PUBMED], [INFOTRIEVE]
  • Potter, D. W., Hinson, J. A. (1987a). The 1- and 2-electron oxidation of acetaminophen catalyzed by prostaglandin H synthase. J. Biol. Chem. 262:974–980. [PUBMED], [INFOTRIEVE]
  • Potter, D. W., Hinson, J. A. (1987b). Mechanisms of acetaminophen oxidation to N-acetyl-P-benzoquinone imine by horseradish peroxidase and cytochrome P-450. J. Biol. Chem. 262:966–973. [PUBMED], [INFOTRIEVE]
  • Potter, W. Z., Davis, D. C., Mitchell, J. R., Jollow, D. J., Gillette, J. R., Brodie, B. B. (1973). Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J. Pharmacol. Exp. Ther. 187:203–210. [PUBMED], [INFOTRIEVE]
  • Potter, W. Z., Thorgeirsson, S. S., Jollow, D. J., Mitchell, J. R. (1974). Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology 12:129–143. [PUBMED], [INFOTRIEVE]
  • Potter, D. W., Miller, D. W., Hinson, J. A. (1985). Identification of acetaminophen polymerization products catalyzed by horseradish peroxidase. J. Biol. Chem. 260:12174–12180. [PUBMED], [INFOTRIEVE]
  • Potter, D. W., Miller, D. W., Hinson, J. A. (1986). Horseradish peroxidase-catalyzed oxidation of acetaminophen to intermediates that form polymers or conjugate with glutathione. Mol. Pharmacol. 29:155–162. [PUBMED], [INFOTRIEVE], [CSA]
  • Prabhu, S., Fackett, A., Lloyd, S., McClellan, H. A., Terrell, C. M., Silber, P. M., Li, A. P. (2002). Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem.-Biol. Interact. 142:83–97. [PUBMED], [INFOTRIEVE], [CSA]
  • Prasad, J. S., Chen, N. Q., Liu, Y. X., Goon, D. J., Holtzman, J. L. (1990). Effects of ethanol andinhibitors on the binding and metabolism of acetaminophen and N-acetyl-p-benzoquinone imine by hepatic microsomes from control and ethanol-treated rats. Biochem. Pharmacol. 40:1989–1995. [PUBMED], [INFOTRIEVE], [CSA]
  • Premdas, P. D., Bowers, R. J., Forkert, P. G. (2000). Inactivation of hepatic CYP2E1 by an epoxide of diallyl sulfone. J. Pharmacol. Exp. Ther. 293:1112–1120. [PUBMED], [INFOTRIEVE], [CSA]
  • Prescott, L. F. (2000). Paracetamol: past, present, and future. Am. J. Ther. 7:143–147. [PUBMED], [INFOTRIEVE], [CSA]
  • Price, E. J., Venables, P. J. (1995). Drug-induced lupus. Drug Safety. 12:283–289. [PUBMED], [INFOTRIEVE], [CSA]
  • Price, D. K., Ando, Y., Kruger, E. A., Weiss, M., Figg, W. D. (2002). 5′-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther. Drug Monit. 24:104–110. [PUBMED], [INFOTRIEVE], [CSA]
  • Pritchard, J. F., Schneck, D. W., Hayes, A. H. Jr. (1980). The inhibition of rat hepatic microsomal propranolol metabolism by a covalently bound reactive metabolite. Res. Commun. Chem. Pathol. Pharmacol. 27:211–222. [PUBMED], [INFOTRIEVE]
  • Prueksaritanont, T., Ma, B., Tang, C., Meng, Y., Assang, C., Lu, P., Reider, P. J., Lin, J. H., Baillie, T. A. (1999). Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br. J. Clin. Pharmacol. 47:291–298. [PUBMED], [INFOTRIEVE], [CSA]
  • Prussick, R., Mahmoud, A. M. A., Rosenthal, D., Guyatt, G. (1992). The protective effect of vitamin E on the haemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch. Dermatol. 128:210–213. [PUBMED], [INFOTRIEVE]
  • Pumford, N. R., Halmes, N. C. (1997). Protein targets of xenobiotic reactive intermediates. Annu. Rev. Pharmacol. Toxicol. 37:91–117. [PUBMED], [INFOTRIEVE], [CSA]
  • Pumford, N. R., Hinson, J. A., Potter, D. W., Rowland, K. L., Benson, R. W., Roberts, D. W. (1989). Immunochemical quantitation of 3-(cystein-S-yl)acetaminophen adducts in serum and liver proteins of acetaminophen-treated mice. J. Pharmacol. Exp. Ther. 248:190–196. [PUBMED], [INFOTRIEVE]
  • Pumford, N. R., Hinson, J. A., Benson, R. W., Roberts, D. W. (1990). Immunoblot analysis of protein containing 3-(cystein-S-yl)acetaminophen adducts in serum and subcellular liver fractions from acetaminophen-treated mice. Toxicol. Appl. Pharmacol. 104:521–532. [PUBMED], [INFOTRIEVE]
  • Pumford, N. R., Martin, B. M., Hinson, J. A. (1992). A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein. Biochem. Biophys. Res. Commun. 182:1348–1355. [PUBMED], [INFOTRIEVE]
  • Pumford, N. R., Martin, B. M., Thomassen, D., Burris, J. A., Kenna, J. G., Martin, J. L., Pohl, L. R. (1993). Serum antibodies from halothane hepatitis patients react with the rat endoplasmic reticulum protein ERp72. Chem. Res. Toxicol. 6:609–615. [PUBMED], [INFOTRIEVE], [CSA]
  • Pumford, N. R., Halmes, N. C., Hinson, J. A. (1997a). Covalent binding of xenobiotics to specific proteins in the liver. Drug Metab. Rev. 29:39–57. [PUBMED], [INFOTRIEVE], [CSA]
  • Pumford, N. R., Halmes, N. C., Martin, B. M., Cook, R. J., Wagner, C., Hinson, J. A. (1997b). Covalent binding of acetaminophen to N-10-formyltetrahydrofolate dehydrogenase in mice. J. Pharmacol. Exp. Ther. 280:501–505. [PUBMED], [INFOTRIEVE], [CSA]
  • Qiu, Y., Burlingame, A. L., Benet, L. Z. (1998a). Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin—studies by tandem mass spectrometry. Drug Metab. Dispos. 26:246–256. [PUBMED], [INFOTRIEVE], [CSA]
  • Qiu, Y. C., Benet, L. Z., Burlingame, A. L. (1998b). Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J. Biol. Chem. 273:17940–17953. [PUBMED], [INFOTRIEVE]
  • Raftery, M. J., Geczy, C. L. (2002). Electrospray low energy CID and MALDI PSD fragmentations of protonated sulfinamide cross-linked peptides. J. Am. Soc. Mass Spectrom. 13:709–718. [PUBMED], [INFOTRIEVE], [CSA]
  • Rahman, K. (2001). Historical perspective on garlic and cardiovascular disease. J. Nutr. 131:977S–979S. [PUBMED], [INFOTRIEVE]
  • Rahman, M. H., Maruyama, T., Okada, T., Imai, T., Otagiri, M. (1993). Study of interaction of carprofen and its enantiomers with human serum albumin—II. Stereoselective site-to-site displacement of carprofen by ibuprofen. Biochem. Pharmacol. 46:1733–1740., [PUBMED], [INFOTRIEVE], [CSA]
  • Ramos-e-Silva, M., Rebello, P. F. (2001). Leprosy. Recognition and treatment. Am. J. Clin. Dermatol. 2:203–211. [PUBMED], [INFOTRIEVE], [CSA]
  • Rathbun, R. C., Rossi, D. R. (2002). Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann. Pharmacother. 36:702–706. [PUBMED], [INFOTRIEVE], [CSA]
  • Raunio, H., Rautio, A., Gullstén, H., Pelkonen, O. (2001). Polymorphisms of CYP2A6 and its practical consequences. Br. J. Clin. Pharmacol. 52:357–363. [PUBMED], [INFOTRIEVE], [CSA]
  • Reichardt, P., Schreiber, A., Wichmann, G., Metzner, G., Efer, J., Raabe, F. (2003). Identification and quantification of in vitro adduct formation between protein reactive xenobiotics and a lysine-containing model peptide. Environ. Toxicol. 18:29–36. [PUBMED], [INFOTRIEVE], [CSA]
  • Reilly, T. P., Ju, C. (2002). Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr. Opin. Allergy Clin. Immunol. 2:307–315. [PUBMED], [INFOTRIEVE], [CSA]
  • Reilly, D. K., Rivera-Calimlim, L., van Dyke, D. (1980). Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin. Pharmacol. Ther. 28:278–286. [PUBMED], [INFOTRIEVE]
  • Reilly, T. P., Woster, P. M., Svensson, C. K. (1999). Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: implications for differences in adverse drug reactions. J. Pharmacol. Exp. Ther. 288:951–959. [PUBMED], [INFOTRIEVE], [CSA]
  • Reilly, T. P., Lash, L. H., Doll, M. A., Hein, D. W., Woster, P. M., Svensson, C. K. (2000). A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J. Invest. Dermatol. 114:1164–1173. [PUBMED], [INFOTRIEVE]
  • Reist, M., Carrupt, P. A., Francotte, E., Testa, B. (1998). Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem. Res. Toxicol. 11:1521–1528. [PUBMED], [INFOTRIEVE], [CSA]
  • Rendic, S. (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34:83–448. [PUBMED], [INFOTRIEVE], [CSA]
  • Rendic, S., Di Carlo, F. J. (1997). Human cytochrome P450 enzyme: a status report summarizing their reactions, substrates, induction, and inhibitors. Drug Metab. Rev. 29:413–580. [PUBMED], [INFOTRIEVE], [CSA]
  • Rettie, A. E., Rettenmeier, A. W., Howald, W. N., Baillie, T. A. (1987). Cytochrome P450-catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science 235:890–893. [PUBMED], [INFOTRIEVE]
  • Rettie, A. E., Boberg, M., Rettenmeier, A. W., Baillie, T. A. (1988). Cytochrome P-450-catalyzed desaturation of valproic acid in vitro. Species differences, induction effects, and mechanistic studies. J. Biol. Chem. 263:13733–13738. [PUBMED], [INFOTRIEVE]
  • Rettie, A. E., Sheffels, P. R., Korzekwa, K. R., Gonzalez, F. J., Philpot, R. M., Baillie, T. A. (1995). CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid. Biochemistry 34:7889–7895. [PUBMED], [INFOTRIEVE]
  • Richardson, P., Hideshima, T., Anderson, K. (2002). Thalidomide: emerging role in cancer medicine. Annu. Rev. Med. 53:629–657. [PUBMED], [INFOTRIEVE], [CSA]
  • Rieder, M. J., Uetrecht, J., Shear, N. H., Spielberg, S. P. (1988). Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J. Pharmacol. Exp. Ther. 244:724–728. [PUBMED], [INFOTRIEVE], [CSA]
  • Riley, R. J., Maggs, J. L., Lambert, C., Kitteringham, N. R., Park, B. K. (1988). An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. Br. J. Clin. Pharmacol. 26:577–588. [PUBMED], [INFOTRIEVE]
  • Riley, R. L., Lambert, C., Kitteringham, N. R., Park, B. K. (1989). A stereochemical investigation of the cytotoxicity of mianserin metabolites in vitro. Br. J. Clin. Pharmacol. 27:823–830. [PUBMED], [INFOTRIEVE]
  • Riley, R. J., Roberts, P., Coleman, M. D., Kitteringham, N. R., Park, B. K. (1990a). Bioactivation of dapsone to a cytotoxic metabolite: in vitro use of a novel two compartment system which contains human tissues. Br. J. Clin. Pharmacol. 30:417–426. [PUBMED], [INFOTRIEVE]
  • Riley, R. J., Roberts, P., Kitteringham, N. R., Park, B. K. (1990b). Formation of cytotoxic metabolites from phenytoin, imipramine, desipramine, amitriptyline and mianserin by mouse and human hepatic microsomes. Biochem. Pharmacol. 39:1951–1958., [PUBMED], [INFOTRIEVE], [CSA]
  • Rinaldi, R., Eliasson, E., Swedmark, S., Morgenstern, R. (2002). Reactive intermediates and the dynamics of glutathione transferases. Drug Metab. Dispos. 30:1053–1058. [PUBMED], [INFOTRIEVE], [CSA]
  • Ritter, J. K. (2000). Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem.-Biol. Interact. 129:171–193. [PUBMED], [INFOTRIEVE], [CSA]
  • Rivory, L. P., Bowles, M. R., Robert, J., Pond, S. M. (1996a). Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol. 52:1103–1111. [PUBMED], [INFOTRIEVE], [CSA]
  • Rivory, L. P., Riou, J. F., Haaz, M. C., Sable, S., Vuilhorgne, M., Commercon, A., Pond, S. M., Robert, J. (1996b). Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res. 56:3689–3694. [PUBMED], [INFOTRIEVE]
  • Rivory, L. P., Haaz, M. C., Canal, P., Lokiec, F., Armand, J. P., Robert, J. (1997). Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin. Cancer Res. 3:1261–1266. [PUBMED], [INFOTRIEVE], [CSA]
  • Roberts, P., Kitteringham, N. R., Park, B. K. (1993). Elucidation of the structural requirements for the bioactivation of mianserin in-vitro. J. Pharm. Pharmacol. 45:663–665. [PUBMED], [INFOTRIEVE]
  • Robin, M. A., Maratrat, M., Le Roy, M., Le Breton, F. P., Bonierbale, E., Dansette, P., Ballet, F., Mansuy, D., Pessayre, D. (1996). Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J. Clin. Invest. 98:1471–1480. [PUBMED], [INFOTRIEVE], [CSA]
  • Roche, M., Zampelas, A., Knapper, J. M. E., Kafatos, A., Webb, D., Brooks, C., Jackson, K. G., Gibney, M. J., Williams, C. M. (1998). Effect of long-term olive oil dietary intervention on postprandial triacylglycerol and factor VII metabolism. Am. J. Clin. Nutr. 68:552–560. [PUBMED], [INFOTRIEVE], [CSA]
  • Rodrigues, A. D., Rushmore, T. H. (2002). Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr. Drug Metab. 3:289–309. [PUBMED], [INFOTRIEVE]
  • Rogers, J. F., Nafziger, A. N., Bertino, J. S. Jr. (2002). Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med. 113:746–750. [PUBMED], [INFOTRIEVE]
  • Rolan, P. E. (1994). Plasma protein binding displacement interactions—why are they still regarded as clinically important? Br. J. Clin. Pharmacol. 37:125–128. [PUBMED], [INFOTRIEVE], [CSA]
  • Romero Maldonado, N., Sendra Tello, J., Raboso Garcia-Baquero, E., Harto Castano, A. (2002). Anticonvulsant hypersensitivity syndrome with fatal outcome. Eur. J. Dermatol. 12:503–505. [PUBMED], [INFOTRIEVE], [CSA]
  • Romet, M., Abbott, F. S., Tang, W., Huang, H. S., Whitehouse, L. W. (1996). Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione-depleted rat hepatocytes. Toxicology 112:69–85. [CSA]
  • Rosenberg, P. A. (1988). Catecholamine toxicity in cerebral cortex in dissociated cell culture. J. Neurosci. 8:2887–2892. [PUBMED], [INFOTRIEVE]
  • Rosenblat, M., Belinky, P., Vaya, J., Levy, R., Hayek, T., Coleman, R., Merchav, S., Aviram, M. (1999). Macrophage enrichment with the isoflavan glabridin inhibits NADPH oxidase-induced cell-mediated oxidation of low density lipoprotein: a possible role for protein kinase C. J. Biol. Chem. 274:13790–13799. [PUBMED], [INFOTRIEVE]
  • Ross, D., Kepa, J. K., Winski, S. L., Beall, H. D., Anwar, A., Siegel, D. (2000). NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem.-Biol. Interact. 129:77–97. [PUBMED], [INFOTRIEVE]
  • Roujeau, J. C., Stern, R. S. (1994). Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331:1272–1285. [PUBMED], [INFOTRIEVE], [CSA]
  • Rubinstein, E. (2001). Comparative safety of the different macrolides. Int. J. Antimicrob. Agents. 18:S71–S76. [PUBMED], [INFOTRIEVE]
  • Sadeque, J. M., Fisher, M. B., Korzekwa, K. R., Gonzalez, F. J., Rettie, A. E. (1997). Human CYP2C9, and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J. Pharmacol. Exp. Ther. 283:698–703., [PUBMED], [INFOTRIEVE], [CSA]
  • Sadrieh, N., Thomas, P. E. (1994). Characterization of rat cytochrome P450 isozymes involved in the covalent binding of cyclosporin A to microsomal proteins. Toxicol. Appl. Pharmacol. 127:222–232. [PUBMED], [INFOTRIEVE], [CSA]
  • Sahali-Sahly, Y., Balani, S. K., Lin, J. H., Baillie, T. A. (1996). In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. Chem. Res. Toxicol. 9:1007–1012. [PUBMED], [INFOTRIEVE], [CSA]
  • Saili, A., Sarna, M. S. (1991). Tolbutamide: teratogenic effects. Indian Pediatr. 28:936–940. [PUBMED], [INFOTRIEVE], [CSA]
  • Salazar-Paramo, M., Rubin, R. L., Garcia-De La Torre, I. (1992). Systemic lupus erythematosus induced by isoniazid. Ann. Rheum. Dis. 51:1085–1087. [PUBMED], [INFOTRIEVE]
  • Sallee, F. R., Pollock, B. G. (1990). Clinical pharmacokinetics of imipramine and desipramine. Clin. Pharmacokinet. 18:346–364. [PUBMED], [INFOTRIEVE]
  • Sallustio, B. C., Foster, D. J. (1995). Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. Drug Metab. Dispos. 23:892–899. [PUBMED], [INFOTRIEVE], [CSA]
  • Sallustio, B. C., Knights, K. M., Roberts, B. J., Zacest, R. (1991). In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins. Biochem. Pharmacol. 42:1421–1425. [PUBMED], [INFOTRIEVE], [CSA]
  • Sallustio, B. C., Fairchild, B. A., Pannall, P. R. (1997). Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-beta-D-glucuronide. Drug Metab. Dispos. 25:55–60. [PUBMED], [INFOTRIEVE], [CSA]
  • Sallustio, B. C., Sabordo, L., Evans, A. M., Nation, R. L. (2000). Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr. Drug Metab. 1:163–180. [PUBMED], [INFOTRIEVE]
  • Saltiel, E., Ward, A. (1987). Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 34:222–262. [PUBMED], [INFOTRIEVE]
  • Sampaio, E. P., Sarno, E. N., Galilly, R., Jet, L. (1991). Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173:699–703. [PUBMED], [INFOTRIEVE]
  • Sampaio, E. P., Kaplan, G., Miranda, A. (1993). The influence of thalidomide on the clinical and immunologic manifestation of erythema nodusum leprosum. J. Infect. Dis. 168:408–414. [PUBMED], [INFOTRIEVE]
  • Santos, A., Zanetta, S., Cresteil, T., Deroussent, A., Pein, F., Raymond, E., Vernillet, L., Risse, M. L., Boige, V., Gouyette, A., Vassal, G. (2000). Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res. 6:2012–2020. [PUBMED], [INFOTRIEVE], [CSA]
  • Satoh, H., Fukuda, Y., Anderson, D. K., Ferrans, V. J., Gillette, J. R., Pohl, L. R. (1985a). Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes. J. Pharmacol. Exp. Ther. 233:857–862. [PUBMED], [INFOTRIEVE]
  • Satoh, H., Gillette, J. R., Davies, H. W., Schulick, R. D., Pohl, L. R. (1985b). Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol. Pharmacol. 28:468–474. [PUBMED], [INFOTRIEVE], [CSA]
  • Satoh, H., Martin, B. M., Schulick, A. H., Christ, D. D., Kenna, J. G., Pohl, L. R. (1989). Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc. Natl. Acad. Sci. U. S. A. 86:322–326. [PUBMED], [INFOTRIEVE], [CSA]
  • Sattler, M., Guengerich, F. P., Yun, C. H., Christians, U., Sewing, K. F. (1992). Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20:753–761. [PUBMED], [INFOTRIEVE], [CSA]
  • Sauer, H., Gunther, J., Hescheler, J., Wartenberg, M. (2000). Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am. J. Pathol. 156:151–158. [PUBMED], [INFOTRIEVE]
  • Sayo, H., Saito, M. (1990). The mechanism of myeloperoxidase-catalysed oxidation of aminopyrine. Xenobiotica 20:957–965., [PUBMED], [INFOTRIEVE], [CSA]
  • Sayo, H., Saito, M., Lee, E., Kariya, K. (1989). Chloroperoxidase-catalyzed oxidation of aminopyrine. Chem. Pharm. Bull. (Tokyo) 37:3347–3350.
  • Scheffner, S., Konig, S., Rauterberg-Ruland, I., Kochen, W., Hofmann, W. J., Unkelbach, S. (1988). Fatal liver failure in 16 children with valproate therapy. Epilepsia 29:530–542. [PUBMED], [INFOTRIEVE], [CSA]
  • Schmeiser, H. H., Janssen, J. W., Lyons, J., Scherf, H. R., Pfau, W., Buchmann, A., Bartram, C. R., Wiessler, M. (1990). Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res. 50:5464–5469. [PUBMED], [INFOTRIEVE]
  • Schmeiser, H. H., Bieler, C. A., Wiessler, M., van Ypersele de Strihou, C., Cosyns, J. P. (1996). Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56:2025–2028. [PUBMED], [INFOTRIEVE]
  • Schmeiser, H. H., Frei, E., Wiessler, M., Stiborova, M. (1997). Comparison of DNA adduct formation by aristolochic acids in various in vitro activation systems by 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis 18:1055–1062. [PUBMED], [INFOTRIEVE]
  • Schmiedlin-Ren, P., Edwards, D. J., Fitzsimmons, M. E., He, K., Lown, K. S., Woster, P. M., Rahman, A., Thummel, K. E., Fisher, J. M., Hollenberg, P. F., Watkins, P. B. (1997). Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 25:1228–1233. [PUBMED], [INFOTRIEVE], [CSA]
  • Schuetz, E. G., Beck, W. T., Schuetz, J. D. (1996). Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:311–318. [PUBMED], [INFOTRIEVE], [CSA]
  • Schumacher, H., Smith, R. L., Williams, R. T. (1965). The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. 25:324–337. [PUBMED], [INFOTRIEVE]
  • Schutz, H., Feldmann, K. F., Faigle, J. W., Kriemler, H. P., Winkler, T. (1986). The metabolism of 14C-oxcarbazepine in man. Xenobiotica 16:769–778. [PUBMED], [INFOTRIEVE]
  • Sciulli, M. G., Seta, F., Tacconelli, S., Capone, M. L., Ricciotti, E., Pistritto, G., Patrignani, P. (2003). Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. Br. J. Pharmacol. 138:634–641. [PUBMED], [INFOTRIEVE], [CSA]
  • Scott, L. J., Perry, C. M. (2000). Delavirdine: a review of its use in HIV infection. Drugs 60:1411–1444. [PUBMED], [INFOTRIEVE]
  • Scozzafava, A., Casini, A., Supuran, C. T. (2002). Targeting cysteine residues of biomolecules: new approaches for the design of antiviral and anticancer drugs. Curr. Med. Chem. 9:1167–1185. [PUBMED], [INFOTRIEVE]
  • Sedek, G., Jorga, K. M., Burns, R., Schmitt, M., Leese, P. (1997). Effect of tolcapone on plasma levodopa levels after coadministration with levodopa/carbidopa to healthy volunteers. Clin. Neuropharmacol. 10:531–541.
  • Seitz, S., Kretzrommel, A., Elferink, R. P. J. O., Boelsterli, U. A. (1998). Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (mrp2). Chem. Res. Toxicol. 11:513–519. [PUBMED], [INFOTRIEVE], [CSA]
  • Sekikawa, H., Yagi, N., Lin, E. T., Benet, L. Z. (1995). Apparent intramolecular acyl migration and hydrolysis of furosemide glucuronide in aqueous solution. Biol. Pharm. Bull. 18:134–139. [PUBMED], [INFOTRIEVE], [CSA]
  • Serino, F., Grevel, J., Napoli, K. L., Kahan, B. D., Strobel, H. W. (1993). Generation of oxygen free radicals during the metabolism of cyclosporine A: a cause–effect relationship with metabolism inhibition. Mol. Cell. Biochem. 122:101–112. [PUBMED], [INFOTRIEVE], [CSA]
  • Shader, R. I., Fogelman, S. M., Greenblatt, D. J. (1997). Newer antidepressants: hypotheses and evidence. J. Clin. Psychopharmacol. 17:1–3. [PUBMED], [INFOTRIEVE], [CSA]
  • Shan, B., Medina, J. C., Santha, E., Frankmoelle, W. P., Chou, T. C., Learned, R. M., Narbut, M. R., Stott, D., Wu, P., Jaen, J. C., Rosen, T., Timmermans, P. B., Beckmann, H. (1999). Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc. Natl. Acad. Sci. U. S. A. 96:5686–5691., [PUBMED], [INFOTRIEVE], [CSA]
  • Shanks, G. D., Edstein, M. D., Suriyamongkol, V., Timsaad, S., Webster, H. K. (1992). Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. Am. J. Trop. Med. Hyg. 46:643–648. [PUBMED], [INFOTRIEVE], [CSA]
  • Sharis, P. J., Cannon, C. P., Loscalzo, J. (1998). The antiplatelet effects of ticlopidine and clopidogrel. Ann. Intern. Med. 129:394–405. [PUBMED], [INFOTRIEVE], [CSA]
  • Shaw, L. M., Pawinski, T., Korecka, M., Nawrocki, A. (2002). Monitoring of mycophenolic acid in clinical transplantation. Ther. Drug Monit. 24:68–73. [PUBMED], [INFOTRIEVE], [CSA]
  • Sheikhzadeh, A., Schafer, U., Schnabel, A. (2002). Drug-induced lupus erythematosus by amiodarone. Arch. Intern. Med. 162:834–836. [PUBMED], [INFOTRIEVE], [CSA]
  • Shek, L. P. C., Lim, D. L. C. (2002). Thalidomide in Behcet's disease. Biomed. Pharmacother. 56:31–35. [PUBMED], [INFOTRIEVE], [CSA]
  • Shelton, C. E., Connelly, J. F. (1996). Valproic acid: a migraine prophylaxis alternative. Ann. Pharmacother. 30:865–866. [PUBMED], [INFOTRIEVE], [CSA]
  • Shen, S., Marchick, M. R., Davis, M. R., Doss, G. A., Pohl, L. R. (1999). Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem. Res. Toxicol. 12:214–222. [PUBMED], [INFOTRIEVE], [CSA]
  • Shibata, S. (2000). A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi-J. Pharm. Soc. Jpn. 120:849–862. [CSA]
  • Shimada, T., Hayes, C. L., Yamazaki, H., Amin, S., Hecht, S. S., Guengerich, F. P., Sutter, T. R. (1996). Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 56:2979–2984. [PUBMED], [INFOTRIEVE]
  • Shimizu, A., Nakanishi, T., Kishikawa, M., Miyazaki, A. (2002). Detection and identification of protein variants and adducts in blood and tissues: an application of soft ionization mass spectrometry to clinical diagnosis. J. Chromatogr., B 776:15–30.
  • Shipkova, M., Armstrong, V. W., Weber, L., Niedmann, P. D., Wieland, E., Haley, J., Tonshoff, B., Oellerich, M. (2002). Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther. Drug Monit. 24:390–399. [PUBMED], [INFOTRIEVE], [CSA]
  • Shipkova, M., Armstrong, V. W., Oellerich, M., Wieland, E. (2003). Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit. 25:1–16. [PUBMED], [INFOTRIEVE], [CSA]
  • Shishido, S., Koga, H., Harada, M., Kumemura, H., Hanada, S., Taniguchi, E., Kumashiro, R., Ohira, H., Sato, Y., Namba, M., Ueno, T., Sata, M. (2003). Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37:136–147. [PUBMED], [INFOTRIEVE]
  • Simon, T., Becquemont, L., Mary-Krause, M., de Waziers, I., Beaune, P., Funck-Brentano, C., Jaillon, P. (2000). Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther. 67:432–437. [PUBMED], [INFOTRIEVE], [CSA]
  • Simonsen, U. (2002). Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. Int. J. Impot. Res. 14:178–188. [PUBMED], [INFOTRIEVE], [CSA]
  • Sinclair, J., Jeffery, E., Wrighton, S., Kostrubsky, V., Szakacs, J., Wood, S., Sinclair, P. (1998). Alcohol-mediated increases in acetaminophen hepatotoxicity: role of CYP2E and CYP3A. Biochem. Pharmacol. 55:1557–1565. [PUBMED], [INFOTRIEVE], [CSA]
  • Singh, S., Asad, S. F., Ahmad, A., Khan, N. U., Hadi, S. M. (2001). Oxidative DNA damage by capsaicin and dihydrocapsaicin in the presence of Cu(II). Cancer Lett. 169:139–146. [PUBMED], [INFOTRIEVE], [CSA]
  • Sinha, B. K. (1987). Activation of hydrazine derivatives to free radicals in the perfused rat liver: a spin-trapping study. Biochim. Biophys. Acta 924:261–269. [PUBMED], [INFOTRIEVE]
  • Sinz, M. W., Woolf, T. F. (1997). Characterization of the induction of rat microsomal cytochrome P450 by tacrine. Biochem. Pharmacol. 54:425–427. [PUBMED], [INFOTRIEVE], [CSA]
  • Skipper, P. L. (1996). Influence of tertiary structure on nucleophilic substitution reactions of proteins. Chem. Res. Toxicol. 9:918–923., [PUBMED], [INFOTRIEVE], [CSA]
  • Skipper, P. L., Tannenbaum, S. R. (1990). The role of protein adducts in the study of chemical carcinogenesis. Prog. Clin. Biol. Res. 340C:301–310. [PUBMED], [INFOTRIEVE]
  • Slott, V. L., Hales, B. F. (1987). Enhancement of the embryotoxicity of acrolein, but not phosphoramide mustard, by glutathione depletion in rat embryos in vitro. Biochem. Pharmacol. 36:2019–2025. [PUBMED], [INFOTRIEVE]
  • Smith, B. R. (2001). Thyroid autoantibodies. Scand. J. Clin. Lab. Invest. 235:45–52. [CSA]
  • Smith, P. C., Liu, J. H. (1993). Covalent binding of suprofen acyl glucuronide to albumin in vitro. Xenobiotica 23:337–348. [PUBMED], [INFOTRIEVE], [CSA]
  • Smith, P. C., Liu, J. H. (1995). Covalent binding of suprofen to renal tissue of rat correlates with excretion of its acyl glucuronide. Xenobiotica 25:531–540. [PUBMED], [INFOTRIEVE], [CSA]
  • Smith, P. C., McDonagh, A. F., Benet, L. Z. (1986). Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J. Clin. Invest. 77:934–939. [PUBMED], [INFOTRIEVE]
  • Smith, P. C., Benet, L. Z., McDonagh, A. F. (1990). Covalent binding of zomepirac glucuronide to proteins: evidence for a Shiff base mechanism. Drug Metab. Dispos. 18:639–644. [PUBMED], [INFOTRIEVE]
  • Smith, B. J., Curtis, J. F., Eling, T. E. (1991). Bioactivation of xenobiotics by prostaglandin H synthase. Chem.-Biol. Interact. 79:245–264. [PUBMED], [INFOTRIEVE]
  • Smith, G. C., Kenna, J. G., Harrison, D. J., Tew, D., Wolf, C. R. (1993). Autoantibodies to hepatic microsomal carboxylesterase in halothane hepatitis. Lancet 342:963–964. [PUBMED], [INFOTRIEVE]
  • Smith, K. S., Smith, P. L., Heady, T. N., Trugman, J. M., Harman, W. D., Macdonald, T. L. (2003). In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem. Res. Toxicol. 16:123–128. [PUBMED], [INFOTRIEVE], [CSA]
  • Smoak, I. W. (1999). Cromakalim: embryonic effects and reduction of tolbutamide-induced dysmorphogenesis in vitro. Teratology 60:260–264. [PUBMED], [INFOTRIEVE], [CSA]
  • Sogami, M., Nagoka, S., Era, S., Honda, M., Noguchi, K. (1984). Resolution of human mercapt- and nonmercaptalbumin by high-performance liquid chromatography. Int. J. Pept. Protein Res. 24:96–103. [PUBMED], [INFOTRIEVE], [CSA]
  • Someya, T., Shibasaki, M., Noguchi, T., Takahashi, S., Inaba, T. (1992). Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. Psychopharmacology 12:169–174.
  • Soskic, V., Godovac-Zimmermann, J. (2001). Improvement of an in-gel tryptic digestion method for matrix-assisted laser desorption/ionization-time of flight mass spectrometry peptide mapping by use of volatile solubilizing agents. Proteomics 1:1364–1367. [PUBMED], [INFOTRIEVE], [CSA]
  • Sosler, S. D., Behzad, O., Garratty, G., Lee, C. L., Postoway, N., Khomo, O. (1985). Immune hemolytic anemia associated with probenecid. Am. J. Clin. Pathol. 84:391–394. [PUBMED], [INFOTRIEVE]
  • Spahn-Langguth, H., Dahms, M., Hermening, A. (1996). Acyl glucuronides. Covalent binding and its potential relevance. Adv. Exp. Med. Biol. 387:313–328. [PUBMED], [INFOTRIEVE], [CSA]
  • Spahn-Lugguth, H., Benet, L. Z. (1992). Acyl glucuronide revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab. Rev. 24:5–48.
  • Spaldin, V., Madden, S., Pool, W. F., Woolf, T. F., Park, B. K. (1994). The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br. J. Clin. Pharmacol. 38:15–22. [PUBMED], [INFOTRIEVE], [CSA]
  • Spaldin, V., Madden, S., Adams, D. A., Edwards, R. J., Davies, D. S., Park, B. K. (1995). Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab. Dispos. 23:929–934. [PUBMED], [INFOTRIEVE], [CSA]
  • Spencer, J. P., Jenner, P., Daniel, S. E., Lees, A. J., Marsden, D. C., Halliwell, B. (1998). Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71:2112–2122. [PUBMED], [INFOTRIEVE]
  • Spielberg, S. P. (1996). N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J. Pharmacokinet. Biopharm. 24:509–519., [PUBMED], [INFOTRIEVE], [CSA]
  • Spielberg, S. P., Gordon, G. B., Blake, D. A., Mellits, E. D., Bross, D. S. (1981). Anticonvulsant toxicity in vitro: possible role of arene oxides. J. Pharmacol. Exp. Ther. 217:386–389. [PUBMED], [INFOTRIEVE], [CSA]
  • Spigelski, D., Jones, P. J. (2001). Efficacy of garlic supplementation in lowering serum cholesterol levels. Nutr. Rev. 59:236–241. [PUBMED], [INFOTRIEVE], [CSA]
  • Spina, M., Cohen, G. (1989). Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 86:1398–1400. [PUBMED], [INFOTRIEVE]
  • Spina, E., Pisani, F., Perucca, E. (1996). Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin. Pharmacokinet. 31:198–214. [PUBMED], [INFOTRIEVE], [CSA]
  • Spina, E., Avenoso, A., Facciola, G., Salemi, M., Scordo, M. G., Giacobello, T., Madia, A. G., Perucca, E. (2000). Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther. Drug Monit. 22:481–485. [PUBMED], [INFOTRIEVE], [CSA]
  • Spinler, S. A., Cheng, J. W., Kindwall, K. E., Charland, S. L. (1995). Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin. Pharmacol. Ther. 57:89–94. [PUBMED], [INFOTRIEVE], [CSA]
  • Spracklin, D. K., Hankins, D. C., Fisher, J. M., Thummel, K. E., Kharasch, E. D. (1997). Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J. Pharmacol. Exp. Ther. 281:400–411. [PUBMED], [INFOTRIEVE], [CSA]
  • Sridar, C., Kent, U. M., Notley, L. M., Gillam, E. M., Hollenberg, P. F. (2002). Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J. Pharmacol. Exp. Ther. 301:945–952. [PUBMED], [INFOTRIEVE], [CSA]
  • Stebbing, J., Benson, C., Eisen, T., Pyle, L., Smalley, K., Bridle, H., Mak, I., Sapunar, F., Ahern, R., Gore, M. E. (2001). The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer 85:953–958. [PUBMED], [INFOTRIEVE]
  • Stedman, C. (2002). Herbal hepatotoxicity. Semin. Liver Dis. 22:195–206. [PUBMED], [INFOTRIEVE], [CSA]
  • Stephens, T. (1988). Proposed mechanisms of action of thalidomide. Teratology 38:229–239. [PUBMED], [INFOTRIEVE]
  • Stephens, T. D., Bunde, C. J. W., Fillmore, B. J. (2000). Mechanism of action in thalidomide teratogenesis. Biochem. Pharmacol. 59:1489–1499. [PUBMED], [INFOTRIEVE], [CSA]
  • Stiborova, M., Fernando, R. C., Schmeiser, H. H., Frei, E., Pfau, W., Wiessler, M. (1994). Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 15:1187–1192. [PUBMED], [INFOTRIEVE]
  • Stiborova, M., Frei, E., Breuer, A., Bieler, C. A., Schmeiser, H. H. (1999). Aristolactam I a metabolite of aritolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp. Toxicol. Pathol. 51:421–427. [PUBMED], [INFOTRIEVE], [CSA]
  • Stiborova, M., Frei, E., Breuer, A., Wiessler, M., Schmeiser, H. H. (2001a). Evidence for reductive activation of carcinogenic aristolochic acids by prostaglandin H synthase—(32)P-postlabeling analysis of DNA adduct formation. Mutat. Res. 493:149–160. [PUBMED], [INFOTRIEVE]
  • Stiborova, M., Frei, E., Wiessler, M., Schmeiser, H. H. (2001b). Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem. Res. Toxicol. 14:1128–1137. [PUBMED], [INFOTRIEVE], [CSA]
  • Stiborova, M., Frei, E., Sopko, B., Wiessler, M., Schmeiser, H. H. (2002). Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23:617–625. [PUBMED], [INFOTRIEVE]
  • Stichtenoth, D. O., Frolich, J. C. (2003). The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 63:33–45. [PUBMED], [INFOTRIEVE]
  • Stickel, F., Egerer, G., Seitz, H. K. (2000). Hepatotoxicity of botanicals. Public Health Nutr. 3:113–124. [PUBMED], [INFOTRIEVE], [CSA]
  • Stickel, F., Seitz, H. K., Hahn, E. G., Schuppan, D. (2001). Hepatotoxicity of herbal remedies. Z. Gastroenterol. 39:225. [PUBMED], [INFOTRIEVE]
  • Stoilov, I., Akarsu, A. N., Sarfarazi, M. (1997). Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenitalglaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. 6:641–647. [PUBMED], [INFOTRIEVE], [CSA]
  • Stormer, E., von Moltke, L. L., Shader, R. I., Greenblatt, D. J. (2000a). Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab. Dispos. 28:1168–1175. [PUBMED], [INFOTRIEVE], [CSA]
  • Stormer, E. S., von Moltke, L. L., Greenblatt, D. J. (2000b). Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J. Pharmacol. Exp. Ther. 295:793–801. [PUBMED], [INFOTRIEVE], [CSA]
  • Strange, R. C., Spiteri, M. A., Ramachandran, S., Fryer, A. A. (2001). Glutathione-S-transferase family of enzymes. Mutat. Res. 482:21–26. [PUBMED], [INFOTRIEVE]
  • Streeter, A. J., Timbrell, J. A. (1985). The in vitro metabolism of hydralazine. Drug Metab. Dispos. 13:255–259. [PUBMED], [INFOTRIEVE], [CSA]
  • Stricker, B. H., Barendregt, J. N., Claas, F. H. (1985). Thrombocytopenia and leucopenia with mianserin-dependent antibodies. Br. J. Clin. Pharmacol. 19:102–104. [PUBMED], [INFOTRIEVE]
  • Strickler, S. M., Dansky, L. V., Miller, M. A., Seni, M. H., Andermann, E., Spielberg, S. P. (1985). Genetic predisposition to phenytoin-induced birth defects. Lancet 2:746–749. [PUBMED], [INFOTRIEVE]
  • Stupans, I., Stretch, G., Hayball, P. (2000). Olive oil phenols inhibit human hepatic microsomal activity. J. Nutr. 130:2367–2370. [PUBMED], [INFOTRIEVE]
  • Stupans, I., Murray, M., Kirlich, A., Tuck, K. L., Hayball, P. J. (2001). Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein. Food Chem. Toxicol. 39:1119–1124. [PUBMED], [INFOTRIEVE], [CSA]
  • Suchy, F. J., Balistreri, W. F., Buchino, J. J., Sondheimer, J. M., Bates, S. R., Kearns, G. L., Stull, J. D., Bove, K. E. (1979). Acute hepatic failure associated with the use of sodium valproate. N. Engl. J. Med. 300:962–966. [PUBMED], [INFOTRIEVE]
  • Suganuma, T., Ishizaki, T., Chiba, K., Hori, M. (1981). The effect of concurrent administration of valproate sodium on phenobarbital plasma concentration/dosage ratio in pediatric patients. J. Pediatr. 99:314–317. [PUBMED], [INFOTRIEVE]
  • Sugiyama, Y., Kato, Y., Chu, X. (1998). Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother. Pharmacol. 42:S44–S49. [PUBMED], [INFOTRIEVE]
  • Suhy, D. A., Simon, K. D., Linzer, D. I.H., O'Halloran, T. V. (1999). Metallothionein is part of a zinc-scavenging mechanism for cell survival under conditions of extreme zinc deprivation. J. Biol. Chem. 274:9183–9192. [PUBMED], [INFOTRIEVE]
  • Summan, M., Cribb, A. E. (2002). Novel non-labile covalent binding of sulfamethoxazole reactive metabolites to cultured human lymphoid cells. Chem.-Biol. Interact. 142:155–173. [PUBMED], [INFOTRIEVE]
  • Surh, Y. (1999). Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat. Res. 428:305–327. [PUBMED], [INFOTRIEVE]
  • Surh, Y. J., Lee, S. S. (1995). Capsaicin, a double edged sword: toxicity, metabolism, and chemopreventative potential (review). Life Sci. 56:1845–1855. [PUBMED], [INFOTRIEVE]
  • Surh, Y. J., Lee, E., Lee, J. M. (1998a). Chemopreventive properties of some pungent ingredients present in red pepper and ginger. Mutat. Res. 402:259–267. [PUBMED], [INFOTRIEVE]
  • Surh, Y. J., Lee, E., Lee, J. M. (1998b). Chemoprotective properties of some pungent ingredients present in red pepper and ginger. Mutat. Res. 402:259–267. [PUBMED], [INFOTRIEVE]
  • Suzuki, K. (2001). Neutrophil functions of patients with vasculitis related to myeloperoxidase-specific anti-neutrophil antibody. Int. J. Hematol. 74:134–143. [PUBMED], [INFOTRIEVE], [CSA]
  • Szilagyi, Z., Fenselau, C. (2000). Molecular dynamics simulation of metallothioneindrug complexes. Drug Metab. Dispos. 28:174–179. [PUBMED], [INFOTRIEVE], [CSA]
  • Sztajnkrycer, M. D. (2002). Valproic acid toxicity: overview and management. J. Toxicol., Clin. Toxicol. 40:789–801., [CSA]
  • Takeda, M., Khamdang, S., Narikawa, S., Kimura, H., Kobayashi, Y., Yamamoto, T., Cha, S. H., Sekine, T., Endou, H. (2002). Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. 300:918–924. [PUBMED], [INFOTRIEVE], [CSA]
  • Tanaka, E. (1999). Clinically significant pharmacokinetic drug interactions with benzodiazepines. J. Clin. Pharm. Ther. 24:347–355. [PUBMED], [INFOTRIEVE], [CSA]
  • Tang, W., Borel, A. G., Fujimiya, T., Abbott, F. S. (1995). Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol. 8:671–682. [PUBMED], [INFOTRIEVE], [CSA]
  • Tang, W., Borel, A. G., Abbott, F. S. (1996). Conjugation of glutathione with a toxic metabolite of valproic acid (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione-S-transferases. Drug Metab. Dispos. 24:436–446. [PUBMED], [INFOTRIEVE], [CSA]
  • Tang, W., Stearns, R. A., Wang, R. W., Chiu, S. H., Baillie, T. A. (1999). Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem. Res. Toxicol. 12:192–199. [PUBMED], [INFOTRIEVE], [CSA]
  • Tartara, A., Galimberti, C. A., Manni, R., Parietti, L., Zucca, C., Baasch, H., Caresia, L., Muck, W., Barzaghi, N., Gatti, G. (1991). Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br. J. Clin. Pharmacol. 32:335–340. [PUBMED], [INFOTRIEVE]
  • Tebbe, M. J., Jensen, C. B., Spitzer, W. A., Franklin, R. B., George, M. C., Phillips, D. L. (1999). The effects of antirhino- and enteroviral vinylacetylene benzimidazoles on cytochrome P450 function and hepatic porphyrin levels in mice. Antivir. Res. 42:25–33. [PUBMED], [INFOTRIEVE], [CSA]
  • Teo, S. K., Sabourin, P. J., O'Brien, K., Kook, K. A., Thomas, S. D. (2000). Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J. Biochem. Mol. Toxicol. 14:140–147. [PUBMED], [INFOTRIEVE], [CSA]
  • Terrier, N., Benoit, E., Senay, C., Lapicque, F., Radominska-Pandya, A., Magdalou, J. (1999). Human and rat liver UDP-glucuronosyltransferases are targets of ketoprofen acyl glucuronide. Mol. Pharmacol. 56:226–234. [PUBMED], [INFOTRIEVE], [CSA]
  • Tettey, J. N., Maggs, J. L., Rapeport, W. G., Pirmohamed, M., Park, B. K. (2001). Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14:965–974. [PUBMED], [INFOTRIEVE], [CSA]
  • Teyssier, C., Guenot, L., Suschetet, M., Siess, M. H. (1999). Metabolism of diallyl disulfide by human liver microsomal cytochromes P-450 and flavin-containing monooxygenases. Drug Metab. Dispos. 27:835–841. [PUBMED], [INFOTRIEVE], [CSA]
  • Thomassen, D., Pearson, P. G., Slattery, J. T., Nelson, S. D. (1991). Partial characterization of biliary metabolites of pulegone by tandem mass spectrometry. Drug Metab. Dispos. 19:997–1003. [PUBMED], [INFOTRIEVE]
  • Thompson, C. (1999). Mirtazapine versus selective serotonin reuptake inhibitors. J. Clin. Psychiatry 60:18–22. [PUBMED], [INFOTRIEVE]
  • Thompson, D. C., Perera, K., Fisher, R., Brendel, K. (1994). Cresol isomers: comparison of toxic potency in rat liver slices. Toxicol. Appl. Pharmacol. 125:51–58. [PUBMED], [INFOTRIEVE], [CSA]
  • Tinel, M., Belghiti, J., Descatoire, V., Amouyal, G., Letteron, P., Geneve, J., Larrey, D., Pessayre, D. (1987). Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem. Pharmacol. 36:951–955. [PUBMED], [INFOTRIEVE], [CSA]
  • Tinel, M., Descatoire, V., Larrey, D., Loeper, J., Labbe, G., Letteron, P., Pessayre, D. (1989). Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J. Pharmacol. Exp. Ther. 250:746–751. [PUBMED], [INFOTRIEVE]
  • Tingle, M. D., Jewell, H., Maggs, J. L., O'Neill, P. M., Park, B. K. (1995). The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem. Pharmacol. 50:1113–1119. [PUBMED], [INFOTRIEVE], [CSA]
  • Tingle, M. D., Mahmud, R., Maggs, J. L., Pirmohamed, M., Park, B. K. (1997). Comparison of themetabolism and toxicity of dapsone in rat, mouse and man. J. Pharmacol. Exp. Ther. 283:817–823. [PUBMED], [INFOTRIEVE], [CSA]
  • Tornqvist, M., Mowrer, J., Jensen, S., Ehrenberg, L. (1986). Monitoring of environmental cancer initiators through hemoglobin adducts by a modified Edman degradation method. Anal. Biochem. 154:255–266. [PUBMED], [INFOTRIEVE]
  • Tornqvist, M., Fred, C., Haglund, J., Helleberg, H., Paulsson, B., Rydberg, P. (2002). Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications. J. Chromatogr., B 778:279–308.
  • Toth, B., Gannett, P. (1992). Carcinogenicity of lifelong administration of capsaicin of hot pepper in mice. In Vivo 6:59–63. [PUBMED], [INFOTRIEVE]
  • Tozser, J. (2001). HIV inhibitors: problems and reality. Ann. N.Y. Acad. Sci. 946:145–159. [PUBMED], [INFOTRIEVE]
  • Tran, J. Q., Gerber, J. G., Kerr, B. M. (2001). Delavirdine: clinical pharmacokinetics and drug interactions. Clin. Pharmacokinet. 40:207–226. [PUBMED], [INFOTRIEVE], [CSA]
  • Triggle, D. J. (1991). Sites, mechanisms of action, and differentiation of calcium channel antagonists. Am. J. Hypertens. 4:S422–S429.
  • Triggle, D. J. (1996). Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist. Am. J. Cardiol. 78:7–12. [PUBMED], [INFOTRIEVE], [CSA]
  • Trivier, J.-M., Libersa, C., Belloc, C., Lhermitte, M. (1993). Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P4503A enzymes (first report). Life Sci. 52:91–96.
  • Tsarbopoulos, A., Gikas, E., Rapadopoulos, N., Aligiannis, N., Kafatos, A. (2003). Simultaneous determination of oleuropein and its metabolites in plasma by high-performance liquid chromatography. J. Chromatogr., B, Anal. Technol. Biomed. Life Sci. 785:157–164.
  • Tsatalas, C., Chalkia, P., Garyfallos, A., Kakoulidis, I., Xanthakis, I. (1995). Ticlopidine-induced aplastic anaemia: case report and review of the literature. Clin. Drug Investig. 9:127–130.
  • Tsuchiya, Y., Sato, T., Kiyohara, C., Yoshida, K., Ogoshi, K., Nakamura, K., Yamamoto, M. (2002). Genetic polymorphisms of cytochrome P450 1A1 and risk of gallbladder cancer. J. Exp. Clin. Cancer Res. 21:119–124. [PUBMED], [INFOTRIEVE], [CSA]
  • Tuck, K. L., Hayball, P. J. (2002). Major phenolic compounds in olive oil: metabolism and health effects. J. Nutr. Biochem. 13:636–644. [PUBMED], [INFOTRIEVE]
  • Uehleke, H., Tabarelli, S. (1973). N-Hydroxylation of 4,4-diaminodiphenyl-sulfone (dapsone) by liver microsomes and in dogs and humans. Naunyn-Schmeideberg's Arch. Pharmacol. 278:55–68.
  • Uetrecht, J. P. (1985). Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J. Pharmacol. Exp. Ther. 232:420–425. [PUBMED], [INFOTRIEVE]
  • Uetrecht, J. (1990). Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions. Crit. Rev. Toxicol. 20:213–235. [PUBMED], [INFOTRIEVE]
  • Uetrecht, J. (2001). Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov. Dev. 4:55–59. [CSA]
  • Uetrecht, J., Sokoluk, B. (1992). Comparative metabolism and covalent binding of procainamide by human leukocytes. Drug Metab. Dispos. 20:120–123. [PUBMED], [INFOTRIEVE]
  • Uetrecht, J., Zahid, N. (1988). N-Chlorination of phenytoin by myeloperoxidase to a reactive metabolite. Chem. Res. Toxicol. 1:148–151. [PUBMED], [INFOTRIEVE]
  • Uetrecht, J. P., Zahid, N. (1991). N-Chlorination and oxidation of procainamide by myeloperoxidase: toxicological implications. Chem. Res. Toxicol. 4:218–222. [PUBMED], [INFOTRIEVE], [CSA]
  • Uetrecht, J., Zahid, N., Shear, N. H., Biggar, W. D. (1988). Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J. Pharmacol. Exp. Ther. 245:274–279. [PUBMED], [INFOTRIEVE]
  • Uetrecht, J. P., Shear, N. H., Zahid, N. (1993). N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system. Drug Metab. Dispos. 21:830–834. [PUBMED], [INFOTRIEVE], [CSA]
  • Uetrecht, J. P., Zahid, N., Whitfield, D. (1994). Metabolism of vesnarinone by activatedneutrophils: implications for vesnarinone-induced agranulocytosis. J. Pharmacol. Exp. Ther. 270:865–872. [PUBMED], [INFOTRIEVE], [CSA]
  • Uetrecht, J. P., Ma, H. M., MacKnight, E., McClelland, R. (1995). Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. Chem. Res. Toxicol. 8:226–233. [PUBMED], [INFOTRIEVE], [CSA]
  • Uetrecht, J., Zahid, N., Tehim, A., Fu, J. M., Rakhit, S. (1997). Structural features associated with reactive metabolite formation in clozapine analogues. Chem.-Biol. Interact. 104:117–129. [PUBMED], [INFOTRIEVE], [CSA]
  • Upton, A., Johnson, N., Sandy, J., Sim, E. (2001). Arylamine N-acetyltransferases—of mice, men and microorganisms. Trends Pharmacol. Sci. 22:140–146. [PUBMED], [INFOTRIEVE]
  • Urade, R., Takenaka, Y., Kito, M. (1993). Protein degradation by ERp72 from rat and mouse liver endoplasmic reticulum. J. Biol. Chem. 268:22004–22009. [PUBMED], [INFOTRIEVE]
  • Usuki, E., Pearce, R., Parkinson, A., Castagnol, N. Jr. (1996). Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem. Res. Toxicol. 9:800–806. [PUBMED], [INFOTRIEVE], [CSA]
  • Usuki, E., Van der Schyf, C. J., Castagnoli, N. Jr. (1998). Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP. Drug Metab. Rev. 30:809–826. [PUBMED], [INFOTRIEVE], [CSA]
  • Vadher, A., Lalljee, M. (1992). Patient treatment compliance in leprosy—a critical review. Int. J. Lepr. 60:587–607.
  • Vage, C., Svensson, C. K. (1994). Evidence that the biotransformation of dapsone and monoacetyldapsone to their respective hydroxylamine metabolites in rat liver microsomes is mediated by cytochrome P450 2C6/2C11 and 3A1. Drug Metab. Dispos. 22:572–577. [PUBMED], [INFOTRIEVE], [CSA]
  • van Bladeren, P. J. (2000). Glutathione conjugation as a bioactivation reaction. Chem.-Biol. Interact. 129:61–76. [PUBMED], [INFOTRIEVE], [CSA]
  • Van der Schyf, C. J., Castagnoli, K., Usuki, E., Fouda, H. G., Rimoldi, J. M., Castagnoli, N. Jr. (1994). Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice. Chem. Res. Toxicol. 7:281–285. [PUBMED], [INFOTRIEVE], [CSA]
  • van der Ven, A. J., Vree, T. B., van Ewijk-Beneken Kolmer, E. W., Koopmans, P. P., van der Meer, J. W. (1995). Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole. Br. J. Clin. Pharmacol. 39:621–625. [PUBMED], [INFOTRIEVE], [CSA]
  • van der Weide, J., Steijns, L. S. (1999). Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann. Clin. Biochem. 36:722–729. [PUBMED], [INFOTRIEVE]
  • Vaught, J. B., McGarvey, P. B., Lee, M. S., Garner, C. D., Wang, C. Y., Linsmaier-Bednar, E. M., King, C. M. (1981). Activation of N-hydroxyphenacetin to mutagenic and nucleic acid-binding metabolites by acyltransfer, deacylation, and sulfate conjugation. Cancer Res. 41:3424–3429. [PUBMED], [INFOTRIEVE]
  • Vergani, D., Tsantoulas, D., Eddleston, A. L., Davis, M., Williams, R. (1978). Sensitisation to halothane-altered liver components in severe hepatic necrosis after halothane anaesthesia. Lancet 2:801–803. [PUBMED], [INFOTRIEVE]
  • Vergani, D., Mieli, V. G., Alberti, A., Neuberger, J., Eddleston, A. L., Davis, M., Williams, R. (1980). Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med. 303:66–71. [PUBMED], [INFOTRIEVE]
  • Veronese, M. E., Mackenzie, P. I., Doecke, C. J., McManus, M. E., Miners, J. O., Birkett, D. J. (1991). Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 175:1112–1118. [PUBMED], [INFOTRIEVE], [CSA]
  • Villa, P., Corti, F., Guaitani, A., Bartosek, I., Casacci, F., De Marchi, F., Pacei, E. (1986). Effects of a new fluorinated macrolide (P-0501A) and other erythromycins on drug metabolizing enzymes in rat liver. J. Antibiot. (Tokyo). 39:463–468.
  • Villegas, J. F., Barabe, D. N., Stein, R. A., Lazar, E. (2001). Adverse effects of herbal treatment of cardiovascular disease: what the physician must know. Heart Dis. 3:169–175., [PUBMED], [INFOTRIEVE]
  • Visiol, F., Galli, C. (2002). Biological properties of olive oil phytochemicals. Crit. Rev. Food Sci. Nutr. 42:209–221. [CSA]
  • Visioli, F., Poli, A., Gall, C. (2002). Antioxidant and other biological activities of phenols from olives and oliv oil. Med. Res. Rev. 22:65–75. [PUBMED], [INFOTRIEVE]
  • Vogel, C. (2000). Prostaglandin H synthases and their importance in chemical toxicity. Curr. Drug Metab. 1:391–404. [PUBMED], [INFOTRIEVE]
  • Volland, C., Sun, H., Dammeyer, J., Benet, L. Z. (1991). Stereoselective degradation of the fenoprofen acyl glucuronide enantiomers and irreversible binding to plasma protein. Drug Metab. Dispos. 19:1080–1086. [PUBMED], [INFOTRIEVE]
  • von Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Duan, S. X., Fogelman, S. M., Daily, J. P., Harmatz, J. S., Shader, R. I. (1998). Protease inhibitors as inhibitors of human cytochrome P450: high risk associated with ritonavir. J. Clin. Pharmacol. 38:106–111. [PUBMED], [INFOTRIEVE], [CSA]
  • von Moltke, L. L., Durol, A. L., Duan, S. X., Greenblatt, D. J. (2000). Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur. J. Clin. Pharmacol. 56:259–261. [PUBMED], [INFOTRIEVE], [CSA]
  • von Rosensteil, N. A., Adam, D. (1995). Macrolide antibacterials. Drug interactions of clinical significance. Drug Safety 13:105–122. [PUBMED], [INFOTRIEVE], [CSA]
  • von Schmiedeberg, S., Fritsche, E., Ronnau, A. C., Specker, C., Golka, K., Richter-Hintz, D., Schuppe, H. C., Lehmann, P., Ruzicka, T., Esser, C., Abel, J., Gleichmann, E. (1999). Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv. Exp. Med. Biol. 455:147–152. [PUBMED], [INFOTRIEVE], [CSA]
  • Voorman, R. L., Maio, S. M., Hauer, M. J., Sanders, P. E., Payne, N. A., Ackland, M. J. (1998a). Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab. Dispos. 26:631–639. [PUBMED], [INFOTRIEVE], [CSA]
  • Voorman, R. L., Maio, S. M., Payne, N. A., Zhao, Z., Koeplinger, K. A., Wang, X. (1998b). Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J. Pharmacol. Exp. Ther. 287:381–388. [PUBMED], [INFOTRIEVE], [CSA]
  • Vorhees, C. V., Acuff, K. D., Weisenburger, W. P., Minck, D. R. (1990). Teratogenicity of carbamazepine in rats. Teratology 41:311–317. [PUBMED], [INFOTRIEVE]
  • Vree, T. B., Beneken Kolmer, E. W.J. (1992). Direct measurement of probenecid and its glucuronide conjugate by means of high-pressure liquid chromatography in plasma and urine of humans. Pharm. Weekbl. Sci. 14:83–87. [PUBMED], [INFOTRIEVE]
  • Vree, T. B., Kolmer, E. W.J.V., Wuis, E. W., Hekster, Y. A., Broekman, M. M.M. (1993). Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. Pharm. World Sci. 15:197–202. [PUBMED], [INFOTRIEVE], [CSA]
  • Walchner, M., Meurer, M., Plewig, G., Jet, L. (2000). Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int. J. Dermatol. 39:383–388. [PUBMED], [INFOTRIEVE], [CSA]
  • Walle, T., Conradi, E. C., Walle, U. K., Fagan, T. C., Gaffney, T. E. (1979). Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol. Clin. Pharmacol. Ther. 26:686–695. [PUBMED], [INFOTRIEVE]
  • Walsh, J. S., Reese, M. J., Thurmond, L. M. (2002). The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem.-Biol. Interact. 142:135–154. [PUBMED], [INFOTRIEVE]
  • Wang, M., Dickinson, R. G. (1998). Disposition and covalent binding of diflunisal and diflunisal acyl glucuronide in the isolated perfused rat liver. Drug Metab. Dispos. 26:98–104. [PUBMED], [INFOTRIEVE], [CSA]
  • Wang, J. S., Wang, W., Xie, H. G., Huang, S. L., Zhou, H. H. (1997). Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. Br. J. Clin. Pharmacol. 44:195–198. [PUBMED], [INFOTRIEVE], [CSA]
  • Wang, H. F., Figueiredo Pereira, M. E., Correia, M. A. (1999a). Cytochrome P450 3A degradationin isolated rat hepatocytes: 26S proteasome inhibitors as probes. Arch. Biochem. Biophys. 365:45–53. [PUBMED], [INFOTRIEVE], [CSA]
  • Wang, J. S., Backman, J. T., Wen, X., Taavitsainen, P., Neuvonen, P. J., Kivistö, K. T. (1999b). Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Pharmacol. Toxicol. 85:201–205. [PUBMED], [INFOTRIEVE], [CSA]
  • Wang, J. S., Backman, J. T., Taavitsainen, P., Neuvonen, P. J., Kivisto, K. T. (2000). Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab. Dispos. 28:959–965. [PUBMED], [INFOTRIEVE], [CSA]
  • Wang, M., Gorrell, M. D., McCaughan, G. W., Dickinson, R. G. (2001). Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. Life Sci. 68:785–797. [PUBMED], [INFOTRIEVE]
  • Wang, M., Gorrell, M. D., Abbott, C. A., Jaggi, R., Marguet, D., Dickinson, R. G. (2002). Hepatic covalent adduct formation with zomepirac in the CD26-deficient mouse. J. Gastroenterol. Hepatol. 17:66–71. [PUBMED], [INFOTRIEVE], [CSA]
  • Ward, H. A., Russo, G. G., Shrum, J. (2002). Cutaneous manifestations of antiretroviral therapy. J. Am. Acad. Dermatol. 46:284–293. [PUBMED], [INFOTRIEVE], [CSA]
  • Ware, J. A., Graf, M. L., Martin, B. M., Lustberg, L. R., Pohl, L. R. (1998). Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats: possible role in allergic reactions. Chem. Res. Toxicol. 11:164–171. [PUBMED], [INFOTRIEVE], [CSA]
  • Wargovich, M. J., Woods, C., Hollis, D. M., Zander, M. E. (2001). Herbals, cancer prevention and health. J. Nutr. 131:3034S–3036S. [PUBMED], [INFOTRIEVE]
  • Waring, J. F., Jolly, R. A., Ciurlionis, R., Lum, P. Y., Praestgaard, J. T., Morfitt, D. C., Buratto, B., Roberts, C., Schadt, E., Ulrich, R. G. (2001). Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 175:28–42. [PUBMED], [INFOTRIEVE], [CSA]
  • Watanabe, J., Shimada, T., Gillam, E. M., Ikuta, T., Suemasu, K., Higashi, Y., Gotoh, O., Kawajiri, K. (2000). Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10:25–33. [PUBMED], [INFOTRIEVE], [CSA]
  • Watkins, P. B., Whitcomb, R. W. (1998). Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338:916–917. [PUBMED], [INFOTRIEVE], [CSA]
  • Watkins, P. B., Zimmerman, H. J., Knapp, M. J., Gracon, S. I., Lewis, K. W. (1994). Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 271:992–998. [PUBMED], [INFOTRIEVE]
  • Watt, J. A., Dickinson, R. G. (1990). Reactivity of diflunisal acyl glucuronide in human and rat plasma and albumin solutions. Biochem. Pharmacol. 39:1067–1075. [PUBMED], [INFOTRIEVE]
  • Weinshilboum, R. M., Otterness, D. M., Szumlanski, C. L. (1999). Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39:19–52. [PUBMED], [INFOTRIEVE], [CSA]
  • Wells, P. G., Vo, H. P. (1989). Effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on phenytoin-induced embryopathy in mice. Toxicol. Appl. Pharmacol. 97:398–405. [PUBMED], [INFOTRIEVE], [CSA]
  • Wells, P. G., Kupfer, A., Lawson, J. A., Harbison, R. D. (1982). Relation of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mouse: evaluation of mephenytoin and its metabolite, nirvanol. J. Pharmacol. Exp. Ther. 221:228–234. [PUBMED], [INFOTRIEVE], [CSA]
  • Wells, P. G., Nagai, M. K., Greco, G. S. (1989a). Inhibition of trimethadione and dimethadione teratogenicity by the cyclooxygenase inhibitor acetylsalicylic acid: a unifying hypothesis for the teratologic effects of hydantoin anticonvulsants and structurally related compounds. Toxicol. Appl. Pharmacol. 97:406–414. [PUBMED], [INFOTRIEVE], [CSA]
  • Wells, P. G., Zubovits, J. T., Wong, S. T., Molinari, L. M., Ali, S. (1989b). Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and alpha-phenyl-N-t-butylnitrone: implications for bioactivation by prostaglandin synthetase. Toxicol. Appl. Pharmacol. 97:192–202. [PUBMED], [INFOTRIEVE], [CSA]
  • Wells, P. G., Kim, P. M., Laposa, R. R., Nicol, C. J., Parman, T., Winn, L. M. (1997). Oxidative damage in chemical teratogenesis. Mutat. Res. 396:65–78., [PUBMED], [INFOTRIEVE]
  • Wen, X., Wang, J. S., Kivisto, K. T., Neuvonen, P. J., Backman, J. T. (2001). In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br. J. Clin. Pharmacol. 52:547–553. [PUBMED], [INFOTRIEVE], [CSA]
  • Wen, X., Wang, J. S., Neuvonen, P. J., Backman, J. T. (2002). Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 57:799–804. [PUBMED], [INFOTRIEVE], [CSA]
  • Wesierska-Gadek, J., Grimm, R., Hitchman, E., Penner, E. (1998). Members of the glutathione S-transferase gene family are antigens in autoimmune hepatitis. Gastroenterology 114:329–335. [PUBMED], [INFOTRIEVE], [CSA]
  • Wheeler, C. H., Berry, S. L., Wilkins, M. R., Corbett, J. M., Ou, K., Gooley, A. A., Humphery-Smith, I., Williams, K. L., Dunn, M. J. (1996). Characterisation of proteins from two-dimensional electrophoresis gels by matrix-assisted laser desorption mass spectrometry and amino acid compositional analysis. Electrophoresis 17:580–587. [PUBMED], [INFOTRIEVE], [CSA]
  • White, I. N., De Matteis, F., Gibbs, A. H., Lim, C. K., Wolf, C. R., Henderson, C., Smith, L. L. (1995). Species differences in the covalent binding of[14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem. Pharmacol. 49:1035–1042. [PUBMED], [INFOTRIEVE], [CSA]
  • Whiteford, H., Klug, P., Evans, L. (1984). Disturbed cardiac function possibly associated with mianserin therapy. Med. J. Aust. 140:166–167. [PUBMED], [INFOTRIEVE], [CSA]
  • Widner, H. (2003). Strategies to modify levodopa treatment. Adv. Neurol. 91:229–236. [PUBMED], [INFOTRIEVE], [CSA]
  • Wikberg, T., Vuorela, A., Ottoila, P., Taskinen, J. (1993). Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos. 21:81–92. [PUBMED], [INFOTRIEVE]
  • Williams, J. D. (2001). Evaluation of safety of macrolides. Int. J. Antimicrob. Agents 18:77–81. [CSA]
  • Williams, A. M., Dickinson, R. G. (1994). Studies on the reactivity of acyl glucuronides. 6. Modulation of reversible and covalent interaction of diflunisal acyl glucuronide and its isomers with human plasma protein in vitro. Biochem. Pharmacol. 47:457–467. [PUBMED], [INFOTRIEVE], [CSA]
  • Williams, D., Feely, J. (2002). Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41:343–370. [PUBMED], [INFOTRIEVE], [CSA]
  • Williams, G. C., Sinko, P. J. (1999). Oral absorption of the HIV protease inhibitors: a current update. Adv. Drug Deliv. Rev. 39:211–238. [PUBMED], [INFOTRIEVE], [CSA]
  • Williams, A. M., Worrall, S., de Jersey, J., Dickinson, R. G. (1992). Studies on the reactivity of acyl glucuronides—III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans. Biochem. Pharmacol. 43:745–755. [PUBMED], [INFOTRIEVE], [CSA]
  • Williams, A. M., Worral, S., Dejersey, J., Dickinson, R. G. (1995). Studies on the reactivity of acyl glucuronides. 8. Generation of an antiserum for the detection of diflunisal-modified proteins in diflunisal-dosed rats. Biochem. Pharmacol. 49:209–217. [PUBMED], [INFOTRIEVE], [CSA]
  • Williams, D. P., Pirmohamed, M., Naisbitt, D. J., Maggs, J. L., Park, B. K. (1997). Neutrophil cytotoxicity of the chemically rective metabolite(s) of clozapine: possible role in agranulocytosis. J. Pharmacol. Exp. Ther. 283:1375–1382. [PUBMED], [INFOTRIEVE], [CSA]
  • Williams, D. P., Pirmohamed, M., Naisbitt, D. J., Uetrecht, J. P., Park, B. K. (2000). Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol. Pharmacol. 58:207–216. [PUBMED], [INFOTRIEVE], [CSA]
  • Williams, J. A., Ring, B. J., Cantrell, V. E., Campanale, K., Jones, D. R., Hall, S. D., Wrighton, S. A. (2002). Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab. Dispos. 30:1266–1273. [PUBMED], [INFOTRIEVE], [CSA]
  • Winfred, R. I., Nanda, S., Horvath, G., Elnicki, M. (1999). Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor. South Med. J. 92:918–920. [PUBMED], [INFOTRIEVE], [CSA]
  • Winn, L. M., Wells, P. G. (1997). Evidence for embryonic prostaglandin H synthase-catalyzedbioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Free Radic. Biol. Med. 22:607–621. [PUBMED], [INFOTRIEVE], [CSA]
  • Winter, H. R., Wang, Y., Unadkat, J. D. (2000). CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab. Dispos. 28:865–868. [PUBMED], [INFOTRIEVE], [CSA]
  • Wolf, R., Tuzun, B., Tuzun, Y. (2000). Dapsone: unapproved uses of indications. Clin. Dermatol. 18:37–53. [PUBMED], [INFOTRIEVE], [CSA]
  • Wolf, R., Matz, H., Orion, E., Tuzun, B., Tuzun, Y. (2002). Dapsone. Dermatol. Online J. 8:2. [PUBMED], [INFOTRIEVE], [CSA]
  • Wolf, D. L., Rodriguez, C. A., Mucci, M., Ingrosso, A., Duncan, B. A., Nickens, D. J. (2003). Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. J. Clin. Pharmacol. 43:43–51. [PUBMED], [INFOTRIEVE], [CSA]
  • Wolkenstein, P., Tan, C., Lecoeur, S., Wechsler, J., Garcia-Martin, N., Charue, D., Bagot, M., Beaune, P. (1998). Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem.-Biol. Interact. 113:39–50. [PUBMED], [INFOTRIEVE], [CSA]
  • Wong, S. L., Cavanaugh, J., Shi, H., Awni, W. M., Granneman, G. R. (1996). Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin. Pharmacol. Ther. 60:48–53. [PUBMED], [INFOTRIEVE], [CSA]
  • Wong, S. G., Card, J. W., Racz, W. J. (2000). The role of mitochondrial injury in bromobenzene and furosemide induced hepatotoxicity. Toxicol. Lett. 116:171–181. [PUBMED], [INFOTRIEVE], [CSA]
  • Woolf, T. F., Pool, W. F., Bjorge, S. M., Chang, T., Goel, O. P., Purchase, C. F. II, Schroeder, M. C., Kunze, K. L., Trager, W. F. (1993). Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. Drug Metab. Dispos. 21:874–882. [PUBMED], [INFOTRIEVE], [CSA]
  • Woolf, G. M., Petrovic, L. M., Rojter, S. E., Wainwright, S., Villamil, F. G., Katkov, W. N., Michieletti, P., Wanless, I. R., Stermitz, F. R., Beck, J. J. (1994). Acute hepatitis associated with the Chinese herbal product, Jin Bu Huan. Ann. Intern. Med. 121:729–735. [PUBMED], [INFOTRIEVE], [CSA]
  • Woosley, R. L., Drayer, D. E., Reidenberg, M. M., Nies, A. S., Carr, K., Oates, J. A. (1978). Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N. Engl. J. Med. 298:1157–1159. [PUBMED], [INFOTRIEVE]
  • Wormhoudt, L. W., Commandeur, J. N. M., Vermeulen, N. P. E. (1999). Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit. Rev. Toxicol. 29:59–124. [PUBMED], [INFOTRIEVE], [CSA]
  • Wray, S. D., Hassell, T. M., Phillips, C., Johnston, M. C. (1982). Preliminary study of the effects of carbamazepine on congenital orofacial defects in offspring of A/J mice. Epilepsia 23:101–110. [PUBMED], [INFOTRIEVE], [CSA]
  • Wright, A. M., Bempong, M. L., Kirby, R. L., Bloomquist, J. R. (1998). Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res. 788:215–222. [PUBMED], [INFOTRIEVE]
  • Wrighton, S. A., Stevens, J. C. (1992). The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22:1–21. [PUBMED], [INFOTRIEVE]
  • Wuest, H. M., Fox, R. R., Crary, D. D. (1968). Relationship between teratogeny and structure in the thalidomide field. Experientia 24:993–994. [PUBMED], [INFOTRIEVE]
  • Xia, Z., Lundgren, B., Bergstrand, A., DePiėrre, J. W., Nassberger, L. (1999). Changes in the generation of reactive oxygen species and in mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clomipramine, and citalopram and the effects on these changes by Bcl-2 and Bcl-X(L). Biochem. Pharmacol. 57:1199–1208. [PUBMED], [INFOTRIEVE], [CSA]
  • Xu, Y., Stokes, A. H., Roskoski, R. J., Vrana, K. E. (1998). Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J. Neurosci. Res. 54:691–697. [PUBMED], [INFOTRIEVE], [CSA]
  • Xu, A. S., Macdonald, J. M., Labotka, R. J., London, R. E. (1999). NMR study of the sites of human hemoglobin acetylated by aspirin. Biochim. Biophys. Acta 1432:333–349., [PUBMED], [INFOTRIEVE]
  • Xu, A. S., Ohba, Y., Vida, L., Labotka, R. J., London, R. E. (2000). Aspirin acetylation of betaLys-82 of human hemoglobin. NMR study of acetylated hemoglobin Tsurumai. Biochem. Pharmacol. 60:917–922. [PUBMED], [INFOTRIEVE], [CSA]
  • Yamamoto, Y., Yamazaki, H., Ikeda, T., Watanabe, T., Iwabuchi, H., Nakajima, M., Yokoi, T. (2002). Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab. Dispos. 30:155–160. [PUBMED], [INFOTRIEVE], [CSA]
  • Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F. P., Yokoi, T. (1999). Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and P450 3A4 in human liver microsomes. Drug Metab. Dispos. 27:1260–1266. [PUBMED], [INFOTRIEVE], [CSA]
  • Yamreudeewong, W., DeBisschop, M., Martin, L., Lower, D. (2003). Potentially significant drug interactions of Class III antiarrhythmic drugs. Drug Safety 26:421–438. [PUBMED], [INFOTRIEVE], [CSA]
  • Yang, T. J., Sai, Y., Krausz, K. W., Gonzalez, F. J., Gelboin, H. V. (1998). Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics 8:375–382. [PUBMED], [INFOTRIEVE], [CSA]
  • Yang, T. J., Krausz, K. W., Sai, Y., Gonzalez, F. J., Gelboin, H. V. (1999). Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab. Dispos. 27:102–109. [PUBMED], [INFOTRIEVE], [CSA]
  • Yatham, L. N. (2002). The role of novel antipsychotics in bipolar disorders. J. Clin. Psychiatry 63:10–14. [PUBMED], [INFOTRIEVE]
  • Yee, G. C., Stanley, D. L., Pessa, J. L., Costa, T. D., Beltz, S. E., Ruiz, J., Lowenthal, D. T. (1995). Effect of grapefruit juice on blood cyclosporin concentration. Lancet 345:955–956. [PUBMED], [INFOTRIEVE]
  • Yeo, K. R., Yeo, W. W. (2001). Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br. J. Clin. Pharmacol. 51:461–470. [PUBMED], [INFOTRIEVE], [CSA]
  • Yim, M. B., Yim, H. S., Lee, C., Kang, S. O., Chock, P. B. (2001). Protein glycation: creation of catalytic sites for free radical generation. Ann. N.Y. Acad. Sci. 928:48–53. [PUBMED], [INFOTRIEVE], [CSA]
  • Yoshida, H., Hirozane, K., Kimoto, H., Hayashi, T., Akiyama, T., Katayama, H., Watanabe, M., Yoshitomi, H., Kamiya, A. (1999). Valproic acid elimination rate and urinary excretion of its glucoronide conjugate in patients with epilepsy. Biol. Pharm. Bull. 22:716–720. [PUBMED], [INFOTRIEVE], [CSA]
  • Yu, W. K., Wells, P. G. (1995). Evidence for lipoxygenase-catalyzed bioactivation of phenytoin to a teratogenic reactive intermediate: in vitro studies using linoleic acid-dependent soybean lipoxygenase, and in vivo studies using pregnant CD-1 mice. Toxicol. Appl. Pharmacol. 131:1–12. [PUBMED], [INFOTRIEVE], [CSA]
  • Yu, X., Wu, Z., Fenselau, C. (1995). Covalent sequestration of melphalan by metallothionein and selective alkylation of cysteines. Biochemistry 34:3377–3385. [PUBMED], [INFOTRIEVE]
  • Yuan, R., Flockhart, D. A., Balian, J. D. (1999). Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J. Clin. Pharmacol. 39:1109–1125. [PUBMED], [INFOTRIEVE], [CSA]
  • Zaacks, S. M., Klein, L., Tan, C. D., Rodriguez, E. R., Leikin, J. B. (1999). Hypersensitivity myocarditis associated with ephedra use. J. Toxicol., Clin. Toxicol. 37:485–489. [CSA]
  • Zaia, J., Jiang, L., Han, M. S., Tabb, J. R., Wu, Z., Fabris, D., Fenselau, C. (1996). A binding site for chlorambucil on metallothionein. Biochemistry 35:2830–2835. [PUBMED], [INFOTRIEVE]
  • Zhang, J., Huang, W., Chua, S. S., Wei, P., Moore, D. D. (2002). Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298:422–424. [PUBMED], [INFOTRIEVE]
  • Zhao, X. J., Jones, D. R., Wang, Y. H., Grimm, S. W., Hall, S. D. (2002). Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 32:863–878. [PUBMED], [INFOTRIEVE], [CSA]
  • Zheng, S., Yang, H., Zhang, S., Wang, X., Yu, L. L., Lu, J. Q., Li, J. (1997). Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention. J. Cell. Biochem., Suppl. 27:106–112., [CSA]
  • Zhou, S. F. (2003). Separation and detection methods for covalent drug-protein adducts. J. Chromatogr., B. 797:63–90. [CSA]
  • Zhou, L. X., Pihlstrom, B., Hardwick, J. P., Park, S. S., Wrighton, S. A., Holtzman, J. L. (1996). Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia. Clin. Pharmacol. Ther. 60:191–198. [PUBMED], [INFOTRIEVE], [CSA]
  • Zhou, L., Erickson, R. R., Hardwick, J. P., Park, S. S., Wrighton, S. A., Holtzman, J. L. (1997). Catalysis of the cysteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast line transfected with the cDNAs of various forms of human cytochrome P450. J. Pharmacol. Exp. Ther. 281:785–790. [PUBMED], [INFOTRIEVE], [CSA]
  • Zhou, S. F., Paxton, J. W., Tingle, M. D., Kestell, P., Jameson, M. B., Thomson, P. I., Baguley, B. C. (2001). Identification and reactivity of the major metabolite (b-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. Xenobiotica 31:277–293. [PUBMED], [INFOTRIEVE], [CSA]
  • Zhou, S. F., Kestell, P., Tingle, M. D., Paxton, J. W. (2002). Thalidomide in the treatment of cancer: a potential role in the elderly. Drug Aging 19:85–100. [CSA]
  • Zhou, S. F., Gao, Y. H., Wen, Q. J., Huang, M., Zu, A. L., Paxton, J. W. (2003). Interactions of herbs with cytochrome P450. Drug Metab. Rev. 35:35–98. [PUBMED], [INFOTRIEVE], [CSA]
  • Zhu, Y. P. (2002). Toxicity of the Chinese herb mu tong (Aristolochia manshuriensis): what history tells us. Adverse Drug React. Toxicol. Rev. 21:171–177. [PUBMED], [INFOTRIEVE], [CSA]
  • Zhu, Y. I., Stiller, M. J. (2001). Dapsone and sulfones in dermatology: overview and update. J. Am. Acad. Dermatol. 45:420–434. [PUBMED], [INFOTRIEVE], [CSA]
  • Zia-Amirhosseini, P., Ding, A., Burlingame, A. L., McDonagh, A. F., Benet, L. Z. (1995). Synthesis and mass-spectrometric characterization of human serum albumins modified by covalent binding of two non-steroidal anti-inflammatory drugs: tolmetin and zomepirac. Biochem. J. 311:431–435. [PUBMED], [INFOTRIEVE]
  • Ziegler, M. H., Grafton, T. F., Hansen, D. K. (1993). The effect of tolbutamide on rat embryonic development in vitro. Teratology 48:45–51. [PUBMED], [INFOTRIEVE]
  • Zimmerman, H. J. (2000). Drug-induced liver disease. Clin. Liver Dis. 4:73–96. [PUBMED], [INFOTRIEVE], [CSA]
  • Zimmerman, H. J., Lewis, J. H., Ishak, K. G., Maddrey, W. C. (1984). Ticrynafen-asociated hepatic injury: analysis of 340 cases. Hepatology 4:315–323. [PUBMED], [INFOTRIEVE]
  • Zimniak, L., Awasthi, S., Srivastava, S. K., Zimniak, P. (1997). Increased resistance to oxidative stress in transfected cultured cells overexpressing glutathione S-transferase mGSTA4-4. Toxicol. Appl. Pharmacol. 143:221–229. [PUBMED], [INFOTRIEVE], [CSA]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.